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Introduction
The last years the awareness of the high prevalence of chronic kidney disease (CKD) is 
increased. This is at least partly due to the definition and treatment guidelines published 
by the Kidney Disease Outcomes Quality Initiative (KDOQI) in 2002. In this guideline CKD is 
divided in 5 stages. In table 1 these 5 stages are listed, stage 5 is mostly called End-stage 
Renal Disease (ESRD) [1].
The prevalence of the different stages of CKD between 1999 and 2004 based on data from 
the National Health and Nutrition Examination Survey (NHANES) is also shown in table 1 [2]. 
Other data from the United States showed that in the year 2000 approximately 300.000 
inhabitants of the United States had ESRD (stage 5) and the earlier stages of CKD are expected 
to be about 80 times more prevalent [3,4]. Also in Europe, Japan, China and Thailand these 
figures  are  high  and  increasing  [5-9].  This  development  shows  the  need  for  preventive 
strategies.
During  the  past  two  decades,  several  therapeutic  options  have  been  developed  and 
proven efficacious in slowing the rate of renal function decline. Among these therapeutic 
treatments are low-protein diets, blood pressure  reduction, especially with angiotensin-
converting enzyme inhibitors and angiotensin II antagonists [10-12]. Most of this research 
has  been  performed  in  patients  with  known  renal  diseases  and  already impaired  renal 
function. However, for such treatments to be most efficacious, and perhaps also to be most 
cost-effective, it is necessary to identify patients in an early stage of their disease, before 
significant loss of renal function has occurred.
Unfortunately, such identification is difficult because many renal diseases for which preventive 
strategies can be started do not cause early symptoms and therefore often are diagnosed 
late, when there is already advanced renal failure. The low awareness of CKD has clearly 
been shown by the NHANES among patients with KDOQI stages 1 through 4 for CKD. Only in 
the last stage of CKD, which is characterized by a GFR < 15 ml/min, were most patients aware 
of their illness [13]. Also a study performed recently in Thailand showed that of the 17.5% 
subjects with CKD only 1.9% were aware that they had CKD [8]. Furthermore, some studies 
showed that CKD is also often underdiagnosed by physicians [1,14-16]. A study performed in 
databases of GP’s in Italy showed that only 4.9% of patients with an eGFR between 59 and 30 
ml/min/1.73m2 and 55% of patients with an eGFR less than 30ml/min/1.73m2 were referred 
to a nephrologists [17].
Considering  these  facts  it  is  necessary  to  develop  screening  strategies  for  the  early 
identification of people who are at risk for accelerated renal function loss and may benefit 
from preventive treatment strategies. For effective screening programs we first need to 
identify risk factors for accelerated renal function decline in the general population. In these 
studies the focus should be especially on modifiable risk factors, such as life style factors 
Table 1: stages of CKD
Stage Description GFR (ml/min/1.73 m2) Prevalence in the US
1 Kidney damage with normal or increased GFR ≥90 1.78
2 Kidney damage with mild decreased GFR 60-89 3.24
3 Moderate decreased GFR 30-59 7.69
4 Severe decreased GFR 15-29 0.35
5 Kidney failure <15 or dialysis NAChapter 1
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(e.g. diet, smoking habits, overweight) and factors that can be medically treated (e.g. blood 
pressure, cholesterol). The studies described in this thesis are carried out in the PREVEND 
cohort. 
Overall aim
The overall aim of this thesis is to identity modifiable risk factors for accelerated renal 
function decline in the general population. 
The prevend cohort
All analyses described in this thesis are performed with data of the Prevention of Renal and 
Vascular End-Stage Disease (PREVEND) study in Groningen, The Netherlands [18,19]. The 
PREVEND study is a prospective cohort study with sequential follow-up to investigate the 
natural course of albuminuria and its relation to renal and cardiovascular outcome. In 1997-
1998 all inhabitants of the city of Groningen were invited to collect in a plastic vial a sample 
of a first morning void urine and to fill out a short questionnaire. These were sent by mail to a 
central laboratory for assessment. From the 40.856 subjects who responded all subjects with 
an increased urinary albumin concentration (UAC>10 mg/L) were selected, together with a 
random sample of the population with a UAC <10 mg/L. The final cohort consisted of 8.592 
subjects. These subjects visit an outpatient clinic at regular intervals for detailed assessment 
of their health status. The first screening round took place in 1997-1998. In 2001-2003 6.894 
subjects completed the second screening round. The third screening round was held after 
a mean follow-up of 2.2 years in 2003-2006, which was attended by 5.862 subjects. At each 
screening round participants filled out a questionnaire on demographics, cardiovascular 
and renal history, smoking status and the use of medication. More information about the 
PREVEND study can be found on www.prevend.org 
Outline of the thesis
Chapter 2 starts with a description of the changes in the nephrology practice over the 
last decades. Due to these changes there is a growing need for reliable methods to detect 
patients  at  risk  for  progressive  CKD.    The  methods  available  (screening  for  low  eGFR, 
screening for albuminuria) are described and the accompanying benefits and limitations are 
described. Finally, several aspects of the important question ‘how to use these methods in 
daily practice’ are dealt with. In chapter 3 we evaluated the changes in renal function as well 
as total mortality and cardiovascular mortality and morbidity over time in subjects that were 
identified in a population screening to have one of the three classical renal risk markers, 
being  macroalbuminuria,  erythrocyturia  or  impaired  renal  function.  Furthermore  we 
investigated whether these subjects were already known with their general practitioner with 
this laboratory abnormality before the screening. Chapter 4 focuses on the effect of protein 
intake on renal function decline, all-cause mortality, cardiovascular mortality and morbidity. 
There is evidence that one of the strategies to slow down the rate of renal function decline 
in patients with CKD is the restriction of protein in their diet [20-23]. However, the long-term 
effects of protein intake on cardiovascular and renal outcome in the general population are 
not clear. In chapter 5 we investigated which baseline risk factors were associated with renal 
function decline during follow-up. In this chapter the focus was on modifiable risk factors, 
such as albuminuria, glucose, cholesterol, waist-to-hip ratio and systolic blood pressure. 
Chapter 6 describes the effect of changes in these risk factors, on the subsequent rate of 
renal function decline. In chapter 7 the development and validation of a Renal Risk Score 
are described. In this study a score chart to calculate the risk of having a renal event within Chapter 1
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7 years follow-up is developed and internal validation with bootstrap samples is performed. 
For this study we defined a renal event as having at least one eGFR measurement below 
60 ml/min/1.73m2 and belonging to the subjects with the most pronounced renal function 
decline. In such a score chart the risk for each subject can be estimated based on a limited 
number of clinical characteristics. Finally, in chapter 8 the results described in chapter 2-7 
are summarized and discussed.Chapter 1
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Introduction
Much  attention  is  presently  focused  on  the  detection  of  early  chronic  kidney  disease 
(CKD). This interest is related to the fact that it is becoming more and more accepted that 
an  impaired  kidney  function  and  elevated  albuminuria  are  associated  with  progressive 
cardiovascular disease. It is thus important that easy to apply and reliable techniques be 
available to properly define the presence of renal damage. In this comment, we will describe 
what methods are available to define the presence of CKD, and we will discuss how these 
methods should be used in daily practice.
Changing clinical nephrology practice over the decades
Nephrology practice has dramatically changed since the early sixties of the previous century. 
In the early years of nephrology, most attention was directed towards setting up dialysis 
and transplant programmes. In those years, little attention was paid to the prevention of 
progressive renal function loss. In the nineties, practice started to change, as it became clear 
that progressive CKD in subjects with known renal disease (and thus under the attention of 
the nephrologists) could be slowed down by strict blood pressure control and lowering of 
proteinuria with Angiotensin Converting Enzyme (ACE) inhibitors or angiotensin II receptor 
blockers [1]. Though in the optimal implementation of such renoprotective regimens much 
can still be gained, there are indications that the number of patients with end-stage renal 
disease (ESRD) due to classical renal diseases is diminishing. This favourable sign is, however, 
overruled by the fact that the number of patients with ESRD due to type 2 diabetes mellitus, 
hypertension and generalized atherosclerosis is constantly growing, not only in the elderly 
but also in those under 60 years of age [2]. Unfortunately, these subjects are often brought 
to the attention of the nephrologists only at a time when they are close to the need for 
dialysis, that is at a time when treatment opportunity to prevent a further renal function 
decline is already limited. As such treatments are well available, these patients should be 
detected earlier in the course of their progressive CKD.
How can we detect patients not known with a specific renal 
disease, but at risk for progressive CKD?
As patients with renal failure due to type 2 diabetes, hypertension or generalized vascular 
disease have in most cases never experienced acute symptoms indicative of renal disease, 
such  as  haematuria,  severe  hypertension  or  oedema  (as  patients  with  glomerular  or 
interstitial diseases), programmes have to be designed to detect them at an earlier phase. 
Table 1. The five stages of CKD, according to the level of GFR and the presence of an elevated 
albuminuria.  Given  are  the  percentages  as  found  in  the  PREVEND  study  in  Groningen,  The 
Netherlands (de Zeeuw) and the NHANES study in the USA (Coresh)
GFR Elevated
albuminuria
 PREVEND (%) NHANES (%)
Stage 1 >90 yes 1.3 3.3
Stage 2 60–89 yes 3.8 3.0
Stage 3 30–59 yes/no 5.3 4.3
Stage 4 15–29 yes/no 0.1 0.2
Stage 5 <15 yes/no 0.1 0.2Chapter 2
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The KDOQI guidelines defined the five stages of CKD, dependent on the level of glomerular 
filtration rate (GFR) and the presence of an elevated urinary albumin excretion, defined as 
microalbuminuria (30–300 mg albumin/24 h) or macroalbuminuria (>300 mg albumin/24 h) 
(Table 1) [3]. The publication of these definitions facilitated the ideas of approaching early 
CKD. We could detect subjects at risk for progressive CKD and cardiovascular disease by 
screening for albuminuria. With this approach, we would be able to detect subjects with 
stages 1 and 2 CKD, who cannot be detected by screening only for GFR. Various review 
papers recently described the laboratory methods to measure albuminuria, the way urine 
samples could be collected, the definitions for an abnormally elevated albuminuria, and the 
way in which a population screening on albuminuria might be organized [4–6].
It is beyond the scope of this editorial to discuss the pros and cons of these aspects. The 
second option is screening for GFR, as patients with stages 3 and 4 CKD may have an 
impaired GFR also without having micro- or macroalbuminuria. It is clear that accurate 
GFR  measurements  using  inulin  or  iothalamate  infusions  cannot  be  applied  in  large-
scale screening programmes. Accurate 24 h collections necessary for the calculation of a 
creatinine clearance are also difficult to apply in such programmes. That is the reason why in 
the last decade, much attention was focused on the optimal formula to estimate GFR from 
just one single plasma creatinine measurement and some indices of creatinine production. 
As the latter is determined by muscle mass of the subject, most formulas use age (the elderly 
produce less creatinine), sex (women produce less creatinine), race (whites produce less 
creatinine), and weight or height (leaner and smaller subjects produce less creatinine). The 
most widely used are the Cockcroft–Gault [7] and the Modification of Diet in Renal Disease 
(MDRD) [8] formula (Table 2).
Limitations of estimated GFR measurements
Although GFR estimates are easy to apply, the Cockcroft–Gault and MDRD formula as well 
all the other published formulas have their limitations. It is only if one is aware of these 
limitations that a good use of the formulas can be expected.
The creatinine measurement
A major point of concern that affects both formulas is the accuracy of the creatinine assay 
itself. Calibration of the assay is needed, not only to compare individual laboratory results 
with each other, but also to standardize the results of an individual over time [9]. Calibration 
greatly reduces the bias that is found between estimated GFR and true GFR in many studies. 
Even after calibration, however, still more than half of the results differ more than 15% from 
true GFR, and more than one-third differ by more than 30% from the correct value [10]. 
Table  2.  The  Cockcroft–Gault  formula  and  the  simplified  MDRD  formula  to  estimate 
glomerular filtration rate
Cockcroft–Gault formula
[(140-age)×weight]/72×(serum creatinine)×(0.85 if female)
Simplified MDRD formula
186×(serum creatinine)-1.154×(age)-0.203×(0.742 if female)×(1.210 if black)
Age is included in years, weight in kilogram and serum creatinine in milligram per decilitre. Chapter 2
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Second, serum creatinine is not only dependent on endogenous muscle mass, but also on 
dietary intake of meat, which thus incorrectly may result in a higher serum creatinine value.
The calculation of estimated GFR
There are fundamental differences between the Cockcroft–Gault and the MDRD formula 
to estimate GFR. First, the Cockcroft–Gault formula has originally been validated against 
creatinine  clearance  as  the  gold  standard,  whereas  the  MDRD  formula  was  developed 
against  iothalamate-measured  GFR.  As  creatinine,  but  not  iothalamate,  is  excreted  not 
only by filtration but also by secretion, creatinine clearance always exceeds iothalamate 
clearance. Consequently, the Cockcroft–Gault-based GFR estimates tend to exceed MDRD-
based GFR estimates in most subjects. Second, the Cockcroft–Gault formula (which includes 
weight in the formula) is expressed in millilitres per minute, while the MDRD formula (which 
does not include weight in the formula) is expressed in millilitres per minute per 1.73m2. This 
difference makes a direct comparison between the two difficult. In general, clinicians are not 
used to expressing GFR normalized for standard body surface area.
The bias introduced by the estimates
It has been shown in various studies that MDRD GFR in general underestimates true GFR 
[11–13], especially in patients with normal GFR, whereas Cockcroft–Gault GFR overestimates 
true GFR, especially in patients with impaired kidney function [11]. The biases of the two 
formulas may be quite different in selected populations, defined by age, sex, body mass 
index and also level of GFR [14]. In epidemiological studies, the impact of not just age [15] but 
also of sex, body weight, blood pressure and glucose on renal function will generally result in 
different conclusions when using an indirect instead of a direct measure of GFR [16].
The use of fixed cut-off levels for CKD definitions
One should realize that the KDOQI guidelines make their discrimination on stages of GFR 
based upon fixed cut-off levels, that is a GFR 30–59 (stage 3), or 15–29 ml/min/1.73m2 
(stage 4). It is, however, well-known that GFR decreases with advancing age by about 0.8 
ml/min/year; it is to be expected that we, by using fixed cut-off levels, will diagnose more 
elderly subjects to have the worse CKD stages. This may result in unnecessary diagnostics 
and treatment of the elderly. It will also, and even more unwanted, result in missing this 
diagnosis in the young and male subjects. This problem could be overcome by making age-
specific cut-off values for an impaired GFR. In a recent study in more than 2 million subjects 
from the Veterans Affairs Health Care System, it was shown that the association of eGFR with 
mortality was much steeper in younger compared with older subjects. This led the authors 
to conclude that to properly evaluate the impact of an impaired GFR on mortality, different 
cut-off values should be used for young compared with older subjects [17].
An impaired GFR or progressive renal function impairment?
Subjects that reach CKD stage 5 will at some point in time have passed KDOQI stages 3 and 
4. Screening for estimated GFR therefore seems logical. However, a point of concern is that 
diagnosing someone with a GFR below a certain cut-off level, does not necessarily mean that 
this subject will have a progressive loss of renal function. It may well be that he or she has 
few nephrons and consequently, a low GFR, that however has been and will be stable for 
many years. Indeed, a population survey showed that in patients with an increased serum 
creatinine who were not being treated by renal services, only a minority showed progressive 
renal function decline during 31 months of follow-up [18]. We recently showed over 4.2 Chapter 2
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years of follow-up that the loss of GFR in subjects, selected because of an impaired GFR, was 
not higher than in the background population (with a normal GFR), while the fall in GFR in 
subjects with macroalbuminuria, even those with a better preserved GFR, was much more 
rapid than the background population. Interestingly, cardiovascular prognosis was similarly 
unfavourable in the subjects with impaired GFR and in the subjects with macroproteinuria 
[19]. Thus, it may well be that screening for GFR is not the ideal method to detect patients 
at risk for progressive renal failure. From a renal perspective, it may be more effective to 
adopt a screening strategy that is based on the identification of subjects that have the 
combination of an elevated albuminuria, a decreased GFR and any of the known modifiable 
progression risk factors, such as hypertension, diabetes, smoking and hyperlipidaemia. This 
would imply that in analogy to the Framingham risk score for cardiovascular disease, a risk 
score predicting progressive renal function decline should be applied. Such a renal risk score 
is however, yet to be developed.
What is the role for the nephrologist?
As it has been shown that 5–6% of the population has stages 1 and 2 CKD, and another 5% has 
a stage 3 CKD [20,21], the workload required to detect and especially to follow these subjects 
is tremendous. This will not be feasible for nephrologists, and also not advisable, since many 
of these subjects will not develop stage 5 CKD. The main risk that threatens such subjects 
is cardiovascular disease. Screening for early CKD thus requires a combined approach by 
the (cardiovascular) internist, general practitioner, nurse and technician. The nephrologist 
should take the initiative. The type of health care system in the individual country will dictate 
the optimal design of the screening programme. The components to consider include: who 
will do the testing, who will take care of the individual with an abnormal test result, where 
will the screening take place (e.g. clinic, health fair), and how it will be financially supported.Chapter 2
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Abstract
Macroalbuminuria, erythrocyturia, and impaired renal function are strong predictors of poor 
renal outcome in patients with known renal disease. However, the yield of mass screening 
for these variables to identify individuals who are at risk for GFR loss is yet unknown in a 
Western population.
With the use of data from the Prevention of Renal and Vascular End-Stage Disease (PREVEND) 
study, a prospective, population-based cohort study, the cardiovascular and renal prognosis 
was  investigated  in  patients  with  classical  renal  risk  markers:  Macroalbuminuria  (>300 
mg albumin/24 h urine), erythrocyturia (>250 erythrocytes/L, without leukocyturia), and 
impaired renal function (both 24-h creatinine clearance and Modification of Diet in Renal 
Disease clearance below the fifth percentile of age- and gender-matched control subjects). 
The 8.592 patients who were included in this study were followed for a 4-yr period.
We  identified  134  patients  with  macroalbuminuria,  128  with  erythrocyturia,  and  103 
with impaired renal function. There was only a little overlap among the three groups. The 
prevalence of macroalbuminuria, erythrocyturia, and impaired renal function was calculated 
to be in the general population 0.6, 1.3, and 0.9%, respectively. In all three groups, fewer 
than 30% of patients were known to have this laboratory abnormality before screening. 
The incidence of cardiovascular disease was high in the macroalbuminuria group (e.g., the 
age- and gender-adjusted hazard ratio for mortality as a result of cardiovascular disease 
is 2.6 [1.1 to 6.0]) and for the impaired renal function group 3.4 [1.5 to 8.0]. After a mean 
follow-up of 4.2 yr, the macroalbuminuria group showed a 7.2 ml/min per 1.73 m2 estimated 
GFR (eGFR) loss, compared with 2.3 ml/min per 1.73 m2 in the control group (difference P < 
0.001), whereas the rate of eGFR loss in the impaired renal function group (-0.2 ml/min per 
1.73 m2; P=0.18) and the erythrocyturia group (2.6 ml/min per 1.73 m2) was not different 
from the control group.
Macroalbuminuria and impaired renal function both predict a worse prognosis with respect 
to  cardiovascular  morbidity  and  mortality.  However,  macroalbuminuria  is  a  better  risk 
marker than low eGFR or erythrocyturia to identify in population screening of individuals 
who are at risk for accelerated GFR loss. Chapter 3
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Introduction
Worldwide, the number of people who have ESRD and require dialysis is increasing [1]. In the 
United States, for instance, the number of new patients with ESRD is expected to increase 
between  2000  and  2010  by  48%  [2].  This  development  shows  the  need  for  preventive 
strategies. During the past two decades, several therapeutic options have been developed 
and proved efficacious in slowing the rate of renal function decline. Among these therapeutic 
treatments are low-protein diets, BP  reduction, especially with angiotensin- converting 
enzyme inhibitors and angiotensin II antagonists [3–6], and lipid lowering. However, for such 
treatments to be most efficacious with the least societal economic burden, it is necessary 
to identify patients in an early stage of their disease, before significant loss of renal function 
has occurred. Unfortunately, such identification is difficult because many renal diseases for 
which preventive strategies can be started do not cause early symptoms and therefore often 
are diagnosed late, when there is already advanced renal failure. The National Health and 
Nutrition Examination Survey (NHANES) indeed showed a low awareness of chronic kidney 
disease (CKD) among patients with Kidney Disease Outcomes Quality Initiative (KDOQI) stages 
1 through 4 for CKD. Only in the last stage of CKD, which is characterized by a GFR 15 ml/min, 
were most patients aware of their illness [7,8]. Considering this, it is necessary to develop 
screening strategies for the early identification of people who are at risk for accelerated 
renal function loss and may benefit from preventive treatment strategies. 
Such screening has proved to be effective in high-risk populations, such as diabetics or 
hypertensive populations, or in family members of patients who require dialysis [9–12]. 
Unfortunately, there are few data on the yield of screening programs to identify patients who 
are at risk for accelerated renal function loss in the general population. Putative renal risk 
markers could be high albuminuria, erythrocyturia, and low estimated GFR (eGFR), because 
in patients with renal disease, these variables have been proved to be strong predictors of 
renal outcome [13,14]. 
For this study, we used the data of the Prevention of Renal and Vascular End-stage Disease 
(PREVEND) Study to evaluate the changes in renal function as well as total mortality and 
cardiovascular  mortality  and  morbidity  over  time  in  patients  with  macroalbuminuria, 
erythrocyturia, and impaired renal function. We also calculated the prevalence of these 
classical renal risk markers in the general population and evaluated whether these individuals 
were known to have these laboratory abnormalities before screening took place.
Materials and Methods
Study Population
This  study  was  performed  in  the  individuals  who  participated  in  the  PREVEND  Study. 
This study is designed to investigate prospectively the natural course of albuminuria and 
its relation to renal and cardiovascular disease (CVD) in a large cohort drawn from the 
general population. Details of the study protocol have been described elsewhere [15,16]. 
In summary, in the period 1997 to 1998, all 85.421 inhabitants of the city of Groningen, 
The Netherlands, who were aged 28 to 75 yr were sent a one-page postal questionnaire 
(regarding  demographics,  use  of  medication,  and  presence  of  pregnancy)  and  a  vial  to 
collect an early-morning urine sample; 40.856 (47.8%) individuals responded. Their vials 
were sent to a central laboratory, where urinary albumin and creatinine concentrations 
were measured. After exclusion of individuals who were using insulin (possibly) and pregnant 
women and those who were not able or willing to participate, all individuals with a urinary 
albumin concentration (UAC) of ≥ 10 mg/L (group A; n = 7.768) and an SPSS-generated (SPSS, Chapter 3
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Inc., Chicago, IL) random sample of individuals with a UAC < 10 mg/L (group B; n = 3.395 
of a total of 30.890) were invited for further detailed investigations in an outpatient clinic 
and to collect two consecutive 24-h urine samples. This procedure was followed to obtain 
a cohort that was enriched for the presence of albuminuria, the primary parameter under 
investigation in the PREVEND study. Of group A, 6.000 (77.2%) individuals completed the 
screening protocol of those who were invited, and of group B, 2.592 (76.3%) individuals 
did. These 8.592 individuals form the PREVEND baseline cohort. The 8.592 individuals were 
seen twice at an outpatient clinic, where anthropometric measurements were performed 
and BP was measured. Blood was drawn after an overnight fast. Participants were asked 
to  perform  24-h  urine  collections  on  two  consecutive  days  before  the  second  visit. 
For this study, three subgroups were defined: 
1. Macroalbuminuria: A 24-h urinary albumin excretion (UAE) ≥ 300 mg/24 h
2. Erythrocyturia: ≥ 250 erythrocytes/µl, without leukocyturia
3. Renal function impairment: A creatinine clearance below the 5% age- and gender-matched 
lowest values of both 24-h urinary creatinine clearance and Modification of Diet in Renal 
Disease (MDRD) eGFR. We used this latter combined approach to define renal function 
impairment to be sure not to include falsely individuals with either incomplete 24-h urine 
collections or extremes of body composition. We similarly did not use a fixed cutoff value of 
< 60 ml/min, because that would have led to an overrepresentation of elderly and of female 
individuals. 
Approximately 4 yr later, from 2001 through 2003, all PREVEND participants were invited 
for follow-up investigations at an outpatient clinic. A total of 240 participants had died, and 
1.452 declined participation. Therefore, 6.894 (80.2%) participants completed the follow-up 
investigations. The PREVEND study is approved by the local medical ethics committee and 
conducted in accordance with the guidelines of the declaration of Helsinki. All participants 
who attended the outpatient clinic gave written informed consent. 
Measurements and Definitions
After  the  screening,  both  the  participants  and  their  general  practitioners  received 
a  report  of  the  test  results,  together  with  therapeutic  advice  to  treat  hypertension,   
hypercholesterolemia, and diabetes according to standard guidelines. For our study, the 
general  practitioners  of  the  individuals  with  macroalbuminuria,  erythrocyturia,  and/or 
impaired renal function were sent a questionnaire to evaluate whether they were known to 
have these laboratory abnormalities before the screening.
Plasma and urinary creatinine, plasma cholesterol, and glucose were determined by Kodak 
Ektachem dry chemistry (Eastman Kodak, Rochester, NY), an automated enzymatic method. 
Urinary leukocyte and erythrocyte measurements were done by Nephur-test  leuco sticks 
(Boehringer Mannheim, Mannheim, Germany). Urinary albumin concentration (UAC) was 
determined by nephelometry with a threshold of 2.3 mg/L and intra-assay and interassay 
coefficients of variation of < 2.2 and 2.6%, respectively (Dade Behring Diagnostic, Marburg, 
Germany).
Systolic and diastolic BP was calculated as the mean of the last two BP measurements of the 
two visits. UAE is given as the mean of the two 24-h urine excretions. GFR was assessed by 
calculating creatinine clearance (mean of two 24-h urinary creatinine excretions divided by 
plasma creatinine and corrected for body surface area); furthermore, eGFR was estimated by 
using the four-variable MDRD formula [17]. 
Smoking was defined as current smoking or cessation of smoking < 1 yr before the study. A 
history of CVD was defined as a self-assessed history of myocardial infarction, cerebrovascular Chapter 3
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accident,  or  peripheral  vascular  disease.  Information  on  the  use  of  antihypertensive 
medications in general and for angiotensin-converting enzyme inhibitors or angiotensin 
II antagonists specifically was obtained for approximately 80% of the population under 
investigation by linking the database with pharmacy data. The change in medication use 
is calculated as the percentage of patients who started or stopped using their medication 
during follow-up.
Mortality data were obtained from the National Central Bureau of Statistics, a registry 
for all deaths, subdivided in cardiovascular, malignancies, and other causes. Information 
on  morbidity  was  obtained  from  PRISMANT,  a  database  that  collects  information  on 
hospitalizations on the basis of the International Classification of Diseases, 9th Revision; 
cardiovascular events are defined as the following codes; 410, 411, 413, 414, 430 to 438, 
440 to 442, and 444. Of note, mortality and morbidity data are known for all participants, 
including those who were lost to follow-up.
Statistical Analyses 
All calculations were performed with SPSS version 12.0. Continuous data are reported as 
means ± SD or as medians with the interquartile range in case of skewed data distribution. 
All subgroups were compared with the total population minus the specific subgroup under 
investigation (called the control group) for possible differences in baseline characteristics. 
Differences in baseline characteristics were tested for statistical significance with t test for 
continuous data. Glucose and UAE were transformed into their natural logarithm because 
of  skewed  distribution.  Considering  that  the  selection  of  individuals  into  the  PREVEND 
cohort is based on the UAC (with enrichment for individuals with a UAC > 10 mg/L), the 
prevalence rates of the classical renal risk markers in our cohort may not be comparable to 
those in the general population. Therefore, we assessed prevalence rates in a subsample of 
3.432 individuals that has been formed by reweighing the “oversampled” group A, thereby 
accounting for the enrichment procedure. These individuals form a representative sample 
of the general population. Detailed information about how reweighing was achieved has 
been published previously [18]. Comparison between prevalence rates was carried out with 
  χ2 analysis. Multivariate analysis of survival was performed using Cox proportional hazards 
regression to calculate hazard ratios that were unadjusted as well as adjusted for age and 
gender. All P values are two tailed, and P < 0.05 was considered statistically significant.
Sensitivity analyses were performed to account for the possibility of “competing” risks (e.g., 
participants who died during follow-up could have experienced renal function deterioration 
before  they  died).  Such  sensitivity  analysis  also  was  performed  to  investigate  whether 
imbalance with respect to the number of participants with diabetes among the three study 
groups would be responsible for differences in observed rates in renal function decline. For 
this sensitivity analysis, diabetes was defined as a fasting plasma glucose ≥ 7.0 mmol/l or the 
use of oral glucose-lowering agents.
Results 
Overall, 134 participants in this study had macroalbuminuria, 128 had erythrocyturia, and 
103 had impaired renal function. Table 1 shows the characteristics of the various groups 
under  investigation.  Participants  with  macroalbuminuria  or  impaired  renal  function 
generally had an increased cardiovascular risk profile, as reflected by, for example, a higher 
body  mass  index,  BP,  and  serum  cholesterol.  Participants  with  erythrocyturia  differed 
from the control group insofar as they more often were female and had a higher level of 
albuminuria.  The  prevalence  of  macroalbuminuria,  erythrocyturia,  and  impaired  renal Chapter 3
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function in our study population is presented in Figure 1. This Venn diagram shows that 
only a minority of participants had two or three overlapping symptoms. To calculate the 
prevalence of the three renal risk markers in the general population, we used a subsample 
that was representative of the general population as explained in the Materials and Methods 
section. The prevalence of macroalbuminuria, erythrocyturia, and impaired renal function 
in the general population was calculated to be 0.6, 1.3, and 0.9%, respectively. Information 
from the general practitioners was received on 110 (82%) of the 134 participants with 
macroalbuminuria, on 89 (70%) of the 128 participants with erythrocyturia, and on 59 (57%) 
of the 103 participants with impaired renal function. It was found that only 25, 20, and 27% 
of the participants with macroalbuminuria, erythrocyturia, and impaired renal function were 
already known to have this laboratory abnormality before the screening.
Of  the  total  population,  2.8%  died,  whereas  for  participants  with  macroalbuminuria, 
erythrocyturia, and impaired renal function the percentages of participants who died were 
Table 1: Baseline characteristics 
Total 
population
Macroalbuminuria Erythrocyturia Impaired Renal 
Function
Number  8,592 134 128 103
Age (yr) 49 (13) 58 (13)** 51 (13) 61 (11) **
Male (%) 50 66** 34** 51
Body mass index (kg/m2) 26.1 (4.2) 28.9 (4.6) ** 25.9 (4.4) 27.1 (4.4)
Smoking (%) 38.0 32.6 48.0* 28.2
History of CVD (%) 9.4 29.7** 13.9 30.5**
SBP (mmHg) 129 (20) 152 (25) ** 129 (23) 142 (24) **
DBP (mmHg) 74 (¬10) 83 (10) ** 75 (12) 79 (11) **
Anti-hypertensive Tx (%) 16.8 46.2** 23.0 57.3**
ACEi or A2A (%) 5.8 20.8** 8.8 28.1**
Cholesterol (mmol/L) 5.65 (1.13) 6.13 (1.30) ** 5.77 (1.18) 6.09 (1.49) **
Lipid-lowering Tx (%) 6.9 18.2** 12.5** 29.4**
Glucose (mmol/L) 4.9 (1.2) 5.8 (2.4)** 4.8 (0.8) 5.0 (1.1)
Oral antidiabetic Tx (%) 2.1 9.7** 1.6 2.9
UAC <10 mg/L (%)± 30.2 0** 21.9* 16.5*
Median UAE (mg/day) 9.5 (6.3-17.8) 549 (371-1011)** 23.7 (10.2-91.5) 37.6 (8.2-157.3)**
Macroalbuminuria (%)¶ 1.6 100** 7.0** 17.5**
Erythrocyturia (%) 1.5 6.7** 100** 7.8**
eGFR (ml/min/1.73m2) 80.8 (14.7) 68.4 (20.4) ** 74.9 (15.6) ** 44.6 (11.6) **
Means  (S.D.)  are  given  for  continuous  variables.  Because  of  skewed  distribution  for  UAE  the  median  and 
interquartile range is given.
*  P<0.05 versus total population minus the specific group under investigation
* *  P<0.01 versus total population minus the specific group under investigation
±  Prescreening
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9.7, 5.5, and 16.8%, respectively (Table 2). 
Cardiovascular mortality was high in the 
participants  with  macroalbuminuria 
and  in  the  participants  with  impaired 
renal  function  (4.5  and  5.8%, 
respectively),  compared  with  0.8%  in 
the control group. The same was true 
for  cardiovascular  morbidity,  with 
21.6  and  23.3%,  respectively,  in  the 
macroalbuminuria  and  impaired  renal 
function groups, compared with 6.1% in 
the control population and 8.6% in the 
erythrocyturia group. Hazard ratios are 
shown in Table 2.
Overall,  6.894  individuals  participated 
in  the  second  screening  4.2  yr 
later,  including  86  participants 
with  macroalbuminuria,  97  with 
erythrocyturia,  and  68  with  impaired 
renal  function  (Table  3).  Numbers 
decreased because participants died or withdrew consent before the second screening. 
Baseline characteristics of the participants who were lost to follow-up in the three different 
renal risk groups were not statistically different, compared with participants who completed 
the second screening. BP had fallen more in the group with macroalbuminuria and the group 
with impaired renal function (8.0 and 8.3 mmHg systolic and 3.6 and 4.8 mmHg diastolic, 
respectively) than in the control group (1.7 mmHg systolic and 0.3 mmHg diastolic). This 
probably is due to the use of more antihypertensive drugs in these groups. At the second 
screening, however, both systolic and diastolic BP still were higher in the macroalbuminuria 
group than in the impaired renal function group. During follow-up, renal function had fallen 
more in participants with macroalbuminuria (7.2 ml/min per 1.73 m2 [10.6%]) than in the 
control group (2.3 ml/min per 1.73 m2 [2.8%]) and in the participants with erythrocyturia 
(2.6 ml/min per 1.73 m2 [3.5%]). It is interesting that eGFR fell by only 0.2 ml/min per 1.73 m2 
(0.4%) in participants with impaired renal function. Participants who at baseline had both 
macroalbuminuria and impaired renal function (n  = 18) experienced a rate of renal function 
decline of 9.0 ml/min per 1.73 m2.
Various sensitivity analyses were performed. First, there were more participants with diabetes 
in the macroalbuminuria group when compared with the overall population and the two 
other groups under investigation. After exclusion of individuals with diabetes, the observed 
renal function decline in the macroalbuminuria group was 7.1 ml/min per 1.73 m2, whereas it 
was 7.2 ml/min per 1.73 m2 when individuals with diabetes were included. For cardiovascular 
morbidity and mortality, the incidence rates were similar in the macroalbuminuria group 
when  individuals  with  diabetes  were  excluded  or  included  (mortality  4.4  versus  4.5%, 
respectively [NS]; morbidity 21.1 versus 21.6%, respectively [NS]). Second, we investigated 
“competing” risks as a potential source of bias (e.g., participants who died during follow-up or 
were lost to follow-up for other reasons could have experienced renal function deterioration 
before they died).
We observed a difference in mortality rates between the macroalbuminuria and impaired 
renal function groups (9.7 versus 16.5%, respectively). If it is assumed that the difference in 
Figure  1.  Venn  diagram  indicating  the  prevalence 
of macroalbuminuria, erythrocyturia, and impaired 
renal function in our population of 8592 participants.Chapter 3
30 31
GFR decline between these two groups is due to the difference in mortality rates, then this 
suggests that a relatively small number of participants who died would be responsible for 
this difference. For the difference of 7.0 ml/min per 1.73 m2 between the macroalbuminuria 
and impaired renal function groups to be explained fully by the participants who died during 
follow-up, this would mean that the 6.8% more participants who died in the impaired renal 
function group should have had a renal function decline of almost 120 ml/min per 1.73 m2 
each. If such sensitivity analysis takes into account not only “overmortality” but also all 17 
participants who died in the impaired renal function group and assuming that the deceased 
participants in the macroalbuminuria group had a neutral effect size (i.e., 7.2 ml/min per 
1.73 m2 renal function loss, as in the participants from this group for whom follow-up is 
available), then this would mean that these 17 participants should have experienced a renal 
function decline of 35.2 ml/min per 1.73 m2. If such sensitivity analysis takes into account not 
only the 17 participants who died during follow-up but also all 35 participants who were lost 
to follow-up, again assuming a neutral effect size in the macroalbuminuria group, then this 
would mean that these 35 participants should have experienced a renal function decline of 
21 ml/min per 1.73 m2.
Discussion
In this study, we investigated whether the putative renal risk markers macroalbuminuria, 
impaired renal function, and erythrocyturia can be used for population screening to identify 
individuals who are at risk for accelerated renal function loss. We found that both individuals 
with  macroalbuminuria  and  individuals  with  impaired  renal  function  have  increased 
cardiovascular mortality and morbidity compared with individuals in the control population. 
Table 2. Results with regard to morbidity, mortality, and follow-upa
Total 
Population
Macroalbuminuria  Erythrocyturia  Impaired Renal 
Function 
n at baseline 8592 134 128 103
Mortality         
cardiovascular (%) 68 (0.79) 6 (4.5)b 0 6 (5.8)b
HR, unadjusted (95% CI) Reference 6.3 (2.7 to 14.7) NA 8.6 (3.7 to 19.8)
HR, age and gender adjusted (95% 
CI)
Reference 2.6 (1.1 to 6.0) NA 3.4 (1.5 to 8.0)
noncardiovascular (%) 172 (2.0) 7 (5.2)b  7 (5.5) 11 (11)b
HR, unadjusted (95% CI) Reference 2.9 (1.3 to 6.1) 3.0 (1.4 to 6.3) 6.4 (3.5 to 11.9)
HR, age and gender adjusted
(95% CI)
Reference 1.5 (0.7 to 3.0) 2.6 (1.2 to 6.0) 3.0 (1.6 to 5.6)
Morbidity         
cardiovascular (%) 524 (6.1) 29 (21.6)b 11 (8.6) 24 (23.3)b
HR, unadjusted (95% CI) Reference 2.8 (1.8 to 4.4) 1.5 (0.8 to 2.6) 4.8 (3.2 to 7.3)
HR, age and gender adjusted 
(95% CI)
Reference 1.4 (1.0 to 2.1) 1.4 (0.7 to 2.5) 2.3 (1.5 to 3.4)
Consent withdrawn (%) 1458 (17) 35 (26)b 24 (19) 18 (17)
No. with follow-up (%) 6894 (80) 86 (64)b 97 (76) 68 (66)b
aCI, confidence interval; HR, hazard ratio.
bP < 0.01 versus total population minus the specific group under investigation.Chapter 3
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Table 3: Results with regard to patient characteristics and renal function of subjects with follow-up
Total 
population
Macroalbuminuria  Erythrocyturia Impaired Renal 
Function 
Number 6894 86 97 68
Systolic Blood Pressure (mmHg)
baseline  128 (20) 151 (23)** 127 (23) 142 (22)**
follow-up 127 (19) 143 (23)** 125 (20) 134 (21)**
change  -1.7 (13.1) -8.0 (2.2)** -2.1 (1.6) -8.3 (2.3)**
Diastolic Blood Pressure (mmHg)
baseline  74 (10) 82 (10)** 74 (11) 79 (10)**
follow-up  73 (9) 79 (10)** 73 (10) 74 (9)
change -0.3 (6.6) -3.6 (1.0)** -0.6 (0.8) -4.8 (1.1)**
Antihypertensive treatment (%) 
baseline 15.7 37.1** 17.9 53.9**
follow up 24.8 67.1** 33.3 72.3**
change 12.6 36.8** 18.8 22.6**
Number of antihypertensives
baseline 0.22 0.60** 0.27 0.97**
follow-up 0.39 1.18** 0.49 1.40**
change 0.17 0.58** 0.22 0.43**
ACEi or A2A treatment (%)
baseline 5.2 15.7** 7.1 23.1**
follow-up 11.1 49.4** 13.6 44.6**
change 7.9 36.8** 9.3 24.2**
Serum cholesterol (mmol/L)
baseline 5.64 (1.13) 6.10 (1.34)** 5.74 (1.11) 5.99 (1.52)*
follow-up 5.43 (1.05) 5.55 (1.10) 5.39 (1.10) 5.41 (1.10)
change -0.21 (0.93) -0.55 (0.13) -0.35 (0.10) -0.58 (0.17)
Lipid lowering drugs (%)
baseline 5.1 12.9** 4.8 18.2**
follow-up 11.8 28.0** 10.7 33.3**
change 8.0 17.2** 8.7 12.1**
Urinary Albumin Excretion (mg/d)
baseline  9.2 (6.3-16) 510.5 (359.2-1075)** 19.3 (9.2-85) 24.7 (7.9-85)**
follow-up 8.7 (6.1-16) 468.7 (171.5-1042)** 16.3 (7.4-43) 23.4 (9.3-163)**
change 0.2 (2.4-2.8) -77.0 (-295.2-303.9)** -1.2 (-11.4-5.9) 0.1 (-7.2-22.2)
Erythrocyturia positive (%)
baseline 1.4 5.8* 100** 2.9
follow-up 1.7 5.8* 18** 0
change 0.3 0 -82** -2.9
eGFR (mL/min/1.73m2) 
baseline 80.8 (14) 67.8 (19)** 76.5 (13)** 45.5 (10)**
follow-up 78.5 (17) 60.5 (20)** 73.8 (15)** 45.3 (14)**
change -2.3 (12.3) -7.2 (1.2)** -2.6 (1.0) -0.2 (1.1)**
*  P<0.05 versus total population minus the specific group under investigation
* *  P<0.01 versus total population minus the specific group under investigationChapter 3
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In  contrast,  only  individuals  with 
macroalbuminuria  but  not  those 
with  impaired  renal  function  at 
baseline  had  a  greater  loss  of  renal 
function  during  follow-up  than  the 
control  population.  Individuals  with 
erythrocyturia do not show a worse 
cardiovascular  and  renal  prognosis, 
although they - just as the individuals 
with  macroalbuminuria  and  with 
impaired  renal  function  -  have  a 
higher  noncardiovascular  mortality. 
The prevalence of these three renal 
risk  markers  is  low  in  the  general 
population, and there is little overlap 
among the three. Last, only a minority 
of  the  individuals  who  were  found 
positive were already known to have 
the abnormality.
Our  finding  of  an  increased 
cardiovascular  morbidity  and 
mortality in individuals with macroalbuminuria as well as in individuals with an impaired 
renal function is in agreement with literature: several studies reported a high cardiovascular 
morbidity and mortality among individuals with albuminuria [19–21] and among individuals 
with  impaired  renal  function  [22].  The  finding  that  macroalbuminuria  is  predictive  of 
accelerated renal function loss also is compatible with data from other studies. Iseki et 
al. [13] showed in a large cohort of Japanese individuals who were followed for 17 yr that 
proteinuria as measured by dipstick was predictive of later risk to reach ESRD. It also is 
in line with data in patients with known primary renal disease, in whom proteinuria has 
been found to be a strong risk marker for progressive loss of renal function [23]. Surprising, 
however, eGFR did not fall in the group with impaired renal function at baseline. This 
finding is in line with a recent study in England in individuals with a median eGFR of 28.5 
ml/min per 1.73 m2. The majority of these individuals had stable renal function over 31 
mo [24]. An explanation for the unexpected finding of stable renal function in a group of 
individuals who were selected on the basis of impaired renal function at baseline can be the 
phenomenon of “regression to the mean.” This phenomenon contains two aspects. First, 
regression to the mean can be caused by day-to-day variations of renal function in a given 
individual and, second, to imprecision in the measurement. For instance, individuals who 
collected 24-h urine inadequately at the baseline study well may deliver a better collected 
sample at the second screening. We tried to overcome this bias by requiring not only a low 
24-h creatinine clearance but also a low eGFR according to the MDRD formula, the latter 
not being dependent on urinary values. This leaves us with the possibility of an imprecise 
measurement of plasma creatinine (which is included in both measures of GFR). Therefore, 
regression to the mean cannot be ruled out. The influence of this source of bias can be 
investigated by checking renal function on several occasions over time. Fortunately, the 
PREVEND study is an ongoing cohort study. Participants are seen at our outpatient clinic at a 
3- to 4-yr interval. We were able to do an interim analysis with data of the 4.772 individuals 
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Figure 2. Renal function loss in the different groups 
during 6 yr of follow-up; results of an interim analysis 
performed with data from the third screening.Chapter 3
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who already participated in the third screening. eGFR of the individuals with impaired renal 
function stayed nearly constant, even between the second and third screenings, whereas 
eGFR deteriorated along a straight line in individuals with macroalbuminuria (Figure 2). 
Individuals with impaired renal function at baseline experienced less renal function decline 
during follow-up compared with the overall population. Although these individuals used 
more  interfering  medication,  BP,  glucose,  and  cholesterol  levels  at  baseline  and  during 
follow-up still were higher (or equal) to values in the total population. This suggests that 
the low rate of renal function loss in this group is not due to better medical management 
of this group. Consequently, we conclude from our data that screening on the basis of 
determination of renal function impairment and subsequent treatment may be useful to 
prevent cardiovascular events. It is unlikely, however, that such screening may be helpful to 
prevent progressive renal function deterioration.
The individuals with erythrocyturia showed no significant renal function decline compared 
with the control population. This finding seems at odds with a previous epidemiologic study 
that was performed in the Okinawa region of Japan. Iseki et al. [13,25] used a dipstick to 
identify  people  with  proteinuria  and  erythrocyturia.  They  found  that  both  parameters 
predicted long-term renal function outcome, as assessed by the incidence of ESRD. Of note, 
in this study, only men with erythrocyturia showed a higher risk for ESRD. This is in contrast 
with our data, which do not show a negative impact of erythrocyturia. These contradictory 
findings may be explained by the fact that the study by Iseki et al. was performed in a 
Japanese population, which is known for a relatively high incidence of lupus nephritis and 
IgA nephropathy, both diseases that are characterized in general by erythrocyturia and 
progressive renal function loss [26,27]. Most likely, our data on erythrocyturia do not point 
to a specific renal disease. First, two thirds of the individuals with erythrocyturia at first 
screening consisted of relatively younger women. Second, the presence of erythrocyturia 
showed almost no overlap with the two other risk markers for renal disease, proteinuria, and 
renal function impairment. Third, only in 18% of the individuals with erythrocyturia did this 
abnormality persist at the second screening. Although individuals were asked specifically 
to refrain from urine collection during menstruation, we hypothesize that, at least in part, 
erythrocyturia may be due to menses or to urologic disorders. In concordance with our 
observation, another Japanese study showed that erythrocyturia indicated a higher risk 
for development of renal insufficiency only in combination with proteinuria [28]. On the 
basis of these data, it can be concluded that screening for erythrocyturia is not effective for 
identifying patients who are at risk for rapid renal function decline in a white population.
Although our data argue that screening for macroalbuminuria may help to prevent better 
CVD and renal disease, we should realize that the prevalence of this renal abnormality is 
low in our population. The prevalence that we found is nearly similar to the low prevalence 
of macroalbuminuria that was found in the NHANES III population [29]. The low prevalence, 
of course, is related to the strict cutoff value that is used: UAE ≥ 300 mg/d in two 24-h 
urine collections. In prospective studies, renal function decline and UAE are associated in 
a continuous way [30,31]. It follows, then, that more individuals may be identified when 
the cutoff value for elevated UAE is lowered. The cutoff to be preferred is the value above 
which screening and intervention will be cost-effective [32]. The yield of screening to identify 
individuals who are at risk for renal function deterioration also may be increased by taking 
into account other risk factors, such as high BP, cholesterol, and glucose. The aim of our 
study, however, is not to design an integrated renal risk score but merely to investigate which 
of the three classical renal risk markers performs best in predicting renal function prognosis. 
Of note, the prevalence of impaired renal function also was found to be low, and lower than Chapter 3
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that described in the NHANES study [33] and in a previous publication of the PREVEND study 
[14]. In those reports, however, a fixed cutoff value of < 60 ml/min per 1.73 m2 was used. As 
described in the Materials and Methods section, we chose a more strict approach, aiming 
to identify individuals with the worst renal function, independent of the age- and gender-
related influence on GFR.
Most of the individuals who were positive for these putative renal risk markers were not 
known to have that abnormality. This is in line with data that most individuals with minor 
renal damage are not aware of this [7]. Of note, we found little overlap among the three 
groups with putative renal risk markers. A similar finding was reported from the NHANES 
III study, in which screening for albuminuria and renal failure resulted in the identification 
of two different segments of the population [29]. In this study, 37% of the individuals with 
renal insufficiency (defined as GFR < 30 ml/min) demonstrated no microalbuminuria or 
macroalbuminuria. The authors suggested that their results confirmed that comprehensive 
screening initiatives may need to integrate a number of different criteria to identify individuals 
who are at risk for ESRD and that different criteria may be valuable in different age groups or 
at-risk populations (e.g., individuals with hypertension or diabetes).
Our study has some limitations. First, not all questionnaires were returned by the general 
practitioners, and objective follow- up data were available in only 80% of participants. 
However, the baseline characteristics of the participants who were lost to follow-up were 
not significantly different from the participants for whom follow-up was available. It is 
likely, however, that loss to follow-up will be encountered especially in those who are in 
poor health. It therefore can be expected that, if anything, our results will underestimate 
health care outcome, whereas our main message is that the presence of macroalbuminuria 
heralds bad renal and cardiovascular prognosis. Second, in our study, we used a dipstick test 
to measure erythrocyturia. Complementary microscopic analyses perhaps could increase 
the  ability  to  predict  renal  disease,  because  it  is  possible  to  distinguish  a  nephrologic 
from a urologic origin of erythrocyturia [26,34]. Another solution could be to screen for 
erythrocyturia more than once to separate persistent erythrocyturia from erythrocyturia 
that is caused by, for example, menses. In large-scale screening projects, however, neither 
option is feasible. Third, our results with regard to mortality, morbidity, and renal function loss 
probably are an underestimation of the natural course. After the identification of individuals 
with a laboratory abnormality in our screening program, some of them were treated with 
antihypertensive  medication.  Intervention  can  have  a  biasing  effect  on  follow-up  data. 
However, this is the same for all three groups under investigation. For this reason, it is not 
likely that these effects influence the notion of our conclusion that only macroalbuminuria 
heralds a poor renal prognosis. Fourth, “competing” risk bias may have influenced our results 
(e.g., participants who died or were lost to follow-up in the impaired renal function group 
may have experienced more renal function decline than the participants for whom follow-
up data are available, thus resulting in a lower rate of renal function decline in this group 
of participants in comparison with the participants with macroalbuminuria). We therefore 
performed sensitivity analyses on the basis of worstcase scenarios. These analyses provide 
figures that are highly unlikely from a clinical point of view, suggesting that competing risk 
bias, if present, cannot explain fully the observed difference in rate of renal function decline 
between the groups with macroalbuminuria and impaired renal function at baseline. Finally, 
the PREVEND study is performed in a predominantly white population. Our results therefore 
may not be valid for other, nonwhite populations.Chapter 3
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Conclusion
Most individuals who were identified by this screening were not known to have or were 
treated  for  their  laboratory  abnormality.  Individuals  with  impaired  renal  function  or 
macroalbuminuria are at risk for both cardiovascular morbidity and mortality. However, 
screening for macroalbuminuria is a better strategy than screening for low eGFR to identify 
individuals who are at risk for accelerated GFR loss in population screening. Although the 
prevalence of macroalbuminuria is low, the outcome with regard to renal function decline 
and cardiovascular morbidity and mortality justify screening, because these individuals are 
likely to benefit from early cardio- and renoprotective strategies.Chapter 3
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Abstract
The  long-term  effects  of  higher  dietary  protein  intake  on  cardiovascular  and  renal 
outcomes in the general population are not clear. We analyzed data from 8461 individuals 
who did not have renal disease and participated in two or three subsequent screenings 
(6.4-yr follow-up) in a prospective, community based cohort study (Prevention of Renal 
and  Vascular  ENd-stage  Disease  [PREVEND]).  We  calculated  daily  protein  intake  from 
24-h urinary urea excretion (Maroni formula) and used Cox proportional hazard models 
to analyze the associations between protein intake, cardiovascular events, and mortality. 
We used mixed-effects models to investigate the association between protein intake and 
change in renal function over time. The mean ± SD daily protein intake was 1.20 ± 0.27 g/kg. 
Protein intake was significantly associated with cardiovascular events during follow-up. The 
associations seemed U-shaped; compared with intermediate protein intake, individuals 
with either higher or lower protein intake had higher event rates. All-cause mortality 
and noncardiovascular mortality also were significantly associated with protein intake; 
individuals with low protein intake had the highest event rates. We found no association 
between baseline protein intake and rate of renal function decline during follow-up. In 
summary, in the general population, high protein intake does not promote accelerated 
decline of renal function but does associate with an increased risk for cardiovascular events.Chapter 4
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Introduction
Protein  restriction  is  often  prescribed 
to  slow  the  progression  of  renal  failure 
in  patients  with  chronic  kidney  disease 
(CKD). The Modification of Diet in Renal 
Disease  (MDRD)  study,  designed  to 
clarify  the  role  of  protein  restriction  in 
CKD, supports the role of dietary protein 
restriction  but  provides  no  conclusive 
evidence for renoprotection. [1,2] Meta-
analyses on this topic also do not provide 
convincing  results.  Uncertainty  about 
the optimal level and duration of dietary 
protein  restriction,  together  with  the 
possibility of publication bias, which has 
been  suggested  by  the  authors  of  two 
meta-analyses, [3,4] make it questionable 
whether  low-protein  diets  should  be 
applied  to  patients  with  CKD.  In  the 
Nurses’  Health  Study,  the  influence  of 
daily  protein  intake  (assessed  with  a 
food frequency questionnaire) on the long-term course of renal function was investigated 
in individuals with normal renal function and in individuals with mild renal insufficiency. 
In this study, high protein intake was associated with accelerated renal function decline in 
individuals with a baseline renal function 80 ml/min per 1.73m2 but not in women with normal 
renal function.[5] A few studies have been published on the effects of protein intake on all-
cause mortality, in particular on cardiovascular morbidity and mortality. Interest in these 
effects was based on the fact that in Western populations, dietary pattern changes toward 
diets with high protein intake. Indeed, low-carbohydrate diets, which frequently contain 
a high amount of protein, have become very popular to prevent obesity. [6–10] In one of 
these studies, carried out in a cohort of Swedish women, high protein intake in middle-aged 
women was associated with a higher cardiovascular mortality. [11]  These findings, however, 
were not in line with the results of the Nurses’ Health Study, which showed a decreased 
risk for coronary heart disease in individuals with high protein intake. [12,13] The effect of 
high protein intake on both renal function and cardiovascular mortality and morbidity in the 
general population is thus not well known; therefore, the aim of our study was to investigate 
the associations between protein intake and cardiovascular and renal outcomes in a cohort 
derived from the general population.
Methods
Study Design and Population 
The analyses are based on data of individuals who participated in the first three screening 
rounds  of  the  Prevention  of  Renal  and  Vascular  ENd-stage  Disease  (PREVEND)  study. 
This is a prospective cohort study, designed to investigate the impact of urinary albumin 
excretion on renal and cardiovascular outcomes in the general population. Details of the 
study protocol have been published elsewhere. [24,25] In summary, in 1997 through 1998, 
Figure 1. Outline of the PREVEND study cohort; first 
three screenings.Chapter 4
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Table 1. Baseline characteristics per gender-stratified quintile of daily protein intake
Characteristic 
Gender-stratified quintiles of daily protein intake (g/kg) 
First  Second Third Fourth Fifth P for trend 
Male  0.26 to 0.99 0.99 to 1.13 1.13 to 1.26 1.26 to 1.42 1.42 to 3.27  
Female  0.39 to 0.96 0.96 to 1.10 1.10 to 1.22 1.22 to 1.38 1.38 to 2.88  
N  1692 1692 1693 1692 1692  
Age (yr)b  49.0 (13.3) 50.0 (13.3) 49.7 (12.9) 50.0 (12.4) 50.2 (11.4)  0.010
Smoking (%)  51.4 40.0 34.4 32.7 31.9   <0.001
Cardiovascular 
disease history (%) 
13.8 12.1 11.9 9.7  10.1  <0.001
Weight (kg)b  75.1 (13.4) 76.3 (13.2) 77.3 (13.8) 79.6 (14.0) 82.8 (15.5)  <0.001
BMI (kg/m2)b  24.6 (3.8) 25.3 (3.6) 25.7 (3.8) 26.6 (4.0) 28.2 (4.2) <0.001
SBP (mmHg)b  127 (21) 129 (21) 129 (21) 130 (20) 131 (20) <0.001
DBP (mmHg)b  73 (10) 74 (10) 74 (10) 74 (10) 75 (10)  <0.001
Cholesterol 
(mmol/L)b 
5.6 (1.2) 5.6 (1.1) 5.6 (1.1) 5.7 (1.1) 5.7 (1.1) <0.001
Triglycerides 
(mmol/L)c
1.2 (0.9 to 1.7) 1.1 (0.8 to 1.7) 1.1 (0.8 to 1.7) 1.2 (0.8 to 1.7) 1.2 (0.9 to 1.8)  NS
Glucose (mmol/L)b 4.7 (1.0) 4.8 (1.0) 4.9 (1.2) 4.9 (1.1) 5.1 (1.5)  <0.001
CRP (mg/L)c  1.3 (0.5 to 3.0) 1.2 (0.6 to 2.9) 1.2 (0.5 to 2.9) 1.3 (0.5 to 2.9) 1.5 (0.6 to 3.2)  NS
UAE (mg/24 h)c  7.8 (5.4 to 14.2) 8.9 (6.0 to 16.1) 9.5 (6.4 to 16.7) 10.0  (6.6  to 
19.3)
11.4  (7.4  to 
23.6) 
 <0.001
Urinary urea 
excretion
(mmol/24 h)b 
233 (53) 303 (48) 349 (52) 398 (61) 487 (88)   <0.001 
Urinary sodium 
excretion 
(mmol/24 h)b
106 (39) 127 (40) 141 (43) 154 (46) 180 (54)   <0.001
eGFR (ml/min per 
1.73 m2)b 
81.2 (15.7) 80.1 (15.1) 80.4 (14.2) 80.2 (13.7) 81.1 (13.8)  NS
CRP, C-reactive protein; DBP, diastolic BP; IQR, interquartile range; SBP, systolic BP; UAE, urinary albumin excretion.
bMean (SD).
cMedian (IQR).
all inhabitants of the city of Groningen (Netherlands) aged between 28 to 75 yr were sent 
a questionnaire and a vial to collect a first morning void urine sample. Of these individuals, 
40.856 (47.8%) responded and sent a vial to a central laboratory for urinary albumin and 
urinary creatinine assessment. From these 40.856 individuals, the PREVEND cohort was 
selected with the aim to create a cohort enriched for the presence of high albuminuria. After 
exclusion of patients with type 1 diabetes and pregnant women, all individuals with urinary 
albumin concentration ≥ 10 mg/l (n = 7.768) were invited, 6.000 of whom participated. 
Furthermore, a randomly selected cohort group with urinary albumin concentration < 10 
mg/l (n = 3.394) was invited, 2.592 of whom participated. These 8.592 individuals form the 
actual PREVEND cohort. At approximately 3-yr intervals, participants in this study are invited 
to visit an outpatient department for measurements concerning their health. In total, 8.592 
participants completed the baseline screening in 1997 through 1998. For this study, we Chapter 4
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excluded individuals who indicated having a known renal disease (n = 22) and/or missing data 
on protein intake (n = 109) during the first screening round, leaving data of 8.461 individuals 
for analysis. Data on mortality and morbidity are available from these 8.461 individuals. 
During the interval between the first and the third screenings, 373 individuals died (Figure 
1). The second screening took place from 2001 through 2003 and the third from 2003 
through 2006. Overall, 5.778 individuals completed the third screening round. Data on the 
slope of renal function over time are available from individuals who completed two or three 
screening rounds. The PREVEND study is approved by the local medical ethics committee and 
conducted in accordance with the guidelines of the Declaration of Helsinki. All participants 
gave written informed consent.
Measurements and Definitions
Each screening round consisted of two visits to an outpatient department separated by 
approximately 3 wk. Participants filled out a questionnaire on demographics; cardiovascular 
and renal history; smoking status; and the use of oral antidiabetic, antihypertensive, and 
lipidlowering drugs. Smoking was defined as current smoking or cessation of smoking 1 yr 
before the baseline screening (first screening round). Information on drug use was completed 
with data from community pharmacies. During both study visits per screening round, BP was 
measured in the right arm every minute for 10 and 8 min, respectively, with an automatic 
Dinamap XL Model 9300 series device (Johnson-Johnson Medical, Tampa, FL). For systolic 
and diastolic BP, the mean of the last two recordings from each of the two visits was used. 
Anthropometric measurements were performed, and fasting blood samples were taken. 
In addition, individuals collected urine for two consecutive periods of 24 h. Concentrations 
Table 2. Numbers of cardiovascular events, all-cause mortality, and noncardiovascular mortality 
and mean change in renal outcome per year, and accompanying event rates per quintile of daily 
protein intake
Gender-stratified quintiles of daily protein intake (g/kg/day)
Parameter First
(0.26 to 
0.99)
Second
(0.96 to 
1.13)
Third
(1.10 to 
1.26)
Fourth
(1.22 to 
1.42)
Fifth
(1.38 to 
3.27)
P for 
trend
N 1696 1697 1697 1697 1696
Cardiovascular 
events (n)
121 116 110 102 119 <0.001
Event rate (no. of 
events per 1000 
patient-years)
10.4 9.9 9.1 8.5 9.9
All-cause mortality 
(n)
123 93 79 77 71 <0.001
Event rate (no. of 
events per 1000 
patient-years)
10.3 7.7 6.4 6.3 5.8
Non-cardiovascular 
mortality (n)
94 65 52 45 48 <0.001
Event rate (no. of 
events per 1000 
patient-years)
7.8 5.4 4.2 3.7 3.9
Change in eGFR 
(ml/min/1.73m2/yr)
-0.45 -0.46 -0.50 -0.41 -0.41 NSChapter 4
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of total cholesterol, HDL cholesterol, triglycerides, plasma glucose, C-reactive protein, and 
urinary urea and sodium were measured using standard methods. Dietary protein intake was 
calculated by the method of Maroni and colleagues. [21,22] in each of the two 24-h urine 
collections obtained during the first screening round. For each individual, we expressed the 
estimates of dietary intake per kilogram of “ideal” or “desirable” body weight, derived from 
the BMI equation (weight/height2), and obtained by multiplying the squared value of height 
times a reference BMI value of 22. Dietary sodium intake was calculated based on the daily 
urinary excretion of sodium in the two 24-h urine collections and expressed per kilogram of 
ideal body weight. Urinary albumin concentration was determined by nephelometry (Dade 
Behring Diagnostic, Marburg, Germany), and urinary albumin excretion was given as the 
mean of the two 24-h urinary excretions obtained during the first screening round. Serum 
creatinine was measured by dry chemistry (Eastman Kodak, Rochester, NY), with intra- and 
interassay coefficients of variation of 0.9 and 2.9%, respectively. eGFR was calculated using 
the MDRD study equation, taking into account gender, age, race, and serum creatinine. [26]
Outcome Variables
For cardiovascular outcome, we used the combined incidence of cardiovascular morbidity 
and cardiovascular mortality after the first screening round. Data on mortality were received 
through the municipal register. Cause of death was obtained by linking the number of the 
death certificate to the primary cause of death as coded by the Dutch Central Bureau of 
Statistics. Noncardiovascular mortality was defined as mortality not related to any of the 
cardiovascular causes mentioned at the end of this paragraph. Information on hospitalization 
for cardiovascular morbidity was obtained from PRISMANT, the Dutch national registry of 
hospital discharge diagnoses. The validity of this database has been shown to be good, with 
84% of the primary diagnoses and 87% of the secondary diagnoses matching the diagnoses 
found  in  the  patient  chart.  [27,28]  All  data  were  coded  according  to  the  International 
Classification of Diseases, Ninth Revision (ICD-9) and the classification of interventions. For 
this study, cardiovascular events were defined as acute myocardial infarction (ICD-9 code 
410), acute and subacute ischemic heart disease (ICD-9 411), subarachnoid hemorrhage 
(ICD-9 430), occlusion or stenosis of the precerebral (ICD-9 433) or cerebral arteries (ICD-
9 434), coronary artery bypass grafting or percutaneous transluminal coronary angioplasty, 
and other vascular interventions such as percutaneous transluminal angioplasty or bypass 
grafting  of  aorta  and  peripheral  vessels.  Survival  time  was  defined  for  cardiovascular 
outcome as the period from the date of urine collection to the date of first cardiovascular 
event or December 31, 2005 (end of follow-up). For all-cause mortality, survival time was 
defined as the period from the date of urine collection to the date of death or December 
31, 2005 (end of follow-up). In case a person moved to an unknown destination, the date on 
which the person was removed from the municipal registry was used as censored date. Data 
on renal outcome were obtained from the yearly decline of renal function as calculated by 
the slope of a linear regression line fitted between the two or three serial estimates of GFR 
using least squares regression.
Statistical Analyses
Continuous data are reported as means ± SD. For skewed distributions, the median and 
interquartile range are presented. All P values are two-tailed. P < 0.05 was considered 
statistically significant. Baseline characteristics of our study population are shown with the 
population subdivided into gender-corrected quintiles of protein intake (Table 1). Differences 
in the characteristics among protein intake quintiles were tested for statistical significance Chapter 4
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by χ2 analysis for dichotomous data or ANOVA for continuous data. We performed mixed-
effects models with random intercepts and random slopes to investigate the association 
between protein intake and renal function decline. Such a model estimates the rate of change 
in eGFR over time within and between individuals, taking into account correlations within 
individuals and time, including also individuals with only one or two eGFR measurements. 
[29] To study the impact of protein intake on cardiovascular events and all-cause mortality, 
we used Cox proportional hazard analyses. We performed all analyses univariate, corrected 
only for age and gender and corrected additionally for known cardiovascular risk factors, 
for sodium intake, and finally for BMI. The traditional known cardiovascular risk factors 
we  used  for  adjustment  were  positive  cardiovascular  disease  history,  smoking,  systolic 
BP,  cholesterol/HDL  cholesterol  ratio,  triglycerides,  and  plasma  glucose.  In  each  model, 
we tested for presence of nonlinear associations by adding the quadratic term of protein 
intake to the model. A nonlinear association was considered significant at P < 0.05. We 
tested possible effect modification by implementing interaction terms. The Cox proportional 
hazards assumptions were checked and met. The models were also tested for collinearity. 
For Figure 2, we performed all analyses treating the gender-stratified quintiles of protein 
intake as categorical factors. All analyses were conducted with the use of the statistical 
package SPSS 14.0 (SPSS, Chicago, IL).
Sensitivity Analyses
First, we performed a sensitivity analysis repeating our analyses including only individuals 
with a stable protein intake. We defined stable protein intake as a difference in protein intake 
between the first and second screening rounds of 10%. Second, we performed our analyses 
using protein intake corrected for measured body weight instead of ideal body weight. Last, 
we performed all regression analyses using the “weight” function in R 2.5.0.
Results
Mean ± SD daily protein intake was 1.20 ± 0.27 g/kg for the total population, 1.21 ± 0.27 g/
kg for men, and 1.18 ± 0.26 g/kg for women. Daily protein intake varied widely between 
individuals,  with  the  5th  and  95th  percentiles  being  0.80  to  2.66  g/kg.  Of  the  8.461 
individuals, 502 had an estimated GFR (eGFR) 60 ml/min per 1.73 m2. The characteristics of 
our study population according to the gender-stratified quintiles of protein intake are listed 
in Table 1. In the highest compared with the lowest quintiles of protein intake, individuals 
were heavier and had higher BP, cholesterol, plasma glucose, urinary albumin, and sodium 
excretion. In contrast, the percentage of smokers was lowest in the quintile with the highest 
protein intake, as was the prevalence of a previous cardiovascular disease history. eGFR did 
not differ over the quintiles of protein intake.
Mean follow-up for cardiovascular events was 7.0 ± 1.6 yr, resulting in 59.240 person-years 
of follow-up. The incidence of cardiovascular events during follow-up was highest in the first 
and last quintiles of protein intake (Table 2). The association between protein intake (used as 
a continuous variable) and cardiovascular event rate seemed to be significant and not linear 
but U-shaped. The quadratic term of protein intake could be added to these Cox regression 
models (crude, adjusted for age and gender and adjusted for known cardiovascular risk 
factors [all P < 0.05]). Figure 2 shows the graphic representation of the associations under 
investigation; for these figures, we divided protein intake in quintiles.
Of  note,  the  P  values  in  the  figures  refer  to  the  associations  with  protein  intake  as  a 
continuous variable included in the models. Figure 2A shows the graphic representations of 
the association between protein intake and cardiovascular event rate, corrected for age and Chapter 4
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Figure 2. (A through D) Associations between protein intake (for these figures divided in quintiles) 
and cardiovascular events (A), all-cause mortality (B), noncardiovascular mortality (C), and change in 
renal function (D). (Left) Data adjusted for age and gender. (Right) Data with additional adjustment 
for known cardiovascular risk factors. The P values are based on the Cox proportional hazard and 
mixed-effects models in which protein intake is treated as a continuous variable. These models are 
described in detail in the Results section.Chapter 4
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gender and also corrected for known cardiovascular risk factors. After these adjustments, 
this  association  still  remained  statistically  significant.  To  check  whether  the  association 
between protein intake and the incidence of cardiovascular events was confounded by the 
amount of sodium intake or body mass index (BMI), we also adjusted the model for these 
variables. These adjustments did not materially affect
our findings.
We  next  investigated  the  association  of  protein  intake  with  all-cause  mortality  and 
noncardiovascular mortality. Duration of follow-up for these variables was 7.2 ± 1.3 yr. The 
unadjusted results in Table 2 and the graphic representation of the adjusted Cox regression 
models in Figure 2, B and C, show a negative association between protein intake and all-cause 
and noncardiovascular mortality. Adjustment for age and gender, known cardiovascular risk 
factors, sodium intake, and BMI did not change these results. These associations were also 
analyzed in Cox regression models treating protein intake as a continuous variable. In all of 
these models, protein intake was significantly (negatively) associated with the incidence of 
all-cause and noncardiovascular mortality. The P values in Figure 2, B and C, refer to the 
results of these models.
The change in renal function over time did not differ between the quintiles of protein intake 
(Table 2). To investigate further the relation between the change in renal function, we analyzed 
our data in a mixed-effects model. In the univariate model, no significant association was 
found between the amount of protein intake and the change in renal function. Adjustment 
for age and gender and also further adjustment for known cardiovascular risk factors and 
for sodium intake and BMI did not change these results (Figure 2D). The P values in Figure 
2D refer to the results of the mixed-effects models in which protein intake was treated as a 
continuous variable.
We repeated our analyses by including only individuals with a stable amount of protein 
intake. We also repeated our analyses with the amount of protein intake corrected for 
measured body weight instead of “ideal” body weight. These sensitivity analyses did not 
change our results essentially. Of note, in the final model, including protein intake, age, 
gender, and cardiovascular risk factors, daily sodium intake was not associated with the 
incidence  of  cardiovascular  events,  all-cause  mortality,  noncardiovascular  mortality,  or 
renal function decline. All regression analyses were also performed with inverse weighting 
to correct for the oversampling of individuals with an elevated urine albumin excretion. 
The results we obtained with these weighted analyses were in general comparable with 
the results of the unweighted analyses; however, the association between protein intake 
and noncardiovascular mortality corrected for the cardiovascular risk factors was no longer 
statistically significant in the weighted analyses. Furthermore, we checked our full models 
for effect modification. For that purpose, we added to our models interaction terms between 
protein intake and all of the confounders we adjusted for in our analyses (age, gender and 
cardiovascular risk factors). Interaction terms with P < 0.05 were considered to be significant. 
No significant interactions were found.
Discussion
In this study, we show that, in the general population, a higher protein intake is associated 
with  a  higher  incidence  of  cardiovascular  events.  This  effect  remained  significant  after 
adjustment for cardiovascular risk factors. Second, individuals with the lowest protein intake 
also had a higher cardiovascular event rate. In the latter group, however, noncardiovascular 
and allcause mortality were also higher. We could not show an effect of protein intake on the 
progression of renal function loss.Chapter 4
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The association between high protein intake and high incidence of cardiovascular morbidity 
and mortality is in agreement with some [11] but in contrast with other data. [13] A study of 
42237 Swedish women, 30 to 49 yr of age, showed that a high-protein diet was associated 
with a higher risk for death from cardiovascular causes, whereas the association they found 
between high protein intake and all-cause mortality was NS, as in our study. The unfavorable 
effect of a high-protein diet in the Swedish study, however, was limited to the subgroup of 
women in the age of 40 to 49 yr. [11] In contrast, in the 80,082 women of the Nurses’ Health 
Study, aged 34 to 59 yr, a lower risk for ischemic heart disease was found in individuals with 
a higher intake of total protein.13 There are several reasons to interpret the differences in 
the described impact of a high-protein diet on cardiovascular events. First, the cited studies 
were performed only on women, whereas we included both genders; however, we found 
no interaction between gender and protein intake with outcome. Second, the cited studies 
had a more narrow age range of individuals included than our study. Again, however, in 
our study, no interaction was found between age and protein intake with outcome. Third, 
the cited studies used food frequency questionnaires or 24-h recalls instead of the Maroni 
formula to investigate protein intake. It is known that questionnaire-based methods are 
associated with both random and systematic error.[14,15] Fourth, we are not aware on the 
type of protein ingested. It has been reported, for instance, that the intake of vegetable 
and animal proteins have different effects on cardiovascular outcome, [16] although data 
from the Nurses’ Health Study showed that both animal and vegetable proteins contributed 
similarly. [13] Fifth, it may be that high protein intake is accompanied by other changes in 
the diet, such as a lower carbohydrate and fiber intake, [17] a higher salt intake, and/or a 
change in the total energy intake; therefore, the association we found between high protein 
intake and high cardiovascular event rate may be (partly) accounted for by effects of other 
nutrients whose intake is correlated with protein intake or by a change in total energy intake. 
For instance, in one study, salt intake by itself, also independent of BP, was found to be 
associated with a higher cardiovascular event rate. [18] Although we are not informed on 
the carbohydrate and fiber content of the diet or on total energy intake, we have data on 
salt intake (indirectly obtained from daily sodium excretion) and BMI (as proxy for energy 
intake). In our study protein intake seemed to be positively associated with salt intake. We 
found, however, that adjustment for differences in salt intake or BMI did not influence our 
conclusions. Finally, the cited studies expressed protein intake as percentage of total energy 
intake but did not offer precise information on the impact of protein intake itself.
There are several possible explanations for the association we found between high protein 
intake  and  increased  incidence  of  cardiovascular  events.  It  is  likely  that  the  intake  of 
more protein causes a change in cardiovascular risk factors, which in turn causes a higher 
cardiovascular event rate. Recently, it was indeed described that a diet high in protein and low 
in carbohydrate is associated with an increased prevalence of the metabolic syndrome. [19]   
In line with these data, our results also show increases in most components of the metabolic 
syndrome and in cardiovascular risk factors over the quintiles of protein intake. This can 
be only part of the explanation, however, because the association between high protein 
intake and cardiovascular event rate is still significant after adjustment for cardiovascular risk 
factors. We surprisingly found that low protein intake was also associated with an increase in 
cardiovascular events. Because low protein intake was also associated with a high incidence 
of all-cause and of noncardiovascular mortality, however, we suggest the observed effects 
of low protein intake to be due to malnutrition induced by poor health status of this group. 
[20] In line with that assumption is that body weight was lowest in this group, they contained 
the largest number of smokers, and they more often had a family history of cardiovascular Chapter 4
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disease. Again, however, the effect remained significant after adjustment for these factors.
Our finding of the absence of an effect of protein intake on renal outcome in individuals with 
normal renal function is compatible with results of the Nurses’ Health Study. [5] Thus far, 
most other studies investigating the effect of protein intake on renal outcome have been 
performed on individuals with CKD [1,2] and are therefore difficult to compare with this 
study. We investigated the association between daily protein intake and renal outcome in 
a large population-based cohort. Although the range of daily protein intake between these 
individuals varied widely from 0.3 to 3.3 g/kg, we did not find a relation between protein 
intake and rate of renal function loss over time, even in the subgroup of individuals with 
an eGFR < 60 ml/min per 1.73 m2 and/or individuals with microalbuminuria. It has to be 
emphasized, though, that our study is observational in design. Our data therefore do not 
exclude the possibility that lowering of protein intake in some individuals would favor their 
renal prognosis.
For this study, we estimated protein intake using the Maroni formula, [21] not using food 
frequency questionnaires. The use of this formula will be called a strength by some because 
of the objective way of measuring protein intake and a limitation by others because of the 
lack of detailed information about food intake (e.g., kind of protein and amount of energy 
intake). It has been proved, however, that this formula is a valid method to estimate actual 
protein intake, [22] whereas it is also known that questionnaire-based methods are associated 
with both random and systematic error. [14,15] Moreover, the average amount of protein 
we found in our population is comparable with the values reported in another study using 
the Maroni formula to estimate the amount of protein intake in a Japanese community-
based cohort. [23] Another limitation of this study is that the protein intake we measure 
is susceptible to fluctuations because it reflects protein intake of only a few days before 
the urine collection; therefore, we based our protein intake on the average of two 24-h 
urine collections. In addition, we performed a sensitivity analysis including only individuals 
with a small difference in protein intake between the first and the second screening rounds. 
The results of these analyses were comparable with the primary analyses. Furthermore, if 
fluctuations in measured protein intake would play a role, then they would “dilute” our results, 
whereas the most important conclusion in our study is that high protein intake is significantly 
associated with an increased risk for cardiovascular events. In general, a limitation of all large 
cohort studies is lack of detailed information on some of the potential confounders. This 
may limit the ability of the covariate adjustment to control for confounding. For instance, 
24-h urinary sodium excretion may not fully reflect an individual’s long-term sodium intake. 
Another limitation of our study may be the influence of loss to follow-up. Participants who 
died or were lost to follow-up for other reasons may have been in a worse condition of 
health. In general, such individuals have a higher rate of renal function decline; therefore, 
in our analyses, the impact of risk factors may have been underestimated. By using mixed-
effects model analyses, we took into account the potential bias induced by loss to follow-
up, because, in these analyses, available data of individuals who attended only one or two 
screenings are used.
Last, concerning the association between protein intake and change in renal function, we 
cannot exclude that longitudinal changes in creatinine generation during follow-up, resulting 
from changes in muscle mass or dietary habits, may have influenced the levels of serum 
creatinine and thus the estimated changes in eGFR.
One of the strengths of this study is the use of a large community-based cohort study with 
three eGFR measurements during follow-up and the availability of detailed information on 
cardiovascular risk factors and confounders. Furthermore, to our knowledge, it is one of the Chapter 4
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first studies investigating the effect of daily protein intake on both cardiovascular and renal 
outcomes in the general population.
In conclusion, we showed that high protein intake is associated with a higher incidence of 
cardiovascular events in the general population. This is clinically relevant as dietary patterns 
in the general population change toward more protein intake. In our cohort, with relatively 
normal renal function at baseline, we could not find unfavorable effects of a high-protein 
diet on renal outcome.Chapter 4
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Abstract
We sought to identify predictors of the decline in renal function, especially those that are 
modifiable, in the 5488 participants of the prospective, community-based cohort study 
PREVEND who completed three visits during a mean follow-up of 6.5 years. The change in renal 
function was used as the outcome and this was calculated as the linear regression of three 
estimated GFR measurements obtained during follow-up. Risk factors, known to influence 
renal outcome in patients with primary renal diseases, were used as potential predictors 
in multivariate regression analyses. High systolic blood pressure and plasma glucose were 
found to be independent predictors for an accelerated decline in function for both genders. 
In males, albuminuria was the strongest independent predictor for renal function decline, 
whereas in females albuminuria was univariately associated only after adjustment for age. 
The direction of the association between cholesterol/HDL ratio and decline of renal function 
differed by gender. Surprisingly, in males, waist circumference was an independent predictor 
and positively associated with renal function outcome. These studies show that there are 
gender differences in the standard predictors of the decline in renal function.Chapter 5
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Introduction
Chronic kidney disease (CKD) is a growing public health problem worldwide [1]. In 2000, 
approximately 300 000 patients had end-stage renal disease (ESRD) in the United States alone, 
and this number is expected to double by the year 2010 [2]. Furthermore, the earlier stages 
of CKD are expected to be about 80 times more prevalent [3]. Given these expectations, it 
is evidently important to identify risk factors of renal function decline. Such factors can be 
implemented in screening programs to identify subjects at high risk of renal function decline, 
who may benefit from early preventive treatment. 
Most studies that have been performed on this topic have reported on predictors of the 
development of CKD (eGFR<60 ml/min/1.73m2) or ESRD. However, the adverse consequences 
of renal insufficiency appear not to be limited to those whose renal function falls below 
a certain threshold. For instance, even subjects with relatively minor impairment of renal 
function are already at increased risk of cardiovascular disease [4-8]. The Hoorn study, a 
prospective  population-based  study  including  subjects  with  an  estimated  glomerular 
filtration rate (eGFR) ranging from 17 to 117 mL/min/1.73 m2, reported that a 5 ml/min/1.73 
m2 lower eGFR was associated with a 26% increase in the risk of cardiovascular death over 
the entire range of baseline renal function [4]. Therefore, we aimed to investigate predictors 
of renal function decline, especially modifiable ones, in subjects over a broad eGFR range. For 
this analysis, we used data of subjects who participated in a community-based prospective 
cohort study. As outcome variable we calculated for each participant the slope through three 
eGFR values over time. Multivariate regression analysis was applied to identify variables that 
were associated with renal function decline.
Methods
Study design and population
The analyses are based on data of subjects who participated in the first three screening 
rounds of the PREVEND (Prevention of Renal 
and Vascular ENd-stage Disease) study. This 
is a prospective cohort study, designed to 
investigate  the  impact  of  urinary  albumin 
excretion (UAE) on renal and cardiovascular 
outcome in the general population. In 1997-
1998 the participants of the PREVEND cohort 
were selected from 40856 inhabitants of the 
city of Groningen, the Netherlands. Selection 
was based on the albumin concentration in 
a  spot  morning  urine  sample  to  obtain  a 
cohort enriched for the presence of elevated 
albuminuria levels. At approximately 3-year 
intervals,  participants  in  this  study  are 
invited  to  visit  an  outpatient  department 
for measurements concerning their health 
status.  Details  of  the  study  protocol  have 
been published elsewhere [46,47].
In  total  8.592  participants  completed 
the  first  screening  round  in  1997-1998. 
Approximately 6.5 years later, from 2003-
Figure 1. Flowchart of the PREVEND studyChapter 5
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2006, the third screening round took place. During the interval between the first and the 
third screening round, 377 subjects died and 2.423 patients were lost to follow-up, however 
with vital status known (Figure 1). Thus, 5.862 subjects completed the third screening round. 
For the present study, we excluded subjects who indicated in a questionnaire to have a renal 
disease during the first screening round (n=22). Subjects with missing information on eGFR 
in one of the three screening rounds were also excluded (n=352), leaving 5.488 subjects 
for analysis. The PREVEND study was approved by the local medical ethics committee and 
conducted in accordance with the guidelines of the declaration of Helsinki. All participants 
gave written informed consent.
Measurements and definitions
Each screening round consisted of two visits to an outpatient department separated by 
approximately  three  weeks.  Participants  filled  out  a  questionnaire  on  demographics, 
cardiovascular and renal history, smoking status, menstrual status, and the use of oral 
antidiabetic,  antihypertensive  and  lipid  lowering  drugs.  A  positive  family  history  of 
cardiovascular disease was defined as having a first degree family member who experienced 
a cerebrovascular accident, myocardial infarction or intervention for peripheral vascular 
disease before the age of 65 years. Postmenopausal status for females was defined as the 
absence of menstruation for at least six months before the first screening. Smoking was 
defined as current smoking, or cessation of smoking less than a year before the baseline 
screening. Information on drug use was completed with data from community pharmacies. 
During both study visits per screening round, blood pressure was measured in the right arm, 
every minute for 10 and 8 minutes, respectively, by an automatic Dinamap XL Model 9300 
series device (Johnson-Johnson Medical INC, Tampa, Florida). For systolic blood pressure, 
the mean of the last two recordings from each of the two visits was used. Anthropometrical 
measurements were performed, and fasting blood samples were taken. In addition, subjects 
collected urine for two consecutive periods of 24 hours. Concentrations of total cholesterol, 
HDL-cholesterol, triglycerides, glucose, C-reactive protein, and urinary urea and sodium 
were measured using standard methods. Serum creatinine was measured by dry chemistry 
(Eastman  Kodak,  Rochester,  New  York,  USA),  with  intra-  and  interassay  coefficients  of 
variation of 0.9% and 2.9%, respectively. Urinary albumin concentration was determined 
by nephelometry (Dade Behring Diagnostic, Marburg, Germany), and UAE was given as the 
mean of the two 24-h urinary excretions. eGFR was estimated using the Modification of Diet 
in Renal Disease (MDRD) study equation, taking into account gender, age, race, and serum 
creatinine [48]. 
Statistical Analyses
Baseline characteristics of subjects included in the present analysis are given in table 1. 
Continuous data are reported as the mean and standard deviation. For skewed distributions, 
the median and interquartile range are presented. To identify risk factors of renal function 
decline we performed linear regression analyses. For all our regression models we used 
change in eGFR over time as outcome variable. This variable was defined for each subject 
as the slope of the linear regression line through their three eGFR measurements that were 
obtained at the consecutive screening rounds in the PREVEND study. As possible predictors 
of renal function decline, all variables tested are enlisted in table 1, as these have all been 
suggested to influence renal outcome in patients with known renal disease.  When necessary, 
these variables were Ln-transformed to obtain normal data distribution. First, we performed 
univariate regression analysis. Second, we repeated this analysis, with correction for age and Chapter 5
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gender, as these factors are non-modifiable. We also corrected for baseline eGFR to reduce 
the effect of regression to the mean. Third, we performed forward multivariate regression 
analysis. A P-value of 0.05 was adopted as the entry criterion for including variables in the 
regression model. Because of the reasons described above gender, age, and baseline eGFR 
were forced in the model. Because the use of medication interfering with the variables under 
study (e.g. antihypertensives) may influence results, we corrected the multivariate models 
(table 4 and 5) for the use of medication. All variables under study were tested for possible 
non-linear associations by adding quadratic terms to the multivariate regression model 
and to test their inclusion for statistical significance. Furthermore, we explored possible 
effect modification by implementing interaction terms, for all variables that significantly 
contributed to the multivariate regression model in the model. It was a priori decided that, in 
case a significant interaction was to be found, all models were to be built taking into account 
this interaction. Lastly, graphical representations were made of the final models, showing 
the relation between the most important predictors and the change in renal function. For 
this analysis the mean slope of renal function over time was calculated per quintile of each 
predicting variable.
All analyses were conducted with the statistical package SPSS 14.0 (SPSS, Chicago, IL). A 
P-value of 0.05 or less was adopted to indicate statistical significance.
Table  1.  Baseline  characteristics  for  the  overall  study  population  and  for  males  and  females 
separately
Overall (N= 5488) Males (N=2770) Females (N=2718) P value
Age (yrs) 49 (12) 50 (12) 48 (11) <0.001
Smoking (%) 34.5 34.3 34.7 NS
Positive family history (%) 31.3 31.1 31.4 0.003
Waist circumference (cm) 88.1 (12.7) 93.3 (10.8) 82.8 (12.3) <0.001
SBP (mmHg) 128 (19) 133 (18) 123 (19) <0.001
Antihypertensive medication (%) 14.5 15.5 13.5 0.012
ACEi/A2A medication (%) 4.2 5.1 3.2 <0.001
Cholesterol/HDL ratio 4.6 (1.8) 5.2 (1.9) 4.0 (0.5) <0.001
Triglycerides (mmol/L)† 1.1 (0.8-1.7) 1.3 (0.9-1.9) 1.0 (0.8-1.5) <0.001
Lipid lowering medication (%) 6.2 7.0 5.4 <0.001
Glucose (mmol/L) 4.9 (1.2) 5.0 (1.3) 4.7 (1.0) <0.001
Anti-diabetic medication (%) 1.3 1.4 1.2 NS
CRP (mg/L)† 1.20 (0.53-2.74) 1.16 (0.52-2.49) 1.24 (0.53-3.03) 0.001
UAE (mg/24h)† 9.0 (6.2-15.3) 10.0 (6.8-18.8) 8.1 (5.8-12.9) <0.001
Urinary urea excretion (mmol/24h) 361 (103) 397 (105) 324 (88) <0.001
Urinary sodium excretion 
(mmol/24h)
143 (50) 159 (52) 127 (42) <0.001
eGFR (ml/min/1.73m2) 80.7 (13.9) 83.8 (14.3) 77.5 (12.7) <0.001
ACEi, angiotensin converting enzyme inhibitors; A2A, angiotensin-II antagonists; CRP, hs C-reactive protein; eGFR, 
estimated glomerular filtration rate (MDRD); HDL, highdensity lipoprotein; SBP, systolic blood pressure; NS, not 
significant; UAE, urinary albumin excretion. Values are given as mean (s.d.), or median (interquartile range) in 
case of skewed data (†) distribution. Statistical analyses, to test the differences between males and females, were 
performed with t-test, Mann–Whitney test in case of skewed distribution, or χ2 test in case of categorical variables.Chapter 5
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Sensitivity analyses 
Various  sensitivity  analyses  were  performed.  First,  we  performed  a  sensitivity  analysis 
including only subjects in whom a “reliable” slope of renal function over time could be 
calculated. To judge slopes as reliable, we calculated for every observed eGFR measurement 
the theoretical 99% confidence interval of the expected eGFR value. This confidence interval 
is determined by intra-patient day-to-day coefficient of variation (CV) in true GFR, and by 
measurement error in serum creatinine. The CV in true GFR and creatinine measurement 
in our institution has previously been shown to be 2.2% and 1.1%, respectively [49,50]. 
The overall coefficient of variation for the expected GFR can be calculated according to the 
formula √((CV true GFR)2 + (CV creatinine)2), and the 99% confidence interval. In case all three 
observed eGFR values of a subject were within the calculated 99% confidence intervals of 
the expected eGFR values we defined the slope as reliable (males n=2.007, females n=1.911). 
Second, we performed sensitivity analyses to test whether loss to follow-up influenced 
results. For this reason, we repeated our analyses using a mixed effects model with random 
intercepts and random slopes. Such a model estimates the rate of change in eGFR over time, 
including also subjects with only one or two eGFR measurements [42]. Third, we repeated 
our analyses using the following outcomes; (a) percentage change in eGFR, and (b) slopes 
through the reciprocals of serum creatinine. Fourth, to investigate whether the enrichment 
for albuminuria in our cohort influenced the results we performed our analyses in a subcohort 
representative for the general population (N=2.269). A detailed description how this cohort 
was formed has previously been published [51].  
Results
Mean follow-up of the 5.488 subjects in this analysis was 6.5 years (35.500 person-years 
of follow-up). Baseline characteristics of the overall study population are given in table 1.   
Of note, the results of multivariate linear regression analyses showed that gender was a 
strong effect modifier, because a significant interaction term was found between UAE and 
gender  (P<0.001),  and  between  cholesterol/HDL  ratio  and  gender  (P=0.005)  versus  the 
change in eGFR over time. The statistical significance of these interaction terms indicate that 
the association between UAE versus outcome and cholesterol/HDL ratio versus outcome 
is not similar in males and females. Therefore, we stratified all further analyses by gender. 
Consequently, table 1 shows also baseline characteristics for males (n=2.770) and females 
(n=2.718)  separately.  At  baseline  males  had  a  significantly  higher  waist  circumference, 
systolic blood pressure, percentage ACEi/A2A treatment, cholesterol/HDL ratio, percentage 
lipid lowering treatment, triglycerides, plasma glucose and a higher UAE, urea and sodium 
excretion and also a higher eGFR. For males the range of UAE is 1.18-2960 mg/24hr and 
for females 1.0-3610 mg/24hr. For males the eGFR values are between 23.2 and 155.9 
ml/min/1.73m2 and for females between 21.9 and 136.3 ml/min/1.73m2. The mean eGFR 
slope over time in males was -0.55 ± 1.47), and in females -0.33 ± 1.41 ml/min*1.73m2*year 
(P<0.001 for males vs. females). The mean serum creatinine levels during the three screening 
rounds were 83.6 ± 14.4 μmol/l, 84.9 ± 19.0 μmol/l and 85.1 ± 22.9 μmol/l, respectively. 
Table 2 shows the results of the univariate linear regression analyses, and table 3 the effect 
of correction for age and baseline eGFR. In both males and females systolic blood pressure, 
plasma glucose, and UAE were significantly and negatively associated with slope of renal 
function, indicating that a higher systolic blood pressure, plasma glucose and UAE were 
associated with a larger decline in eGFR. Other variables were only associated with renal 
function decline in one of the genders. For instance, Ln CRP was only associated with renal 
function decline in females. Surprisingly, some variables were associated differently in the Chapter 5
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Table 2. Univariate associations between baseline characteristics and change in renal function 
during follow-up (assessed as slope through three eGFR values over time per individual)
Males (N=2770) Females (N=2718)
Standardized beta P-value Standardized beta P-value
Smoking  .005 NS -.003 NS
Positive family history  -.003 NS -.010 NS
Waist circumference  .052 0.006 -.023 NS
SBP  -.074 <0.001 -.046 0.016
Cholesterol/HDL ratio .069 <0.001 -.049 0.011
Ln_Triglycerides .054 0.005 .015 NS
Glucose -.135 <0.001 -.104 <0.001
Ln_CRP -.026 NS -.028 NS
Ln_UAE -.126 <0.001 -.038 0.045
Urinary urea excretion .025 NS -.025 NS
Urinary sodium excretion .021 NS -.027 NS
CRP, hs C-reactive protein; eGFR, estimated glomerular filtration rate (MDRD); HDL, high density lipoprotein; NS, 
not significant; SBP, systolic blood pressure; UAE, urinary albumin excretion. In case of skewed distribution, data 
were Ln-transformed to obtain normal data distribution. A negative standardized beta indicates that the higher 
the value of the variable under study, the more negative the slope of renal function over time is
Table 3 Associations between baseline characteristics and change in renal function during follow-up 
(assessed as slope through three eGFR values over time per individual), with correction for baseline 
eGFR and age.
Male (N=2770) Female (N=2718)
Standardized beta P-value Standardized beta P-value
Smoking  .027 NS .018 NS
Positive family history  -.005 NS .002 NS
Waist circumference  .048 0.014 -.039 0.046
SBP  -.092 <0.001 -.074 <0.001
Cholesterol/HDL ratio .052 0.005 -.056 0.004
Ln_Triglycerides .029 NS -.010 NS
Glucose -.126 <0.001 -.094 <0.001
Ln_CRP -.017 NS -.038 0.041
Ln_UAE -.145 <0.001 -.046 0.012
Urinary urea excretion .020 NS -.026 NS
Urinary sodium excretion .022 NS -.022 NS
CRP, hs C-reactive protein; eGFR, estimated glomerular filtration rate (MDRD); HDL, high density lipoprotein; NS, 
not significant; SBP, systolic blood pressure; UAE, urinary albumin excretion. In case of skewed distribution, data 
were Ln-transformed to obtain normal data distribution. A negative standardized beta indicates that the higher 
the value of the variable under study, the more negative the slope of renal function over time.Chapter 5
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two genders: in males lower waist circumference and a lower cholesterol/HDL ratio predicted 
accelerated renal function decline, whereas in females an opposite association was found.
Tables 4 and 5 present the results of the gender-specific multivariate linear regression models. 
A higher (absolute) standardized beta value indicates a stronger association between the 
independent variable and the outcome change in eGFR over time. In males, a higher systolic 
blood pressure, plasma glucose, and UAE, were associated with more renal function decline. 
In contrast, waist circumference and cholesterol/HDL ratio were associated with less renal 
function decline over time. The quadratic terms of UAE and cholesterol/HDL ratio were 
significant in the linear regression model. In females, results were slightly different, insofar 
that only systolic blood pressure, plasma glucose, and cholesterol/HDL ratio were associated 
with more renal function decline, whereas triglycerides were found to be associated with less 
renal function decline. In this model inclusion of the quadratic term of SBP was significant.
Figure 2 presents the graphical interpretation of the associations between independent 
variables and eGFR slope that were identified by multivariate regression analysis. More renal 
function decline is observed in the higher range of systolic blood pressure, glucose and UAE, 
Table 4. Multivariate model for males explaining change in renal function during follow-up (assessed 
as slope through three eGFR values over time per individual)
Male (N=2770)
Standardized beta P-value
Ln_UAE2 -.581 <0.001
Cholesterol/HDL ratio2 .129 <0.001
Waist circumference .102 <0.001
Glucose -.096 <0.001
SBP -.064 0.003
eGFR, estimated glomerular filtration rate (MDRD); HDL, high-density lipoprotein; SBP, systolic blood pressure; 
UAE, urinary albumin excretion. Variables included in the multivariate prediction model are statistically significant 
associated with slope of renal function over time. The model is adjusted for baseline eGFR, age, and the use of 
medication. In case quadratic terms of variables proved to contribute significantly to the model (indicated with 2), 
the single term was also forced into the model. For reasons of clarity, only results with respect to the quadratic 
term are shown in the table. In case of skewed distribution, data were Ln-transformed to obtain normal data 
distribution. A negative standardized beta indicates that the higher the value of the variable under study, the more 
negative the slope of renal function over time. The variables are ranked on the order of the standardized beta.
Table  5.  Multivariate  model  for  females  explaining  change  in  renal  function  during  follow-up 
(assessed as slope through three eGFR values over time per individual)
Female (N=2718)
Standardized beta P-value
SBP2 -.359 0.026
Glucose -.067 0.002
Cholesterol/HDL ratio -.061 0.014
Ln_Triglycerides .052 0.038
eGFR, estimated glomerular filtration rate (MDRD); HDL, high-density lipoprotein; SBP, systolic blood pressure. 
Variables included in the multivariate prediction model are statistically significant associated with slope of renal 
function over time. The model is adjusted for baseline eGFR, age, and the use of medication. In case, quadratic 
terms of variables proved to contribute significantly to the model (indicated with  2), the single term was also 
forced into the model. For reasons of clarity, only results with respect to the quadratic term are shown in the 
table. In case of skewed distribution, data were Ln-transformed to obtain normal data distribution. A negative 
standardized beta indicates that the higher the value of the variable under study, the more negative the slope of 
renal function over time. The variables are ranked in order of the standardized beta. Chapter 5
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both in males and in females. The curves for cholesterol/HDL ratio and waist circumference 
versus change in eGFR over time however, show opposite patterns for males and females. 
A priori defined sensitivity analyses were performed. To investigate whether inclusion of 
only subjects with reliable slopes influences the results, we excluded the 773 males and 
812 females with observed eGFR values that were not within the 99% confidence interval 
of the expected eGFR value. The results obtained were only slightly different. In males, the 
cholesterol/HDL ratio was not significantly associated with change in renal function, whereas 
in females only triglycerides were not found to be associated with outcome anymore. The 
sensitivity analysis performed with a mixed effects model with random intercepts and random 
slopes resulted in models with the same variables included. Additionally we investigated 
the  potential  role  of  hormonal  status.  For  this  purpose  we  repeated  the  multivariate 
linear regression analysis only in post-menopausal females (N=1.107). Similar results were 
obtained as in the overall group of females. Furthermore, we performed an analysis using a 
relative instead of absolute measure for renal function decline and an analysis using slopes 
through the reciprocals of serum creatinine values as outcome variables. The results of these 
analyses were essentially similar to our primary analyses, as were the results of the analyses 
performed in a subcohort representative for the general population.
Discussion
In this study, we investigated which modifiable risk factors are associated with change in 
renal function during follow-up in a community-based study cohort. We found different 
results for males versus females. In males UAE was the strongest independent predictor of 
greater renal function decline, together with plasma glucose and systolic blood pressure. In 
contrast, waist circumference and cholesterol/HDL ratio were associated with a better renal 
function outcome. In females systolic blood pressure and plasma glucose were independent 
risk predictors of renal function decline, while triglycerides were associated with better renal 
prognosis.
The interest in identification of modifiable risk factors of renal function decline is increasing. 
Such risk factors may be used to estimate a subject’s risk of future renal function decline, 
and may also form the basis for preventive intervention. The mean eGFR decline we found 
in this study is low, probably not pathological and does not warrant intervention. However, 
the goal of this study was to identify predictors of accelerated renal function loss. Such risk 
predictors may be used to estimate a subject’s risk of future renal function, and may also 
form the basis for preventive intervention. Most observational studies investigating this 
issue apply “threshold” analysis, using a cut-off value to indicate that subjects reach a certain 
stage of CKD. Most common cut-off values are  the incidence of ESRD (defined as start of 
renal replacement therapy), or de novo KDOQI CKD stage 3 or 4 (defined as eGFR below 
60 or 30 ml/min/1.73m2) [9-12]. This study applies a “slope” analysis. The choice of slope 
versus threshold analysis has received scant attention, but has important implications. This is 
illustrated by the following theoretical example. It is known that in obese subjects GFR values 
estimated with the MDRD formula are considerably lower than their true GFR, because in 
general obesity is associated with more muscle mass [13]. Therefore, obese subjects at similar 
baseline true GFR and at similar rate of true GFR loss as non-obese subjects, will reach an 
MDRD formula based eGFR threshold of 30 or 60 ml/min/1.73m2 earlier than their non-obese 
counterparts. This suggests that obesity is a risk factor for renal function decline, whereas 
a slope analysis would not have led to this conclusion. One might consider that application 
of an eGFR independent threshold, such as the occurrence of ESRD, might circumvent this 
problem. However, obesity has been found to be associated with better survival in subjects Chapter 5
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Figure 2. Graphical representation of the association between risk predictors and change in renal 
function during follow-up (assessed as slope through three eGFR values over time per individual). 
The Loess method (locally weighted polynomial regression analysis) 52 is used to plot these associations. Using 
this method makes it possible to show a possible nonlinear relationship, as the plots are ‘distribution free’. The 
histograms (expressed as percentage) present the distributions of the predictors. HDL, high-density lipoprotein; 
SBP, systolic blood pressure; UAE, urinary albumin excretionChapter 5
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in renal replacement therapy [14]. In case this would also be true for KDOQI CKD stage 4, 
obese subjects would survive “preferentially”. This will result in the observation that the 
proportion of obese subjects that reaches ESRD is higher than in the general population, 
again leading to the possible incorrect conclusion that obesity is associated with worse 
renal function outcome. For these reasons, together with the fact that we wanted to study 
risk factors of renal function decline over the entire eGFR range, we adopted a slope based 
analysis with change in renal function during follow-up as outcome parameter. We also 
performed our analyses using slopes based on the reciprocals of serum creatinine values, 
and using relative change in eGFR as outcome parameters. These analyses resulted in the 
identification of the same predictors, making our results convincing.
Applying  a  slope  based  analysis,  we  found  in  both  males  and  females  higher  systolic 
blood pressure and higher plasma glucose to be major determinants of change in renal 
function.  This  is  in  line  with  other  studies  investigating  community-based  populations, 
but applying threshold analysis. High plasma glucose has been shown to be a risk factor of 
the development of CKD [15] and ESRD [16]. The same holds true for high blood pressure 
[12,17-19]. Interestingly, similar to our study, a study performed in Maryland, USA, showed 
in both males and females a strong relationship between systolic blood pressure and the 
development of CKD, with  the relationship being strongest in females and the cumulative 
incidence of ESRD increasing exponentially in the more severe stages of hypertension [20]. 
Of note, we found a difference of 10 mmHg in SBP levels between males and females. This 
result is in line with other community-based studies [21-24]. 
We found UAE to be the best predictor of renal function decline in males. This association 
was independent of the effects of systolic blood pressure and plasma glucose. Although 
most evidence on the impact of urinary albumin leakage and renal prognosis is based upon 
data on overt proteinuria in subjects with non-diabetic [25,26] and diabetic [27,28] renal 
disease, there is also evidence that lower amounts of protein leakage predict renal function 
decline in the general population. Iseki et al showed that subjects with trace dipstick positive 
proteinuria already have an increased incidence of ESRD during follow-up [29], as did the 
MRFIT study [10]. In a previous analysis we found in the PREVEND study that, after 4.2 years 
of follow-up, subjects with microalbuminuria progress more frequently to an eGFR below a 
threshold of 60 ml/min/1.73m2 than subjects without microalbuminuria [30]. Remarkably, 
the present study found that UAE was not an independent predictor for renal function 
decline in females. However, in females the negative association between UAE and renal 
function  decline  was  significant  when  tested  univariately,  and  also  when  corrected  for 
baseline eGFR and age. We repeated our analyses using the albumin/creatinine ratio (ACR) 
with correction for age and gender [31,32]. The results of these analyses also showed that 
albuminuria was an independent predictor for renal function decline in males, but not in 
females. Most studies concerning predictors of renal function decline do not report gender 
differences in outcome. Possibly this was not studied specifically, and therefore gender 
differences may have remained unnoticed. Furthermore, we should take into account that 
we applied a slope based analysis, in contrast to other studies. Indeed, when we performed 
a threshold analysis and investigated which subjects developed an eGFR less than 60 ml/
min/1.73m2 during follow-up, we also found no significant interaction between gender and 
UAE on outcome (P=0.53). However, our data on gender specific renal effects are in line with 
a previous report showing that males have a higher UAE for a given age, plasma glucose and 
BMI than females [33]. 
Another gender difference was observed with respect to the impact of cholesterol/HDL 
ratio on change in renal function. In females, a higher cholesterol/HDL ratio was associated Chapter 5
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with more renal function decline, whereas we found the opposite in males. Literature on 
cholesterol as an independent predictor for renal function impairment is not consistent, with 
some community-based studies finding total cholesterol and/or triglycerides not to be an 
independent predictor for the onset of CKD [9] or ESRD [34], whereas others did find these 
variables to be associated with worse renal outcome [34-36]. A possible explanation for 
these inconsistent results might be differences in length of follow-up, with especially studies 
with longer follow-up suggesting that high cholesterol and/or triglycerides influence renal 
function outcome negatively [36,37].
Surprisingly, we found that a greater waist circumference was not associated with a worse 
renal prognosis. In fact, in males waist circumference was associated with a better renal 
prognosis.  Several  other  community-based  studies  reported  an  association  between  a 
higher BMI and increased risk for CKD [11,38,39]. As mentioned before, these contradictory 
findings might be due to the fact that in the present study a slope based analysis is used, 
whereas  other  studies  applied  a  threshold  analysis.  When  we  analyzed  which  subjects 
developed an eGFR less than 60 ml/min/1.73m2 during follow-up, we did not find a positive 
association between waist circumference and change in renal function, neither in the overall 
population, nor when we analyzed males separately. Another explanation may again be 
duration of follow-up. Data from the Okinawa screening project in Japan showed that 10 
years follow-up was not sufficient to establish a relationship between BMI and the risk of 
developing ESRD [40], whereas data of 17 years follow-up did show such an association [38]. 
Another study with longer duration of follow-up (13.2 years) also showed an association 
between  obesity and renal prognosis [41].  Thus, it could be that the follow-up of 6 years in 
our study is not sufficient to find a negative association between waist circumference and 
renal function decline. However, the fact that we found in our slope based analyses even a 
positive association between waist circumference and change in renal function in males is 
surprising, and worth further study. 
Strengths of this study are the use of a large prospective community-based cohort, with three 
eGFR estimates available. Our study is one of the first studies that investigates risk factors of 
renal function decline by a slope based analysis. Of course, also limitations should be kept in 
mind. First, the relatively short follow-up in our study and the fact that there are only three 
eGFR measurements available may have influenced the precision of the calculated slope. 
Therefore, we performed a sensitivity analysis, including only subjects with “reliable” slopes. 
This did not essentially affect our results. Second, by using the calculated slope we assume 
a linear change in renal function over time. Although it is generally used in nephrology, it is 
questionable whether this assumption of linearity is correct. However, on the present data 
(three values available) it is appropriate to assume a linear change [42]. Third, our results may 
be biased by the influence of loss to follow-up. Participants who died or were lost to follow-
up for other reasons may have been in a worse condition of health. In general, such subjects 
have a higher rate of renal function decline. Therefore, in our analyses the impact of risk 
factors may have been underestimated. To investigate the potential bias induced by loss to 
follow-up we performed a mixed effets models analysis, which takes into account also data 
available of subjects who attended only one or two screenings. This again did not influence 
our main conclusions. Fourth, we used the MDRD formula to estimate the GFR. It is known 
that the use of the MDRD formula has shortcomings [43,44]. Estimating GFR with the MDRD 
formula may introduce bias [45]. Since this bias is systematic, that is constant in a particular 
subject, this bias is expected not to influence our analyses since we use change in eGFR as 
outcome parameter, and not the absolute value of eGFR. In addition, at this moment there 
is no other feasible method to estimate GFR and the MDRD based GFR estimates are easy Chapter 5
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to interpret for clinicians. Fifth, we studied a relatively healthy Caucasian population. Our 
findings may therefore not be valid for other populations. 
In  conclusion,  this  community-based  observational  population  study  investigated  which 
modifiable  variables  were  associated  with  change  in  renal  function  during  follow-up, 
applying a slope based analysis. Results differed between males and females. High systolic 
blood pressure and plasma glucose were found to be independent predictors for worse 
renal outcome in both males and females. In males, UAE was identified as the strongest 
independent predictor for renal function decline. In females UAE was only univariately 
and after adjustment for age associated with change in renal function. The direction of the 
association between cholesterol/HDL ratio and change in renal function was different in 
males and females. In males, predictors independently associated with a better renal function 
outcome were waist circumference and cholesterol/HDL ratio, whereas in females this was 
higher triglycerides. Our findings suggest that in future studies possible gender specific risk 
predictors for renal function decline should be taken into account. Furthermore, these data 
may help to make renal risk prediction scores to identify subjects in the general population 
at risk of renal function decline, who may benefit from early preventive intervention.Chapter 5
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Abstract
Chronic kidney disease is a growing public health problem worldwide. Previous studies have 
identified several predictors for renal function decline. However, these studies used a single 
measurement of these risk factors. Therefore, the aim of this study was to investigate whether 
besides the baseline values of these risk factors, changes in risk factors are associated with 
subsequent rate of renal function loss. 
Five  thousand,  six  hundred  and  fifty-one  participants  in  the  Prevention  of  Renal  and 
Vascular  ENd-stage  Disease  (PREVEND)  Study,  a  prospective,  population-based  cohort 
study, completed three screening visits during a follow-up of 6.5 years for detailed clinical 
and biochemical measurements. Change in renal function between the second and third 
screening rounds was chosen as the study parameter of interest. Changes in risk factors 
between the first and second screening rounds were incorporated as potential predictors 
for renal function loss in multivariable linear regression analyses. Based on the results of a 
previous study, gender-specific analyses were performed.
In males, an increase in urinary albumin excretion (UAE), systolic blood pressure (SBP) and 
cholesterol was associated with a subsequent higher rate of renal function loss, whereas 
in females, increases in glucose levels were associated with an increase in renal function. 
For males, the analyses showed that both the baseline values and the change in UAE and 
cholesterol  were  significant  predictors  for  increased  rate  of  renal  function  loss  during 
subsequent follow-up. With respect to SBP, when taking also the change in this variable into 
account, the baseline value was no longer a significant predictor for renal function loss.
The results of the present study show the value of screening programs including repeated 
measurements of risk factors. Furthermore, these data indicate that, besides baseline values 
of risk factors, the changes over time in these factors should also be taken into account when 
developing ‘Renal Risk Scores’ to identify subjects in the general population who are at risk 
for accelerated renal function deterioration. Chapter 6
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Introduction
Worldwide, awareness of the high prevalence and burden of chronic kidney disease (CKD) has 
increased [1–3]. There is a general feeling that subjects at risk for accelerated renal function 
loss should be identified as early as possible for timely start of renoprotective treatment. 
To detect high-risk subjects, screening programs could be a valid tool. For such screening 
programs, knowledge on risk factors for CKD is essential.
A population-based cohort study showed that, besides a lower baseline estimated glomerular 
filtration rate (eGFR), the established cardiovascular risk factors age, diabetes, body mass 
index and smoking were associated with a higher risk to develop chronic kidney disease 
[4]. Results from the Prevention of Renal and Vascular ENd-stage Disease (PREVEND) Study 
identified gender-specific predictors for renal function loss. In males, high albuminuria, 
glucose and systolic blood pressure were associated with accelerated renal function loss 
over time, whereas in females, systolic blood pressure, plasma glucose and cholesterol/ HDL 
ratio were associated with accelerated renal function loss [5].
The aforementioned studies used a single measurement of these risk factors at only one time 
point to predict the rate of renal function loss during follow-up. Knowledge on changes in 
these variables during follow-up may be of added value to predict renal function outcome. For 
instance, in patients with known renal disease, a change in albuminuria by antihypertensive, 
and specifically ACEi/ ARB treatment or a low protein diet, is associated with better renal 
outcome [6]. Only a few studies have studied the impact of changes in renal risk factors on 
renal function outcome in the general population [7–11]. Of note, these studies investigated 
the impact of change in only one specific risk factor. Data on multivariable analyses are not 
yet available.
The aim of this study is to investigate whether changes in risk factors for renal function decline 
are associated with the rate of renal function loss during subsequent follow-up. Based on 
our previous results [5], we decided to perform gender-specific analyses. For this study, we 
used data of subjects who participated in three screening rounds of the population-based 
PREVEND Study to relate changes in risk factors between the first and second screening 
rounds to the rate of renal function loss between the second and third screening rounds.
Materials and methods
Study design and population
The analyses are based on data of subjects who participated in the first three screening 
rounds of the PREVEND Study. This is a prospective, population-based cohort study, designed 
to investigate the impact of urinary albumin excretion (UAE) on renal and cardiovascular 
outcome in the general population. In 1997–98, the participants of the PREVEND cohort 
were selected from 40.856 inhabitants of the city of Groningen, the Netherlands. To obtain a 
cohort enriched for the presence of elevated albuminuria levels, selection was based on the 
albumin concentration in a spot morning urine sample. In this ongoing study, participants 
are  invited  to  visit  an  outpatient  for  a  medical  examination  at  approximately  3-year 
intervals. Details of the study protocol have been published elsewhere and can be found on 
www.PREVEND.org.
In total, 8.592 participants completed the first screening round in 1997–98. Approximately 
6.5 years later, from 2003 to 2006, the third screening round took place. During the interval 
between the first and the third screening rounds, 377 subjects died, and 2.415 subjects 
withdrew consent (with vital status known) (Figure 1). Thus, 5.862 subjects completed the 
third screening round. For the present study, we excluded subjects who at the first screening Chapter 6
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round  indicated  to  have  renal 
disease during the first screening 
round (n = 22) and subjects with 
incomplete  information  on  the 
eGFR  measurements,  leaving 
5.651  subjects  for  analysis.  The 
PREVEND  Study  was  approved 
by  the  local  medical  ethics 
committee  and  conducted  in 
accordance  with  the  guidelines 
of  the  Declaration  of  Helsinki. 
All  participants  gave  written 
informed consent.
Measurements and definitions
Each  screening  round  consisted 
of  two  visits  to  an  outpatient 
department  separated  by 
approximately 3 weeks. Participants filled out a questionnaire on demographics, cardiovascular 
and renal history, smoking status and the use of oral antidiabetic, antihypertensive and lipid-
lowering drugs. Smoking was defined as current smoking (including subjects who had quit 
smoking for < 1 year before the screening) or non-smoking (including subjects who had 
quit smoking at least 1 year before the screening). Information on drug use was completed 
with data from community pharmacies, including information on class of antihypertensive 
medication (ACEi/ARB). At both visit days of each screening round, blood pressure was 
measured in the right arm, every minute for 10 and 8 minutes, respectively, by an automatic 
Dinamap XL Model 9300 series device (Johnson-Johnson Medical INC, Tampa, Florida). For 
systolic blood pressure, the mean of the last two recordings from each of the two visit days 
of a screening round was used. Anthropometrical measurements were performed, and 
fasting blood samples were taken. In addition, subjects collected urine for two consecutive 
periods of 24 hours. Concentrations of total cholesterol and plasma glucose were measured 
using standard methods. Serum creatinine was measured by dry chemistry (Eastman Kodak, 
Rochester, New York, USA), with intra-assay coefficient of variation of 0.9% and interassay 
coefficient of variation of 2.9%. To avoid changes over time in creatinine measurements, 
we have a strict protocol with constant quality control. eGFR was estimated using the 
Modification of Diet in Renal Disease (MDRD) study equation, taking into account gender, 
age, race and serum creatinine [12]. Urinary albumin concentration was determined by 
nephelometry (Dade Behring Diagnostic, Marburg, Germany), and UAE was given as the mean 
of the two 24-hour urinary excretions. Changes in UAE, SBP, glucose, cholesterol and waist 
circumference between the first and the second screenings were calculated and expressed 
per year of follow-up. Changes in smoking habits were based on the questionnaires and 
changes in the use of ACEi/ARB, and other antihypertensive medication was based on the 
pharmacy data. The change in subsequent eGFR was calculated between the second and 
third screening rounds and also expressed per year of follow-up.
Statistical analyses
Continuous data were reported as mean and standard deviation. For skewed distributions, 
Figure 1. Outline of the PREVEND Study; first three screenings. 
In right part, the measurements used for the analyses are 
shown.  FU = follow-up.Chapter 6
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median and interquartile range were presented. All P-values were two-tailed. A P-value <0.05 
was considered statistically significant. Baseline characteristics of our study population were 
shown for males and females separate.
For our analyses, we used the following known modifiable cardiovascular risk factors for our 
analyses; UAE, SBP, plasma glucose, cholesterol, waist circumference, smoking and use of 
ACEi/A2A medication and other antihypertensive medication. For blood pressure, we also 
analysed other measurements than SBP (diastolic blood pressure, mean arterial pressure and 
pulse pressure). The results for the different blood pressure measurement were comparable. 
We  chose  to  use  SBP  as  this  variable  is  most  widely  used  in  related  articles.  To  avoid 
colinearity in the multivariable models, only one blood pressure measure was implemented. 
Since a previous analysis showed gender-specific risk factors for renal function outcome, it 
was decided a priori to perform all analyses for males and females separately [5]. To study 
the impact of changes in risk factors on the subsequent rate of renal function loss, linear 
regression analyses were used. The change in eGFR was analysed as a continuous variable; 
therefore, we investigated a large range of eGFR changes including both normal age-related 
changes and abnormal pathological changes in eGFR. Changes in risk factors between the 
first and second screening rounds were used as determinant, and changes in eGFR between 
the second and third screening rounds were used as outcome variable (Figure 1) after initial 
univariable linear regression analyses. Secondly, we corrected our analyses for age, eGFR and 
baseline value of the risk factor. We corrected the models for eGFR to reduce the effect of 
regression to the mean. Finally, we performed forward multivariable regression analyses. To 
adjust for the enrichment of our study cohort with subjects with higher levels of albuminuria, 
all analyses were weighted. All models were tested for possible non-linear associations 
between the changes in the risk factors under investigation and subsequent rate of renal 
function loss. This was tested by adding quadratic terms to the multivariable regression 
model. Quadratic terms with a P-value < 0.05 were considered significant. We tested for 
possible effect modification by means of interaction terms. Lastly, graphical representations 
were made of the associations between the changes in the most important predictors and 
the rate of renal function loss during subsequent follow-up. For females, we repeated the 
analyses including only postmenopausal females to investigate the role of hormonal status. 
We also performed all analyses with IDMS-traceable serum creatinine values. A correction 
factor was used to obtain serum creatinine values that are IDMS-traceable. The appropriate 
MDRD equation was used [13] for this sensitivity analysis. All analyses were conducted with 
the use of the statistical package SPSS 14.0 (SPSS, Chicago, IL).
Results
The mean (± SD) period between the first and second screenings was 4.2 ± 0.42 years and 
between the second and third screenings 2.2 ± 0.34 years. The changes in eGFR in these 
periods  were  -0.53  and  -0.23  ml/min/1.73m2  per  year  follow-up,  respectively.  Baseline 
characteristics of the study cohort including the changes in risk factors (between first and 
second screening rounds expressed per year follow-up) are given in Table 1 for males and 
females, separately. The baseline characteristics of the subjects who completed all three 
screening rounds were comparable with the subjects who did not, concerning age (48.2 
vs 48.7 years), SBP (127 vs 125 mmHg), glucose (4.7 vs 4.7 mmol/l), cholesterol (5.6 vs 5.6 
mmol/l), UAE (7.0 vs 7.0 mg/24 hours), waist (86.9 vs 86.9 cm) and eGFR (80.6 vs 80.3 ml/
min/1.73m2). Among the non-responders, only the percentage smokers (42% vs 32%) and 
use of ACEi medication (3.8% vs 3.0%) were different from responders. At baseline, the 
levels for serum creatinine and eGFR for the total population were 84.7 µmol/L and 78.6 Chapter 6
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Table 1. Baseline characteristics and changes in risk factors between the first and second 
screening rounds for males and females separate.
Males Females
N 2870 2781
Age (years) 50.0 (12.2) 48.2 (11.2)
SBP (mmHg) 133 (18) 123 (19)
Change in SBP (mmHg/yr) -0.6 (3.1) -0.2 (3.0)
Cholesterol (mmol/L) 5.7 (1.1) 5.6 (1.1)
Change in cholesterol (mmol/L/yr) -0.06 (0.21) -0.03 (0.22)
Glucose (mmol/L) 5.0 (1.2) 4.7 (1.0)
Change in glucose (mmol/L/yr) 0.04 (0.32) 0.05 (0.24)
UAE (mg/24h) 10.1 (6.8-19.1) 8.2 (5.8-13.3)
Change in UAE (mg/24h/yr) 1.8 (24.4) -0.4 (25.0)
Waist (cm) 93.3 (10.9) 82.8 (12.3)
Change in waist (cm/yr) 0.9 (1.5) 1.1 (1.8)
Smoking (%) 34.4 35.0
Smoking cessation (%) 20.2 20.6
No smoking (%) 65.6 65.0
Start of smoking (%) 2.9 2.7
ACEi medication (%) 4.9 3.2
ACEi medication cessation (%) 25.5 20.5
No ACEi medication (%) 95.1 96.8
Start of ACEi medication (%) 6.6 4.3
AHT medication (%) 10.0 10.1
AHT medication cessation (%) 36.7 35.2
No AHT medication (%) 90.0 89.9
Start of AHT medication (%) 7.0 7.1
Baseline eGFR (ml/min/1.73m2) 81.4 (14.5) 75.8 (13.1)
Change in eGFR (ml/min/1.73m2)  -0.4 (4.2) 0.01 (4.0)
Normally distributed variables are given as mean (standard deviation). Skewed variables are presented as 
median (interquartile range). Categorical variables are presented as percentages. Abbreviations are: eGFR 
estimated glomerular filtration rate; SBP systolic blood pressure; UAE urinary albumin excretion; ACEi 
angiotensin converting enzyme inhibitors; AHT antihypertensive.Chapter 6
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Figure 2: Relationship between changes in predictors under investigation and the subsequent change in 
eGFR (ml/min/1.73m2/yr) (left axis) in univariate models for males (left) and for women (right). 
The Loess method (locally weighted polynomial regression analysis)[24] is used to plot these associations. Histograms 
represent  the  percentage  of  the  population  (right  axis)  at  a  given  change  in  predictor.  Abbreviations  are  eGFR: 
estimated glomerular filtration rate, SBP: systolic blood pressure, UAE: urinary albumin excretion.
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ml/min/1.73 m2, and for different age groups, 82.3 µmol/l and 84.8 ml/min/1.73 m2 (<40 
years), 84.1 µmol/l and 78.0 ml/min/1.73 m2 (40–65 years) and 92.8 µmol/l and 68.9 ml/
min/1.73 m2 (>65 years), respectively. Serum creatinine is higher and eGFR is lower at older 
age. The changes in serum creatinine and eGFR for the total population were 0.22 µmol/l 
and -0.49 ml/min/1.73 m2, and for different age groups, -0.27 µmol/l and -0.49 ml/ min/1.73 
m2 (<40 years), 0.13 µmol/l and -0.41 ml/min/1.73 m2 (40–65 years) and 1.7 µmol/l and -0.86 
ml/min/1.73 m2 (>65 years). This shows that changes in serum creatinine are limited in the 
young individuals and increase with increasing age. The changes in eGFR are not statistically 
different in older subjects compared with younger subjects (P = 0.3). Table 2 shows the 
results of the univariable linear regression analyses and the results of the adjustment for age, 
eGFR and baseline values of the risk factor under investigation. The results of the univariable 
analyses showed associations between an increase in UAE, SBP and cholesterol in males and 
an increased rate of renal function loss during subsequent follow-up. In females, an increase 
in plasma glucose was associated with a subsequent increase in eGFR. Also after adjustment, 
in males, increases in UAE and cholesterol were significantly associated with an increased 
rate of renal function loss during subsequent follow- up, whereas in females, an increase in 
plasma glucose was associated with an increase in renal function. Changes in the use of ACEi/
ARB medication, antihypertensive medication or smoking habits were not associated with 
subsequent rates of renal function loss.
Tables 3 and 4 present the results of the final gender-specific multivariable linear regression 
models. The first two columns of Tables 3 and 4 present gender-specific multivariable linear 
regression models only including the baseline values of the risk factors. The last two columns 
show the models including also the changes in these risk factors. The first columns of Table 
3 show that a higher baseline value of SBP, cholesterol and UAE were associated with a 
subsequent increased rate of renal function loss. The final model showed that an increase 
in SBP was significantly associated with a subsequent increased rate of renal function loss, 
whereas the baseline value of SBP was no longer significant. This implies that a change in SBP 
is a better predictor compared with the respective baseline value. For UAE and cholesterol 
applies that both the baseline values and the changes in these factors were significantly 
associated with a subsequent increased rate of renal function loss. Of note, the associations 
between changes in SBP and cholesterol were non-linear; therefore, quadratic terms were 
added to the models. For changes in UAE and SBP, as well as cholesterol, this means that 
increases in these risk factors were associated with a subsequent increased rate of renal 
function loss (see also Figure 2). In females, the first model (Table 4) showed that a higher 
baseline SBP and UAE were significant predictors for a subsequent increased rate of renal 
function loss. In the final model, a change in plasma glucose was positively associated with 
the subsequent change in renal function. Figure 2 presents the graphical interpretation of 
the associations between the change in risk factors between the first and second screenings 
and the subsequent rate of renal function loss between the second and third screening 
rounds. The histograms in this figure represent the distribution of the changes in risk factors 
for this population. The results of the subgroup analyses performed in postmenopausal 
women were comparable with the analyses performed in all females (data not shown). The 
sensitivity analysis using IDMS-traceable serum creatinine values showed essentially similar 
results.
Discussion
In this study, we investigated in a population-based study cohort whether, besides baseline 
risk factors, changes in risk factors are associated with the rate of renal function loss during Chapter 6
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Table 3. Multivariable models for males
MALES
Multivariable model including 
baseline values of risk factors
Multivariable model including 
also changes in risk factors
St. beta P-value St. beta P-value
SBP (mmHg) -.038 0.046 -.033 0.159
Change in SBP (mmHg/yr) - - -.006 0.784
Change in SBP2 (mmHg/yr) - - -.045 0.036
Cholesterol (mmol/l) -.515 <0.001 -.484 <0.001
Cholesterol2 (mmol/l)  .602 <0.001  .557 <0.001
Change in cholesterol (mmol/l*yr) - - -.010 0.675
Change in cholesterol2 (mmol/l*yr) - -  .129 <0.001
Ln_UAE (mg/24h)  .267 <0.001  .259 <0.001
Ln_UAE2 (mg/24h) -.313 <0.001 -.289 <0.001
Change in UAE (mg/24h*yr) - - -.042 0.028
Glucose (mmol/l) - NS - NS
Change in glucose (mmol/l*yr) - - - NS
Waist (cm) - NS - NS
Change in waist (cm/yr) - - - NS
The first two columns of the table show the results of the multivariable models including the baseline values of 
the risk factors under investigation. The last columns show the results of the model including baseline factors 
and changes in these factors.  – : factor not included in the model. Abbreviations are: eGFR estimated glomerular 
filtration rate; SBP systolic blood pressure; Ln_UAE natural logarithm of urinary albumin excretion. NS = not 
significant.
Table 4. Multivariable models for females
FEMALES
Multivariable model including 
baseline values of risk factors
Multivariable model including 
also changes in risk factors
St. beta P-value St. beta P-value
SBP (mmHg)  .250 0.101 .254 0.100
SBP2 (mmHg) -.313 0.040 -.317 0.039
Change in SBP (mmHg/yr) - - - NS
Cholesterol (mmol/l) - NS - NS
Change in cholesterol (mmol/l*yr) - - - NS
Ln_UAE (mg/24h)  .137 0.025  .133 0.031
Ln_UAE2 (mg/24h) -.141 0.020 -.139 0.024
Change in UAE (mg/24h*yr) - - - NS
Glucose (mmol/l) - NS  .017 0.424
Change in glucose (mmol/l*yr) - -  .055 0.007
Waist (cm) - NS - NS
Change in waist (cm/yr) - - - NS
The first two columns of the table show the results of the multivariable models including the baseline values of 
the risk factors under investigation. The last columns show the results of the model including baseline factors 
and changes in these factors. – : factor not included in the model. Abbreviations are: eGFR estimated glomerular 
filtration rate; SBP systolic blood pressure; Ln_UAE natural logarithm of urinary albumin excretion. NS = not 
significant.Chapter 6
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subsequent follow-up. We found that, in males, an increase in UAE, SBP and cholesterol 
were associated with subsequent rate of renal function loss, whereas in females, increases 
in plasma glucose levels were associated with an increase in renal function. For males, the 
results showed that both the baseline values and the change in UAE and cholesterol were 
predictors for increased rate of renal function loss during subsequent follow-up. However, 
when taking also the change in SBP into account the baseline value of SBP was no longer 
significant. Information about the effect of changes in risk factors on renal function course 
is limited. In this study, increases in UAE were associated with a subsequent increased rate 
of renal function loss in males, but in females, this association was absent. A previous study, 
also performed in the PREVEND population, showed that, only in males, a high UAE was a 
risk factor for an increased rate of renal function loss independent of other cardiovascular 
risk factors [5]. In males, increased SBP was also associated with a subsequent increased 
rate of renal function loss. Furthermore, our data indicate that an increase in SBP is a better 
predictor for a subsequent increased rate of renal function loss than baseline SBP. This is 
partly in line with another small study, which showed that both an increase in SBP and the 
baseline value of SBP were associated with an increased rate of renal function loss. In this 
small study, no gender differences were reported [10]. Increases in SBP were also associated 
with a subsequent increased rate of renal function loss in a study in treated hypertensive 
males with multiple measures of eGFR and SBP available [11]. Our analyses showed that, in 
males, increases in total cholesterol were associated with a subsequent increased rate of 
renal function loss. Literature on the effect of changes in total cholesterol in cohort studies 
is lacking. However, most literature on the effect of baseline total cholesterol suggests that 
high baseline total cholesterol is a predictor for renal function decline [14,15]. In females, we 
found a positive association between increases in glucose and subsequent increases in eGFR. 
This increase in eGFR induced by hyperglycaemia could reflect hyperfiltration. Hyperfiltration 
is generally seen as an early stage in the pathophysiology of renal disease progression [16]. 
Taking this into account, we expect to find an increased rate of renal function loss in females 
after a longer period of follow-up. A gender difference in the effect of an increase in glucose 
is in line with another study performed in type 1 diabetic patients. In this study, induced 
hyperglycaemia caused an increase in eGFR in females, whereas in males, this increase in 
eGFR was lacking [17].
Starting  or  cessation  of  smoking  was  not  associated  with  changes  in  renal  function 
afterwards. A number of studies reported a negative effect of smoking on rate of renal 
function decline [18–20]. However, there is only little information concerning the effect of 
smoking cessation on the course of renal function. A few studies suggested that smoking 
cessation slows the rate of renal function decline and/or lowers the risk of developing chronic 
kidney disease compared with current smokers [7–9]. Recently, Phisitkul et al showed that 
smoking cessation in subjects with diabetic nephropathy slows down renal function loss [9]. 
Another study, performed in a population-based cohort, showed that the positive effect of 
smoking cessation is associated with the number of years stopped smoking. The age- and 
gender-adjusted odds ratios for developing chronic kidney disease were 1.05 for the subjects 
who stopped >5 years and 3.93 for subjects stopped <5 years (>15 years stopped is used as 
reference category) [7]. According to these results, our relative short follow-up could be the 
reason why we did not find an effect of smoking cessation. 
Changes in the use of ACEi/ARB medication did not influence the subsequent rate of renal 
function loss. Possible explanations for these results could be confounding by indication [21], 
the short-term haemodynamic effects of ACEi/ARB medication (lowering of intraglomerular 
pressure and therefore a slight decrease in GFR) or a lack of power. Of note, for the analyses Chapter 6
80 81
concerning cessation, the use of ACEi/ARB medication only 229 subjects were available and 
only 54 subjects stopped using ACEi/ARB between the first and second screenings.
Strengths of this study are the use of a large prospective population-based cohort, the 
availability of data of three subsequent screening rounds and detailed information on many 
covariates.  The PREVEND  Study is  enriched  for higher levels  of  albuminuria.  Therefore, 
weighted analyses are performed, and this did not influence the results. Some limitations 
should be mentioned. The PREVEND Study is selected from a predominantly Caucasian 
population. Therefore, our findings cannot simply be generalized to other populations. Of 
note, an earlier study performed with the PREVEND data showed that the design of the 
study did not lead to more drug prescription compared with a random selected unscreened 
population. Therefore, the changes in treatment reflect the normal population [22]. The 
follow-up  for  renal  function  between  the  second  and  the  third  screenings  is  relatively 
short (2.2 years) and may be too short to identify all potential risk factors. Previously, we 
found gender-specific predictors for renal function decline, and in the present analyses, 
we identified interactions between gender and several predictors. Based on these results, 
we believe that there is a true gender effect. However, these epidemiological studies offer 
information about these associations but we need more fundamental research to explain 
the biological pathways causing these gender differences. What are the consequences of 
these findings? The burden of chronic kidney disease on the public health-care system is 
increasing, and prevention of CKD is therefore a global challenge [23]. For prevention, early 
identification of subjects at risk for increased rate of renal function loss is essential. This 
might be achievable by development of risk prediction equations. Identified risk factors for 
increased rate of renal function loss could be implemented in such a risk prediction equation. 
This study shows that, in a ‘Renal Risk Score’, not only baseline values but also changes in 
risk factors could be useful to identify subjects in the general population at risk of renal 
function decline, who may benefit from early intervention. However, ‘Renal risk scores’ used 
in large populations should be as simple as possible, and therefore, only baseline values 
will be included. In smaller high risk populations, including changes in risk factors in risk 
scores should be considered. In conclusion, this study shows that, in males, increases in 
UAE, SBP and cholesterol are predictors for subsequent increased rate of renal function loss, 
independent of the baseline values of these known cardiovascular risk factors, whereas in 
females, an increase in glucose was a significant predictor for hyperfiltration. These findings 
emphasize the value of screening programs including repeated measurements of the known 
risk factors for accelerated renal function decline.Chapter 6
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Abstract 
There is a need for prediction scores that identify subjects at increased risk to develop 
progressive chronic kidney disease (CKD). Therefore, this study was performed to develop 
and validate a ‘Renal Risk Score’ for the general population. 
For this study we used data from the PREVEND study, a prospective population-based cohort 
study with a median follow-up of 6.4 years. Subjects with two or three consecutive eGFR 
measurements during follow-up available were included (n=6.809). Subjects were defined 
as having progressive CKD when they belonged to the group of subjects with the 20% most 
rapid renal function decline and having an eGFR value <60ml/min/1.73m2 during follow-up. 
Characteristics of these subjects were: male 50.2 %, age 60.8 yrs, rate of renal function loss 
3.16 ml/min/1.73m2/year. Possible predictors for progressive CKD were selected based on 
univariable logistic regression analyses (P < 0.2).
A final prediction model was built using backward logistic regression analysis. Besides baseline 
eGFR, the model contained age, UAE, SBP, CRP and known hypertension. The area under the 
ROC curve was 0.838. We performed internal validation by using a bootstrapping procedure. 
As expected, after the regression coefficients were corrected for optimism the area under 
the ROC curve was still 0.838. For clinical use we divided all predictors in meaningful clinical 
categories to develop a score chart. With this score chart the risk of having progressive CKD 
can be determined for each individual.
Given the high validity of this Renal Risk Score this score can be of help to identify subjects 
at increased risk for progressive CKD.Chapter 7
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Introduction  
In the past decades, epidemiological studies performed in Japan, Europe and the United 
States have shown that the prevalence of chronic kidney disease (CKD) is high [1-3]. A large 
study performed in the US population showed that 16.8% of the population aged ≥ 20 years 
has CKD [4]. Many of these subjects are not aware of having CKD [5]. Based on these results 
screening for CKD has been suggested. 
Several studies identified risk factors for CKD progression or increased renal function loss 
[6-12]. However, it is also known that only a relatively small percentage of the subjects with 
CKD eventually reach End Stage Renal Disease (ESRD). It is even true that in patients with 
CKD the rate of decline in glomerular filtration rate (GFR) varies and even increases in GFR 
are common [13]. Therefore, the next step should be to identify those subjects who are most 
likely to have progressive CKD. In these subjects intervention could be applied in an early 
phase of their disease to prevent morbidity associated with impaired renal function. Further 
intervention can slow down the rate of renal function decline in the hope to postpone or 
even prevent the need for renal replacement treatment in the long run. To do so “Renal Risk 
Scores” should be developed which are able to predict renal outcome for individual subjects. 
The need for such scores has been advocated in recent reviews, among others by Taal and 
Brenner [14-16]. 
The aim of this study was to develop a “Renal Risk Score” to predict the risk for progressive 
CKD based on the values of several renal risk factors. For this study we used data of the 
PREVEND cohort, an ongoing population-based cohort study.
Methods
Study design and population
The analyses included data of subjects who participated in the first three screening rounds 
of  the  PREVEND  (Prevention  of  Renal  and 
Vascular  ENd-stage  Disease)  study.  This  is 
a  prospective,  population-based  cohort 
study, designed to investigate the association 
between  urinary  albumin  excretion  (UAE) 
and renal and cardiovascular outcome in the 
general  population.  In  1997-1998  the  8.592 
participants  of  the  PREVEND  cohort  were 
selected from 40.856 inhabitants of the city 
of  Groningen,  The  Netherlands.  To  obtain  a 
cohort enriched for the presence of elevated 
albuminuria levels, selection was based on the 
albumin concentration in a spot morning urine 
sample.  In  this  ongoing  study,  participants 
are invited to visit an outpatient clinic for a 
medical examination at approximately 3-year 
intervals. Details of the study protocol have 
been published elsewhere [17-19] and can be 
found on www.PREVEND.org.
In  total  8.592  participants  completed  the 
first  screening  round  in  1997-1998.  The 
second screening round (between 2001-2003) 
Figure 1. Outline of the PREVEND study; first 
three screenings. FU=follow-up.
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was completed by 6.894, whereas the third screening round (between 2003-2006) was 
completed by 5.862 subjects (Figure 1). For the present study, we excluded subjects of whom 
no follow-up eGFR value was available (n=1.699), and in addition, subjects with an eGFR 
value <45 ml/min/1.73m2 at the first screening round (n=64). In general these latter subjects 
are already regarded as subjects with a high renal risk and will be referred to specialist care 
or intervention by a general practitioner will take place. Furthermore, we excluded subjects 
who indicated having a renal disease during the first screening round (n=20). Included for the 
present study are therefore 6.809 subjects. 
The PREVEND study was approved by the local medical ethics committee and conducted 
in accordance with the guidelines of the declaration of Helsinki. All participants gave their 
written informed consent.
Measurements 
Each screening round consisted of two visits to an outpatient department separated by 
approximately  three  weeks.  Participants  filled  out  a  questionnaire  on  demographics, 
cardiovascular and renal disease history, smoking status, and the use of oral antidiabetic, 
antihypertensive and lipid lowering drugs. Information on drug use was completed with 
data  from  community  pharmacies,  including  information  on  class  of  antihypertensive 
medication (e.g. ACEi/ARB). At both visit days blood pressure was measured in the right arm, 
every minute for 10 and 8 minutes, respectively, by an automatic Dinamap XL Model 9300 
series device (Johnson-Johnson Medical INC, Tampa, Florida). For systolic and diastolic blood 
pressure, the mean of the last two recordings from each of the two visit days of a screening 
round  was  used.  Anthropometrical  measurements  were  performed,  and  fasting  blood 
samples were taken. Concentrations of total cholesterol and plasma glucose were measured 
using standard methods. Serum creatinine was measured by dry chemistry (Eastman Kodak, 
Rochester,  New  York,  USA),  with  intra-assay  coefficient  of  variation  of  0.9%  and  inter-
assay coefficient of variation of 2.9%. eGFR was estimated using the Modification of Diet 
in Renal Disease (MDRD) study equation, taking into account gender, age, race, and serum 
creatinine [20]. In addition, subjects collected urine for two consecutive periods of 24 hours. 
Urinary albumin concentration was determined by nephelometry (Dade Behring Diagnostic, 
Marburg, Germany), and UAE was given as the mean of the two 24-hour urinary excretions.  
As a proxy for dietary sodium and protein intake we used the 24-hr urinary excretion of 
sodium and urea, respectively. 
Definitions
A history of cardiovascular disease (CVD) was defined as having a history of myocardial 
infarction and/or a history of a cerebrovascular accident for which the individual had been 
admitted to a hospital, as indicated at the baseline questionnaire. ‘Known hypertension’ and 
‘known diabetes’ was noted when individuals received medical treatment for this condition 
or when the subject indicated this in the questionnaire. Family history for chronic kidney 
disease and coronary heart disease was based on information about first degree relatives 
(data from questionnaires). Smoking was defined as current smoking (including subjects who 
quitted smoking for less than 1 year before the screening) or non-smoking (including subjects 
who quitted smoking at least one year before the screening). Change in renal function was 
calculated as eGFR at follow-up subtracted by eGFR at baseline, divided by duration of follow-
up (expressed in ml/min/1.73 m2 per year). Subjects were defined as having progressive CKD 
when they belonged to the group of subjects with the 20% most rapid renal function decline Chapter 7
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and having an eGFR value <60 ml/min/1.73 m2 during follow-up. For the definition of 20% 
most rapid renal function decline gender-specific values were used.
Statistical Analyses
Continuous data are reported as mean and standard deviation. For skewed distributions, 
median and interquartile range are presented. All p-values are two-tailed. A P-value < 0.05 is 
considered to indicate statistical significance. 
Model development
As possible predictors for progressive CKD we used variables that were obtained at the first 
screening round and that have been suggested in the literature to be renal risk factors; age, 
gender, CVD history, known hypertension, known diabetes, family history for CVD, family 
history for CKD, smoking, systolic blood pressure, body mass index, eGFR, plasma total 
cholesterol, glucose, triglycerides and C-reactive protein (CRP), urinary albumin excretion 
(UAE), and daily intake of sodium and protein. First, we analyzed univariable associations 
between these predictors and incident progressive CKD using logistic regression analysis. 
Variables that had an association with the outcome measure with a P-value <0.2 were 
selected for multivariable analysis. Second, a multivariable model was built using backward 
selection, which will be used as the final model with the continuous predictors. Values of 
UAE, CRP and triglycerides were logarithmically transformed to fulfill the requirement of 
linearity of the logit. The final model was tested for possible non-linear associations between 
continuous predictors and incident progressive CKD by adding quadratic terms. Quadratic 
terms with a P-value < 0.05 were considered significant and were added to the model if 
necessary. 
Model validation
The  performance  of  the  final  model  was  evaluated  by  analysis  of  the  area  under  the 
Receiver Operating Characteristic (ROC) curve. The internal validity of the prediction model 
was evaluated by bootstrapping [21]. Two hundred samples of equal size were drawn at 
random and with replacement from the complete dataset. In these bootstrap samples the 
coefficients of the final regression model were estimated and tested in the original sample. 
The differences between the coefficients in the original sample and bootstrap samples as 
reflected by the slope index, is the measure for the amount of ‘optimism’. Normally, slope 
values lie between 0 and 1. A slope value of 1 means no optimism. The slope index was 
used as a shrinkage method by multiplying coefficients with this slope index to correct for 
optimism .  
Prediction of an individual subject’s risk
A prediction model was developed based on the regression coefficients in the final regression 
model. With this prediction rule the probability of having progressive CKD after a follow-up 
period of 6.4 years was estimated for each individual. The general equation for estimating 
the probability (P) of having progressive CKD is:
The linear predictor (lp) consists of the regression coefficients estimated in the final model, 
multiplied by the values of each predictor for each patient. Chapter 7
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Equati  on 1. Predicti  on rule based on the opti  mism corrected coeﬃ   cients of the multi  variable 
logisti  c regression model.
To facilitate calculati  on of an individual subject’s risk in clinical practi  ce analyses were also 
performed with the predictors of the fi  nal predicti  on model divided in clinically meaningful 
categories (see table 4). With this model a numerical score chart was derived, by rounding 
up the esti  mates of the corresponding regression parameters obtained from the model. The 
performance of this model was also evaluated by analysis of the area under the Receiver 
Operati  ng Characteristi  c (ROC) curve. The diagnosti  c characteristi  cs of this model in terms 
of  sensiti  vity,  specifi  city,  positi  ve  predicti  ve  value  and  negati  ve  predicti  ve  value  were 
calculated.  
All logisti  c regression analyses were weighted to adjust for the enrichment of our study 
cohort with subjects with higher levels of albuminuria. Analyses were conducted with the 
use of the stati  sti  cal package SPSS 16.0 (SPSS, Chicago, IL) and bootstrapping was performed 
in R version 2.10.1 for Windows [22].  
Results
During a median follow-up of 6.4 years (37.384 person years), 272 subjects complied with 
our defi  niti  on of progressive CKD. The baseline characteristi  cs of these 6.809 subjects who 
were included in these analyses were comparable with the subjects who did not parti  cipate 
in follow-up screenings concerning age, glucose, cholesterol and eGFR. The subjects who 
were not included had a slightly higher UAE (9.1 vs 11.2 mg/24 hr) and SBP (128 vs 133 
mmHg). Table 1 shows the baseline characteristi  cs of the 6.809 subjects with and without 
progressive CKD. The subjects who meet the defi  niti  on of progressive CKD are older and 
have a worse cardiovascular risk profi  le (e.g. higher blood pressure, lipid levels, glucose and 
UAE, and a lower baseline eGFR). 
Table 2 shows the results of univariable logisti  c regression analyses. Age, CVD history, known 
hypertension, known diabetes, positi  ve family history for CVD, BMI, SBP, total cholesterol, 
triglycerides, UAE, CRP, urinary sodium and urea excreti  on and baseline eGFR are all associated 
with progressive CKD. Only variables which showed an univariable associati  on (p < 0.2) were 
selected for the backward stepwise analyses. Table 3 presents the fi  nal multi  variable model 
aft  er backward selecti  on analysis. This model includes besides baseline eGFR and eGFR2, 
age, UAE, CRP, SBP and known hypertension. A non-linear associati  on of baseline eGFR with 
the risk of progressive CKD was found. Therefore the quadrati  c term of baseline eGFR was 
included in the model. The multi  variable regression coeffi   cients were additi  onally multi  plied 
with the shrinkage factor (shrinkage factor = 0.98), to correct for ‘opti  mism’. Based on these 
opti  mism corrected coeffi   cients of the multi  variable logisti  c regression model presented in 
table 3, the predicti  on rule as given in equati  on 1 was constructed
With this predicti  on rule the probability to develop progressive CKD within 6.4 years of 
follow-up can be calculated for each individual. The area under the ROC-curve for this model 
was 0.838 [95%CI 0.816 to 0.861], indicati  ng that the discriminati  on of the model is high.
For  clinical  use,  a  model  was  built  with  the  predictors  divided  in  clinically  meaningful 
categories (results are presented in table 4). The regression coeffi   cients of this model are 
also corrected for ‘opti  mism’ by multi  plying the coeffi   cients of the original model by the 
shrinkage factor (shrinkage = 0.97). The accompanying score chart, based on the coeffi   cients Chapter 7
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Table 1: Baseline characteristics for subjects with and without progressive CKD
No progressive CKD Progressive CKD
N (6809) 6537 272
Gender (% male) 49.8 50.2
Age (yrs) 49.0 (11.9) 60.8 (11.3)
Smoking (%) 36.3 32.4
Waist circumference (cm) 88.1 (12.8) 92.6 (12.5)
SBP (mmHg) 127 (19) 145 (25)
DBP (mmHg) 74 (10) 80 (11)
Antihypertensive medication (%) 13.3 41.3
Cholesterol (mmol/l) 5.6 (1.1) 5.9 (1.2)
Triglycerides (mmol/l) 1.1 (0.83-1.66) 1.4 (0.97-2.12)
Lipid lowering medication (%) 5.8 14.1
Glucose (mmol/L) 4.8 (1.1) 5.5 (2.3)
Antidiabetic medication (%) 1.3 5.9
CRP (mg/l) 1.2 (0.5-2.8) 2.0 (0.98-4.30)
UAE (mg/24h) 9.0 (6.2-15.6) 14.9 (7.7-45.1)
Urinary urea excretion (mmol/24 h) 359.3 (104.1) 339.5 (97.9)
Urinary sodium excretion (mmol/24 h) 142.8 (50.7) 138.8 (50.6)
Baseline eGFR (ml/min/1.73m2) 81.4 (13.6) 68.9 (9.1)
Change in eGFR per year (ml/min/1.73m2)  -0.35 (1.52) -3.16 (1.60)
Abbreviations are: eGFR; estimated glomerular filtration rate, SBP; systolic blood pressure, DBP; diastolic blood pressure, CRP; C-reactive 
protein UAE; urinary albumin excretion.
Table 2: Results of the univariable logistic regression analyses for progressive CKD.
OR 95% CI P-value
Age (yrs) 1.07 1.06-1.09 <0.0001
Female gender 1.17 0.90-1.51 0.251
CVD history (yes/no) 2.44 1.51-3.95 <0.0001
Known hypertension (yes/no) 4.50 3.37-6.03 <0.0001
Known diabetes (yes/no) 5.45 2.70-11.02 <0.0001
Positive fam history CVD (yes/no) 1.47 1.13-1.89  0.003
Positive fam history CKD (yes/no) 1.05 0.47-2.34  0.904
Smoking (yes/no) 1.01 0.77-1.32  0.968
BMI (kg/m2) 1.08 1.05-1.11 <0.0001
SBP (mmHg) 1.03 1.03-1.04 <0.0001
Total cholesterol (mmol/l) 1.18 1.06-1.31  0.002
Glucose (mmol/l) 1.27 1.18-1.37 <0.0001
Triglycerides (mmol/l), ln-transformed 1.99 1.58-2.51 <0.0001
UAE (mg/24hr), ln-transformed 1.61 1.41-1.82 <0.0001
CRP (mg/l), ln-transformed 1.43 1.28-1.60 <0.0001
Urinary sodium excretion (mmol/24hr) 0.997 0.994-1.000  0.037
Urinary urea excretion (mmol/24hr) 0.998 0.997-0.999  0.001
Baseline eGFR (ml/min/1.73m2) 0.916 0.905-0.927  <0.0001Chapter 7
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Table 3: The final multivariable logistic regression model for progressive CKD
OR 95% CI P-value
Baseline eGFR (ml/min/1.73m2) 1.45 1.22-1.74 <0.0001
Baseline eGFR2 (ml/min/1.73m2) 0.997 0.996-0.998 <0.0001
Age (yrs) 1.02 1.01-1.04   0.001
UAE (mg/24hr) ), ln-transformed 1.27 1.11-1.48   0.001
CRP (mg/l) ), ln-transformed 1.21 1.07-1.38   0.003
SBP (mmHg) 1.01 1.01-1.02 <0.001
Known hypertension (yes/no) 1.56 1.12-2.20   0.009
Table 4: Results of the univariable and multivariable logistic regression analyses for progressive 
CKD.
N (total) N (events) OR 
(univariable)
OR 
(multivariable)
Age (yrs)
<50 (Reference) 3747 55 1.00 1.00
50-70 2673 162 3.02 1.34
>70 389 55 7.06 2.04
eGFR (ml/min/1.73m2)
>90 (Reference) 1605 5 1.00 1.00
75-90 2869 56 14.9 14.37
60-75 2006 169 60.0 52.13
<=60 329 42 132.2 77.35
UAE (mg/24 hr)
<30 (Reference) 5911 180 1.00 1.00
30-150 728 82 2.69 1.82
150-300 75 10 4.38 2.28
>300 79 20 10.56 3.51
SBP (mmHg)
<160 (Reference) 6329 206 1.00 1.00
160-180 365 40 3.19 1.43
>180 113 26 8.47 3.28
CRP (mg/l)
<3 (Reference) 4959 163 1.00 1.00
3-10 1275 80 1.61 1.23
>=10 253 13 2.27 2.13
Known HT
No (Reference) 6062 183 1.00 1.00
Yes 747 89 4.51 1.94Chapter 7
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of the model in table 4 is presented in table 5. The area under the ROC-curve was 0.825 
[95%CI 0.802 to 0.848], indicating that the discrimination of the model is also high. The 
diagnostic characteristics of the model including categorical predictors are given in table 6.
 
Discussion
In  the  present  study  we  developed  and  validated  a  ‘Renal  Risk  Score’  for  the  general 
population to identify subjects at risk for progressive CKD, with progressive CKD being defined 
as belonging to the group of subjects with the most rapid renal function decline and an eGFR 
< 60 ml/min/1.73m2 during follow-up. Besides baseline eGFR, urinary albumin excretion, 
systolic  blood  pressure,  C-reactive  protein  and  known  hypertension  predict  the  risk  of 
progressive CKD. The area under the ROC-curve for this model including continuous data was 
0.838 [95%CI 0.816 to 0.861], showing that the discriminative ability of the prediction model 
was good. After internal validation, performed by bootstrapping, the performance of the 
model remained 0.838. For clinical use, we developed a score chart using predictors divided 
into clinically useful categories. This score chart offers the possibility to easily determine the 
risk of progressive CKD for an individual subject.
Recently, several prediction models have been developed to predict the new-onset  CKD or 
the progression of renal disease. In general, these prediction models are developed for high 
risk populations, such as populations with known underlying cardiovascular disease [23], or 
with a known renal disease such as IgA nephropathy [24], diabetes type 2 and nephropathy 
[25] or renal artery stenosis [26]. To our knowledge, only two prediction models have been 
developed in the general population to identify subjects with CKD or at risk of developing 
CKD. The first prediction model, named SCORED (Screening for Occult Renal Disease) predicts 
the risk of prevalent CKD (defined as eGFR<60 ml/min/1.73m2) for an individual. This model 
was developed in a general population (n=8.530), comparable with the population we used 
for our model, and used cross-sectional data. As a consequence this model can not predict 
which individuals are at high risk to develop progressive CKD during follow-up. The authors 
were able to predict the risk of prevalent CKD based on age, gender, and the presence of 
several health conditions (anemia, hypertension, diabetes, history of cardiovascular disease, 
history of congestive heart failure, peripheral vascular disease and proteinuria). The area 
under the ROC-curve (0.88) was good, and also the performance in an external dataset was 
acceptable (UAC of the ROC-curve 0.71) [27]. The second prediction model was developed in 
a population-based cohort in the United States and resulted in a prediction model for incident 
CKD (defined as eGFR<60 ml/min/1.73m2) within a follow-up of 9 years [28]. The authors also 
performed a sensitivity analysis defining CKD as developing an eGFR<60 ml/min/1.73m2 and 
a renal function decline of at least 10 ml/min/1.73m2 during the 9-year follow-up period. 
This latter outcome is comparable with the definition we use for progressive CKD. In the 
final  prediction  model  they  included  age,  race,  gender,  anemia,  hypertension,  diabetes 
mellitus, history of cardiovascular disease or heart failure and peripheral vascular disease. 
The performance of this model was reasonable with an area under the ROC-curve of 0.70. 
A comparison between the results of this study and the study we performed, shows that 
both models include age and known hypertension as predictors. However, the area under 
the ROC-curve in our study is higher. This difference can be explained by the fact that the 
nature of the data we used is not comparable. Instead of dichotomized data we included 
continuous data, such as level of SBP, in our analyses. Importantly, in our final model two well 
acknowledged renal risk markers were not taken into account, being baseline albuminuria 
and renal function. Our results show that baseline eGFR, and to a lesser extent also baseline Chapter 7
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albuminuria, contribute significantly to risk prediction.
How could our prediction model be implemented in clinical practice? Our results show that 
it is possible to predict the risk of having progressive CKD within 6.4 years follow-up for 
individuals based on demographical data and relatively simple laboratory measurements. 
Of course, it is rather arbitrary which cut-off values to adopt indicating high risk. Positive 
and  negative  predictive  value  should  be  weighed  against  each  other.  Furthermore,  the 
relevance of the endpoint is important, with relevance being assessed by the individuals 
involved themselves, and by the health care system. The importance of progressive CKD 
as defined in this study may by some be regarded not to be comparable with, for instance, 
death or a major cardiovascular event. Based on the present data we propose to adopt a 
score of 27 or higher to indicate high risk. A score of 27 or higher is found in only 2.1 percent 
of the population, and of these subjects 28.1% will have progressive CKD during follow-up. 
This high risk may justify the start of renoprotective treatment. Adopting this cut-off, results 
in the fact that a relatively large part of the subjects with progressive CKD will be missed 
(84.3%). Introducing an intermediate risk class could be a solution to this problem. Subjects 
with a score of 21 through 26 account for 12.7% of the population and 35.3% of the subjects 
with progressive CKD. Their risk to develop progressive CKD is 16.4%. These subjects could 
be asked to visit a screening facility to repeat measurement of eGFR in for instance two 
and four years. Only those with proven decline in renal function during follow-up should 
start renoprotective treatment. These data show that our prediction model can be used as a 
powerful tool to improve clinical decision making.  
One of the strengths of our study is the use of a large cohort for the development and 
validation of the prediction model. In addition, we were able to develop a score chart, an easy 
tool for clinical practice. Such a score chart facilitates the calculation of the probability for 
individuals to have progressive CKD within 6.4 years of follow-up. Also the inclusion of only 
baseline characteristics that are relatively easy and inexpensive to measure is an advantage. 
Of course limitations of our study need to be mentioned. The prediction model we describe 
in this study is developed in a predominantly Caucasian population and is therefore, not 
necessarily valid for other populations. Validation was performed internally and without data 
of another cohort (external validation). In the literature several methods for internal validation 
have been suggested. Of these methods the bootstrapping method is recommended [29]. By 
applying this method it appeared that ‘optimism’ was very small and, therefore, the internal 
validity of our model was high. High internal validity is generally seen as an indicator for good 
external validity [30]. Furthermore, research on ways to decrease the rate of renal function 
decline  in  high  risk  subjects  is  needed.  In  addition,  the  cost-effectiveness  of  screening 
programmes should be determined. Our present study should be seen as a first, important 
step towards the design of such studies. 
In conclusion, we developed and validated a ‘Renal Risk Score’ for the general population to 
predict for individual subjects the risk of progressive CKD. The final model showed that the 
individual risk of progressive CKD can be assessed by eGFR, age, SBP, UAE, CRP and known 
hypertension. The discriminative ability of this model, and the results of internal validation, 
showed that the performance of the model was good. These data suggest that our ‘Renal 
Risk Score’ can be of help to identify subjects at increased risk for progressive CKD.   Chapter 7
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Table 5: Score chart. 
Score chart
Charateristic Points 
Age (yrs)
<50 (Reference) 0
50-70 1
>70 3
eGFR (ml/min/1.73m2)
>90 (Reference) 0
75-90 13
60-75 19
<=60 21
UAE (mg/24 hr)
<30 (Reference) 0
30-150 3
150-300 4
>300 6
SBP (mmHg)
<160 (Reference) 0
160-180 2
>180 6
CRP (mg/l)
<3 (Reference) 0
3-10 1
>=10 4
Known HT
No (Reference) 0
Yes 3
For each individual subject for all predictors the category and the accompanying points should be determined. 
Subsequently all the scores are added to calculate the ‘Total Score’. The risk (in percentage) of developing 
progressive CKD within 6.4 years of follow-up can be determined based on the total score. 
 Total score Risk (%)
≤20 0% - 5%
20-23 5% - 10%
24-28 10% - 20%
29-30 20% - 30%
31-32 30% - 40%
33-34 40% - 50%
35-36 50% - 60%
37-38 60% - 70%
39-40 70% - 80%
≥41 80% - 86%Chapter 7
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Table 6. Diagnostic characteristics of the prediction model
Total score Population 
(%)
Identified 
events (%)
Sensitivity 
(%)
Specificity 
(%)
PPV NPV
≥32 0.3 2.9 2.9 99.8 33.3 96.3
≥30 0.9 10.8 10.8 99.5 45.8 96.6
≥29 1.1 10.8 10.8 99.2 35.5 96.6
≥28 1.5 10.8 10.8 98.9 26.8 96.6
≥27 2.1 15.7 15.7 98.4 28.1 96.7
≥26 2.8 15.7 15.7 97.7 20.8 96.8
≥25 4.8 25.5 25.5 95.7 19.7 96.8
≥24 6.4 30.4 30.4 94.5 17.7 97.1
≥23 9.2 40.2 40.2 92.0 16.3 97.2
≥22 12.8 46.1 46.1 88.5 13.5 97.5
≥21 15.5 51.0 51.0 85.9 12.3 97.7
≥20 27.1 66.7 66.7 74.5 9.2 98.2
≥19 38.2 84.3 84.3 63.6 8.3 99.1
≥15 45.6 89.2 89.2 62.5 7.3 99.3
≥10 78.2 99.0 99.0 22.6 4.7 99.8
≥5 79.2 99.0 99.0 21.6 4.6 99.8
≥0 100 100.0 100.0 0.0 0.0 100.0Chapter 7
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In 2002 the Kidney Disease Outcome Quality Initi  ati  ve (KDOQI) clinical practi  ce guidelines 
were published on the classifi  cati  on of chronic kidney disease (CKD) [1]. The fi  ve stages of 
chronic kidney disease are mainly based on glomerular fi  ltrati  on rate (GFR). In the fi  rst two 
stages also the presence of renal damage defi  ned as albuminuria is taken into account. In 
stage 1 the eGFR is > 90 and in stage 2 the eGFR is between 60-89 ml/min/1.73m2. The 
last three stages are based enti  rely on the eGFR (stage 3 defi  ned as an eGFR between 30-
59 ml/min/1.73m2, stage 4 eGFR between 15-29 ml/min/1.73m2  and stage 5 eGFR < 15 ml/
min/1.73m2). Of note, the presence of albuminuria in the urine gives no clinical symptoms. 
Since this publicati  on several epidemiological studies showed that the prevalence of CKD 
based on this classifi  cati  on system is high in the general populati  on. For example, a study 
performed in the United States showed that the prevalence of CKD was 13% [2]. Similar 
rates have been shown worldwide, with a CKD prevalence of 13% in China [3], 17.5 % in 
Thailand [4], 16% in Australia [5] and 10 % in Norway [6]. Even more alarming are the low 
percentages of awareness of this conditi  on among the pati  ents involved and their general 
practi  ti  oners [7-9]. This low awareness results in late detecti  on, and consequently in a late 
start of appropriate treatment. Therefore these pati  ents can not benefi  t opti  mally from the 
interventi  ons that can postpone renal replacement therapy. Figure 1 shows that in pati  ents 
with progressive CKD, it is likely that an early identi  fi  cati  on and subsequent early interventi  on 
can postpone the start of renal replacement therapy.
Especially in the Western world, the major causes of CKD are diabetes and hypertension. 
A study performed in the United States showed that over 70% of the incident End-Stage 
Renal Disease (ESRD) cases were accounted for by diabetes and hypertension, whereas less 
than 30% of the CKD cases were due to primary glomerulopathies, inherited conditi  ons 
and autoimmune conditi  ons [10]. It is alarming that the prevalence of hypertension and 
diabetes in the general populati  on is high. For example, the NEOERICA project, performed 
Figure 1: Schemati  c presentati  on of the decline in GFR over years in a subject with progressive 
chronic kidney disease and in a subject without progressive chronic kidney disease (normal ageing). 
Indicated is the hypotheti  cal change in slope when interventi  on focused on the renal risk factors is 
started in a late phase and the (expected) change in slope in case interventi  on is started early. The 
horizontal dott  ed line at an eGFR of 10 ml/min/1.73m2 indicates the rate at which renal replacement 
therapy is needed. Chapter 8
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in a population-based cohort, showed that the prevalence of diabetes was 10.6% and of 
hypertension  55.8% [11]. Risk factors for hypertension and diabetes such as obesity [12], 
lack of physical activity [13] , diets high in fat and increasing caloric intake are rising [14]. 
These data suggest that a rapid increase in the number of patients with CKD may be expected 
in the near future. On the other hand, although the prevalence of the CKD stages 3 (eGFR 
between 30 and 59 ml/min/1.73m2 without renal damage) and 4 (eGFR between 15 and 29 
ml/min/1.73m2, without renal damage) is high, only a small proportion of these patients 
develop ESRD [15;16]. Therefore, it has been advocated that there is a need for ‘Renal Risk 
Scores’ to identify subjects who are at increased risk to develop progressive CKD [17]. 
During the development of such risk scores modifiable risk factors should be of particular 
interest, since, after identification of persons with increased risk of developing progressive 
CKD, these risk factors can be treated. Results from several clinical trials have identified 
interventions that are effective in slowing the rate of progression of chronic kidney disease 
such as strict blood pressure control and lowering of albuminuria  [17]. The MDRD study 
showed that in patients with CKD a low blood pressure goal (125/75 mmHg) resulted in a lower 
rate of renal function decline. The low blood pressure goal had the greatest beneficial effect 
in subjects with proteinuria [18]. Results from the RENAAL study showed that a decrease of 
10 mmHg in systolic blood pressure lowered the risk of progression to ESRD or death by 6.7% 
[19]. It has been proven that intervention in the renin-angiotensin-aldosterone-system, for 
instance with ACE inhibitors and angiotensin-II receptor blockers, decreases not only blood 
pressure, but also reduces proteinuria more than might be expected from blood pressure 
lowering alone [20;21]. A meta-analysis, including data of 11 randomized clinical trials showed 
that the use of ACE-inhibitors in CKD patients lowered the risk of developing ESRD (relative 
risk of 0.70 [95% CI 0.51-0.94] compared with the group who did not use ACE inhibitors) [22]. 
Therefore, ACE inhibitors and angiotensin-II receptor blockers have a renoprotective effect 
that is superior to that of other antihypertensive agents. Another modifiable risk factor 
suggested to be associated with the rate of renal function decline is dietary protein intake. 
It has been shown that protein restricted diets slow the rate of renal function decline [23], 
although a meta-analysis provided no convincing results [24].
The aim of this thesis was to identify predictors for accelerated renal function decline in the 
general population and finally to develop a ‘Renal Risk Score’ to identify subjects at risk to 
progress to ESRD. In this last chapter we summarize and discuss the findings described in this 
thesis. 
In  chapter  2  several  methods  to  detect  subjects  with  early  chronic  kidney  disease  are 
discussed.  Screening  for  low  eGFR  is  a  generally  accepted  method  to  identify  subjects 
with CKD. However, our study shows that there is increasing evidence that screening for 
albuminuria is more beneficial and should definitely be added to screening for low eGFR. 
Recently, several other studies also showed that screening programs to identify subjects at 
increased renal and cardiovascular risk should take the level of albuminuria or a combination 
of low eGFR and albuminuria into account [25;26].  Another study performed with data from 
the PREVEND cohort is also in line with our findings, showing that stratification based on the 
presence or absence of albuminuria defines two separate groups at respectively high and 
low risk for both CVD and accelerated renal function decline [27]. The combination of eGFR 
and albuminuria to predict the progression to ESRD disease is also shown to be effective in 
a large population-based study performed in Norway [15]. All these findings together show 
that albuminuria has established its position as an important screening tool. High excretion Chapter 8
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of urinary albumin (macroalbuminuria) is, in subjects with renal disease, seen as a putative 
renal risk marker. However, the existence and influence of macroalbuminuria in the general 
population is unknown. Thus, in chapter 3 we investigated the renal outcome for subjects 
with macroalbuminuria in the general population. Also the presence of erythrocyturia and 
a low eGFR was studied, since these are putative risk markers for poor renal outcome in 
patients with diagnosed renal disease. Macroalbuminura was defined as ≥ 300 mg/24 hr, 
erythrocyturia as ≥ 250 erythrocytes/l, without leukocyturia and low eGFR was based on 
both 24 hr creatinine clearances and Modification of Diet in Renal Disease clearance below 
the age- and gender specific fifth percentile. In our population of 8.592 subjects, there were 
134 subjects with macroalbuminuria, 128 with erythrocyturia and 103 with a low eGFR. 
It was remarkable that less than 30% of these persons were known to have a laboratory 
abnormality before screening. The cardiovascular mortality and morbidity were high in both 
the macroalbuminuria (4.5 and 21.6%) and the low eGFR subjects (5.8 and 23.3%) compared 
with the total population (0.8 and 6.1%). According to cardiovascular mortality and morbidity 
the figures for the subjects with erythrocyturia were comparable with the total population. 
Concerning the renal outcome these groups were very different. The subjects with a low 
eGFR showed almost no eGFR loss after 4.2 (and 6) years follow-up. However, the subjects 
with macroalbuminuria experienced a large eGFR loss of 7.2 ml/min/1.73m2 after 4.2 years of 
follow-up. The total population and the subjects with erythrocyturia were also comparable 
with respect of their renal outcome (-2.3 and -2.6 ml/min/1.73m2 respectively). The results 
of this study showed that the subjects with a low eGFR had much better prognosis based 
on their renal outcome than the subjects with macroalbuminuria. Therefore, these results 
strongly support the hypothesis that in studies performed to identify subjects at risk to 
develop CKD or ESRD albuminuria should be taken into account. However, we should keep 
in mind that the results described in chapter 3 focused on subjects with macroalbuminuria 
(>300 mg/24-hr) and that the prevalence of macroalbuminuria is 0.6% in the Netherlands.
The fact that a large proportion of CKD is attributable to diabetes and hypertension [10] 
justifies a  focus on the modifiable risk factors for diabetes and hypertension and therefore 
CKD. Obesity, unhealthy diets, lack of physical activity are risk factors leading eventually to 
increases in the prevalence of CKD [14;28]. Especially risk factors which are known to be 
associated with a worse renal outcome in patients already having CKD are of great interest. 
There is evidence that patients with CKD benefit from a protein restricted diet [29;30]. In the 
Western world food patterns change towards diets high in protein. These changes together 
with the results found in CKD populations were the reason to focus on the association 
between protein intake and renal outcome in the general population (chapter 4).  In this 
chapter we focused on the association between the amount of protein intake and renal 
and cardiovascular outcome. This study showed that there was no association between the 
amount of protein intake and the rate of renal function loss after 6.4 years of follow-up in 
the general population. However, there was a U-shaped association between the amount of 
protein intake and cardiovascular morbidity and mortality. Therefore, this study provides no 
evidence for the hypothesis that a high protein intake is a risk factor for renal function loss in 
the general population. However, these data show that both the intake of a low amount and 
a high intake of protein intake is a risk factor for cardiovascular outcome.
 
In the first chapters of this thesis the effects of a low eGFR, macroalbuminuria, erythrocyturia 
and the intake of different amounts of protein on the course of renal function during follow-
up are studied. In chapter 5 and 6 the focus is on the best combination of risk factors and Chapter 8
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changes in risk factors to predict the decline in renal function. The final chapter describes a 
‘Renal Risk Score’, a tool to identify subjects at risk for progressive CKD. 
In chapter 5 data from the first three screenings of the PREVEND cohort study are used 
to identify predictors for accelerated renal function decline. The renal function decline is 
calculated based on the available GFR estimates using linear regression. In these analyses 
we  identified  gender  as  a  significant  effect  modifier,  therefore  we  performed  these 
analyses for males and females separate. Multivariable linear regression analyses showed 
that  in  males  UAE,  systolic  blood  pressure  and  plasma  glucose  were  associated  with 
subsequent accelerated renal function decline during 6.4 years of follow-up. Higher waist 
circumference and cholesterol/HDL ratio were associated with less renal function decline. 
The analyses performed in females showed that systolic blood pressure, plasma glucose and 
cholesterol/HDL ratio were associated with subsequent accelerated renal function loss. High 
levels of triglycerides were associated with less renal function decline. These results are partly 
in line with several other studies in which the effect of a single risk factor or a combination 
of several risk factors on renal function decline was investigated in both population-based 
cohorts and patient populations [31-35].  A logical next step was to investigate whether 
changes in risk factors effected the subsequent change in renal function. The results of these 
analyses in which we analysed the effect of a change in several risk factors between the first 
and second screening examination (mean follow-up 2.2 years) on the subsequent change in 
renal function between the second and third screening are described in chapter 6. In these 
analyses we focused on changes in UAE, SBP, cholesterol, glucose, waist circumference, 
smoking behaviour, use of ACE-inhibiters, use of antihypertensive medication and lipid-
lowering medication. Based on the results of the previous chapter, these analyses were 
performed stratified for gender. The results showed that in males increases in SBP, cholesterol 
and UAE were followed by accelerated renal function decline.  In females an increase in 
glucose was associated with subsequent more renal function decline.
Various studies have shown that the prevalence of CKD is high and will probably increase 
in the near future [11;36-38]. The survival on renal replacement therapy is low and the 
problem of the shortage of kidneys available for donation is definitely not solved in the near 
future. Therefore, the largest profit can be made by identifying subjects at increased risk 
for developing ESRD in a very early stage of their disease. This identification will only lead 
to a large profit, if there is appropriate treatment of these subjects available and in this 
field there is still a lot of research to be done. The identification of the subjects at increased 
risk to develop ESRD, brings me to the final goal of this thesis: to develop and validate a 
‘Renal Risk Score’. The need for such a risk score is repeatedly advocated in the literature 
[39;40]. In chapter 5 we identified predictors for accelerated renal function decline. Based 
on the knowledge gained in the previous chapters we developed a ‘Renal Risk Score’ for the 
general population. First and most important, the use of such a screening tool should be 
easy and simple. Second, another very important characteristic for an efficient risk score is 
the cost-effectiveness. Therefore, we decided to start with a ‘Renal Risk Score’ using only 
baseline values of the risk factors. The developed ‘Renal Risk Score’ is described in chapter 
7. The aim of this ‘Renal Risk Score’ was to predict for each individual the probability to 
develop progressive CKD within 6.4 years of follow-up. For this prediction rule we defined 
progressive CKD as having an eGFR during follow-up below 60 ml/min/1.73m2 and the 20th 
percentile decline in renal function during follow-up. It is known that the number of subjects 
who eventually develop ESRD is low. Therefore, we based our definition both on the level of 
eGFR and the rate of decline. In our opinion, the subjects with a low eGFR and an increased Chapter 8
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decline in renal function are at high risk to develop ESRD or develop cardiovascular disease 
even before they develop ESRD. Possible predictors were selected from previous chapters 
and the literature. Based on univariable logistic regression analyses the candidate predictors 
for the ‘Renal Risk Score’ were selected. The final multivariable model included baseline 
eGFR, age, UAE, CRP, SBP and known hypertension. The area under the ROC curve was high 
(0.838) indicating that it is possible to identify subjects who are likely to develop progressive 
CKD. One of the advantages of this model is that based on simple demographical data and 
laboratory measurements for each individual the probability of developing progressive CKD 
can be estimated. The cost-effectiveness of the risk score is not studied yet. However, we 
can imagine that the use of this score is relatively cheap because only demographic data 
and simple laboratory measurements are used. For future studies it should be interesting 
to investigate the improvement of such a score by taking into account also changes in risk 
factors. However, one should consider that including changes in risk factors the risk score 
might be more difficult to use on population level. Therefore, it could be considered to 
include changes in risk factors only in high-risk populations.
In conclusion, the studies presented in this thesis show that there are several predictors 
for accelerated renal function decline in the general population. Concerning the following 
putative renal risk factors; low eGFR, erythrocyturia and macroalbuminuria, subjects with 
macoralbuminuria had the worse renal function outcome during subsequent follow-up. 
Although, a low protein intake is advised to renal patients, in the general population subjects 
with high protein intake had a worse cardiovascular outcome compared with subject with 
a low protein intake but there was no association between the amount of protein intake 
and renal outcome. Furthermore, several known cardiovascular risk factors were identified 
as predictors for accelerated renal function decline. In males UAE, SBP and plasma glucose 
were associated with more renal function decline. Also increases in UAE, SBP and total 
cholesterol during follow-up were associated with more subsequent renal function loss. In 
females, we identified SBP, glucose and cholesterol/HDL ratio as predictors for accelerated 
renal function decline. To translate the information about risk factors for accelerated renal 
function decline into a useful tool for the clinical practice we developed and validated a 
‘Renal Risk Score’. With this ‘Renal Risk Score’ subjects who are at increased risk to have 
accelerated renal function loss and have an eGFR less than 60 ml/min/1.73m2 within 6.4 yrs 
can be identified based on their baseline eGFR, age, UAE, SBP, CRP and hypertension status. 
After identification of high risk subjects with the ‘Renal Risk Score’ appropriate treatment can 
be started in an early stage to, at least, slow down the renal function decline and hopefully 
to postpone the start of dialysis.  
Future research
Several aspects of the implementation and improvement of the ‘Renal Risk Score’ should 
be focus for future research. First, the model we developed could be extended with new 
risk markers to improve the performance of the model. In the field of nephrology several 
new risk markers for progression of CKD have recently been identified, for instance beta-
trace protein (BTP) [41], neutrophil gelatinase-associated lipocalin (NGAL) [42] and soluble 
TNF-like weak inducer of apoptosis (sTWEAK) [43]. Most of the research in this field focuses, 
however, on subjects with known CKD and therefore the value of these new risk markers in 
the general population is unknown. Hence, evaluation of the value of these new risk markers 
in the general population should be encouraged, as such risk factors could be added to the a 
‘Renal Risk Score’ to improve the performance and the yield of this risk score. Chapter 8
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If  an  association  study  shows  a  strong  association  between  a  particular  new  marker 
and  accelerated  renal  function  decline,  this  poses  a  high  expectation  of  the  marker’s 
performance. Such a new risk marker is only of interest in case its contribution to the risk 
model significantly improves the predictive value of the model. Popular methods to compare 
the performance of two models are the area under the ROC curves, likelihood ratios or the 
c-statistics of the old and new model [44].  However, research showed that these methods 
were not very well equipped to compare the clinical relevance of different models. In 2006, it 
was first described that in some situations the inclusion of a new risk marker did not increase 
the area under the ROC curve, but some subjects were reclassified into another risk category 
[45]. Logically, based on this new classification clinical decisions in these reclassified subjects 
were changed. These results showed that under certain conditions it may be important to 
include a specific marker although the overall performance of a model is not improved, 
but because it results clinical decisions. From 2006 onwards, several methods have been 
developed to compare prediction models based on reclassification measures. Examples are: 
the Reclassification Calibration Statistics, Integrated Discrimination Improvement and Net 
Reclassification Improvement. The Net Reclassification Improvement, for example, is based 
on the net increase versus decrease in risk categories among subjects with the disease minus 
that among subjects without the disease [45;46]. 
Ideally, the addition of a new risk marker to a prediction model leads for subjects that score 
“positive” in that model to a higher probability for these subjects to have the disease and 
for subjects that score “negative” in the model to a lower probability to have the disease. 
Let us assume that in the coming five years, research will show that NGAL is indeed strongly 
associated with accelerated renal function decline in the general population. A logical next 
step is to examine whether this new maker could improve the Renal Risk Score. Suppose, 
the analyses show that the Net Reclassification Improvement is of clinical relevance. Should 
we then decide to extend the renal risk score with NGAL? The answer to this question is 
dependent whether the improvement of the ‘Renal Risk Score’ is worth the extra costs the 
NGAL measurement brings along. 
For this purpose a cost-effectiveness analysis should be performed. In such an analysis the 
costs of the measurements needed to fill the Renal Risk Score, together with the costs as a 
result from the treatment followed after detection of the subjects at high risk, are weighted 
against the benefit from the early detection. The benefit is expressed in Quality Adjusted 
Life Years (QUALY) or in Life Years Gained (LYG), the difference between the two being that 
in QUALYs not only life expectancy but also quality of life is taken into account. Research 
performed in the US showed that the society’s willingness to pay is about $113.000 for each 
QUALY [47]. In The Netherlands there is an (unofficial) threshold of €20.000 per LYG for 
preventive measures to be implemented in health care. In cost-effectiveness analyses the 
costs involved with the measurements and treatment are weighted against the QUALYs or 
LYGs gained. 
Also for the ‘Renal Risk Score’ we developed in this thesis, cost-effectiveness analyses should 
be performed. Of note, in the ‘Renal Risk Score’ only demographic data and simple, low cost 
laboratory measurements are used as predictors. These data and laboratory measurements 
are in most higher risk subjects already available to general practitioners, as they are also 
used for estimation of cardiovascular risk. Studies performed with PREVEND data suggested 
that screening the general population for albuminuria to prevent cardiovascular and renal 
disease is potentially cost-effective for the Dutch situation applying the aforementioned 
threshold of €20.000 per LYG [48]. Taking these considerations into account it is plausible 
that the use of the ‘Renal Risk Score’ may be cost-effective.  Chapter 8
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Another possible concern for this type of screening tools may be the impact of false-positive 
results. If the result of the ‘Renal Risk Score’ shows that a specific subject has an increased 
risk in developing progressive CKD, this subject should be informed. The ideal way to inform 
a subject about this prognosis is to clarify the risk in such a way that the subject will take his 
or her situation serious and will comply with the recommended treatment. However, the 
results of the ‘Renal Risk Score’ showed that in the high risk category not all subjects will 
eventually develop progressive CKD and reach ESRD. Therefore, subjects involved should 
also be informed about the chance of having a false positive result from the ‘Renal Risk 
Score’. The psychological distress such a result can cause should not be neglected. Research 
performed in the field of screening for beast cancer showed that a false-positive result can 
have large consequences on the quality of life and induce symptoms of both anxiety and 
depression [45]. On the other hand, based on PREVEND data it was shown that screening for 
cardiovascular disease risk was associated with an increased use of cardioprotective drugs, 
but not with drugs that are used for anxiety or distress, such as benzodiazepines [49]. In the 
field of cancer screening [50;51], questionnaires have been developed to gain insight in the 
psychological consequences of the screening. Such questionnaires could help to measure the 
impact on the non-physical part of screening for progressive CKD.  
To conclude, the ‘Renal Risk Score’ developed during the realization of this thesis is a promising 
tool for clinical practice, but additional research is needed before it can be implemented.Chapter 8
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Het aantal mensen met een gestoorde nierfunctie is de afgelopen decennia sterk toegenomen. 
Dit  betekent  dat  er  steeds  meer  mensen  moeten  dialyseren  of  een  niertransplantatie 
moeten ondergaan. Een groot probleem is dat mensen met minder goed functionerende 
nieren hier in het beginstadium van hun ziekte zelf weinig van merken. Hierdoor wordt bij 
veel mensen pas in een laat stadium ontdekt dat hun nierfunctie gestoord is. Nierfunctie is 
een maat waarmee wordt aangegeven hoe de nieren functioneren. Een hoge waarde geeft 
aan dat de nieren goed functioneren en het lichaam goed kunnen zuiveren van afvalstoffen. 
Een lage waarde betekent slecht functionerende nieren, waardoor afval zich in het lichaam 
ophoopt. Het belangrijkste doel van het onderzoek beschreven in dit proefschrift, is het 
vinden van factoren die al in een vroeg stadium kunnen voorspellen welke mensen slecht 
functionerende nieren gaan ontwikkelen. Deze factoren zouden gebruikt kunnen worden om 
mensen op te sporen die veel risico lopen op nierfunctie achteruitgang. Eerder opsporen van 
deze mensen kan er uiteindelijk toe leiden dat deze mensen goed kunnen worden behandeld 
en er uiteindelijk minder mensen dialyse of niertransplantatie nodig hebben. Het effect van 
eerder opsporen door middel van voorspellers is ook schematisch weergegeven in figuur 1. 
De bovenste stippellijn (normale veroudering) geeft de normale afname in nierfunctie aan, 
namelijk de afname die veroorzaakt wordt door het ouder worden. De niet onderbroken lijn 
(Nierziekte) die een sterke afname in nierfunctie laat zien geeft aan wat er gebeurt met de 
nierfunctie van mensen die een nierziekte hebben en sneller verlies van nierfunctie hebben. 
Dit zijn dus de mensen die we in de ideale situatie in een vroeg stadium van hun ziekte op 
willen sporen. Het verschil tussen de lijnen met vroege interventie en late interventie geeft 
aan waarom het opsporen van deze mensen in een vroeg stadium zo belangrijk is. Door 
mensen eerder op te sporen en vroeg te behandelen wordt de achteruitgang in nierfunctie 
eerder geremd en zodoende kan dialyse of niertransplantatie (in de figuur is de nierfunctie 
behorend  bij  de  start  van  dialyse  aangegeven  met  de  horizontale  stippellijn)  langdurig 
worden uitgesteld. 
Figuur 1. Schematische weergave van de nierfunctie achteruitgang voor een persoon met een 
nierziekte (niet onderbroken lijn) en een persoon zonder nierziekte (Normale veroudering, bovenste 
stippellijn).110 111
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Voor alle analyses van dit proefschrift zijn data van het PREVEND cohort gebruikt. Dit cohort 
bestaat uit een grote groep volwassen inwoners uit de stad Groningen. Van deze mensen zijn 
vanaf 1997 allerlei gegevens verzameld, waaronder leeftijd, geslacht, bloeddruk waarden, 
hoeveelheid eiwit in de urine, informatie over hart- en vaatziekten en informatie over het 
gebruik van medicijnen. In een periode van ongeveer 6.5 jaar zijn van een groot aantal van 
deze mensen drie keer gegevens verzameld. 
In hoofdstuk 2 worden verschillende manieren om mensen met beginnende schade aan de 
nieren op te sporen besproken en met elkaar vergeleken. De algemeen geaccepteerde en tot 
nu toe meest onderzochte manier is het identificeren van mensen met een lage nierfunctie. 
Het bepalen van de nierfunctie in de klinische praktijk wordt gedaan door labwaarden 
en eigenschappen van een patiënt in een bepaalde formule in te vullen. Echter uit onder 
andere ons eigen onderzoek blijkt dat screenen op verlies van een bepaald eiwit in de urine 
(albuminurie) mogelijk een betere methode is om mensen met beginnende nierschade, die 
zowel een hoog risico lopen op het krijgen van een nierziekte en/of een hart- en vaatziekte 
op te sporen. Ook het screenen op een combinatie van een afgenomen nierfunctie en 
albuminurie lijkt een goede optie. Dit bewijs, samen met bewijs geleverd door andere grote 
onderzoeken, heeft albuminurie als screeningsinstrument op de kaart gezet. 
Het  voorspellend  vermogen  van  eiwitverlies  in  de  urine  (wanneer  dit  veel  is  heet  dit 
macroalbuminurie) op nierfunctie achteruitgang in de normale bevolking is in hoofdstuk 
3 onderzocht. Niet alleen het effect van macroalbuminurie maar ook van twee klassieke 
risicomarkers binnen de nefrologie, namelijk lage nierfunctie en de uitscheiding van rode 
bloedcellen  via  de  urine  (erythrocyturie),  is  onderzocht.  Binnen  de  PREVEND  populatie 
van 8592 deelnemers bleken er tijdens de eerste meting, in de periode tussen 1997 en 
1998, 134 mensen met macroalbuminurie, 128 mensen met erythrocyturie en 103 met 
een lage nierfunctie te zijn. Er was niet veel overlap tussen deze drie groepen. Uit verder 
onderzoek bleek dat van deze drie groepen mensen minder dan 30% met deze afwijking 
bij de huisarts bekend waren. In de jaren na deze metingen is er gekeken naar het aantal 
mensen dat een ernstige (fatale of niet fatale) hart- of vaatziekte heeft gekregen en hoe de 
nieren van deze mensen bleven functioneren. Het aantal hart- en vaatziekten is vervolgens 
vergeleken tussen de 3 groepen en ook met de totale populatie. Hieruit bleek dat de mensen 
die tijdens de eerste meting macroalbuminurie of een lage nierfunctie hadden veel meer 
hart- en vaatziekten hadden ontwikkeld, vergeleken met de totale populatie. Het aantal 
hart- en vaatziekten in de groep mensen met erythrocyturie bleek wat betreft het aantal 
vergelijkbaar te zijn met de totale populatie. Verder is er gekeken naar het verloop van de 
nierfunctie binnen deze groepen mensen in de jaren na de eerste meting. In figuur 2 zijn de 
resultaten van deze metingen per groep (macroalbuminurie, lage nierfunctie, erythrocyturie 
en de totale populatie) getoond.
Deze figuur laat zien dat de mensen met erythrocyturie ook wat betreft de verandering 
in nierfunctie weer erg op de totale populatie lijken. De groep met een lage nierfunctie 
verliest juist minder nierfunctie in de jaren die volgen in vergelijking met de totale populatie. 
Opvallend is dat de afname van nierfunctie in de groep mensen met macroalbuminurie veel 
groter is vergeleken met de totale populatie. Uit deze resultaten kunnen we concluderen 
dat binnen het PREVEND cohort het hebben van erythrocyturie geen verhoogde kans op 
het krijgen van een hart- en vaatziekte geeft en ook geen aanwijzing is dat de nierfunctie 
in de jaren die volgen meer zal afnemen. Het hebben van een lage nierfunctie verhoogt de 
kans op het krijgen van een hart- en vaatziekte, maar is geen aanwijzing voor veel verlies 112 113
van  nierfunctie.  Macroalbuminurie  daarentegen 
lijkt een goede voorspeller te zijn voor zowel een 
verhoogde kans op het krijgen van een hart- en 
vaatziekte als ook op nierfunctieverlies. 
Naast macroalbuminurie kunnen ook veel andere 
factoren, waaronder bepaalde leefgewoontes, van 
invloed zijn op de kans om nierfunctieverlies te 
krijgen of een hart- en vaatziekte te ontwikkelen. 
De  meeste  winst  hierbij  kan  behaald  worden 
door  de  zoektocht  naar  voorspellers  te  richten 
op  beïnvloedbare  factoren.  In  hoofdstuk  4 
staat  het  eten  van  eiwit,  een  voorbeeld  van 
een  beïnvloedbare  risicofactor,  centraal.  In  de 
Westerse  wereld  is  er  een  sterke  toename  in 
de  hoeveelheid  eiwit  en  koolhydraten  in  het 
dagelijkse voedingspatroon. In patiënten met een 
bekende nierziekte is aangetoond dat een hogere 
eiwitinname geassocieerd is met meer verlies van 
nierfunctie vergeleken met patiënten die minder 
eiwit aten. Juist de veranderingen in leefstijl en 
eetpatronen maken het interessant om te onderzoeken of in de algemene bevolking het 
eten van veel eiwit meer nierfunctieverlies tot gevolg heeft. Verder is er onderzocht of het 
eten van veel eiwit leidt tot meer hart- en vaatziekten en meer kans op overlijden. Voor 
het beantwoorden van deze vraag hebben we van de deelnemers uit de PREVEND studie 
de hoeveelheid gegeten eiwit geschat. Deze schatting wordt gebaseerd op de hoeveelheid 
ureum (een afbraakproduct van ingenomen eiwit) in de urine. De hoeveelheid eiwit in de 
voeding blijkt niet van invloed te zijn op de mate van nierfunctieverlies binnen een aantal 
jaren. Over de gevolgen op de langere termijn kunnen we op basis van onze gegevens geen 
uitspraak doen omdat we de deelnemers van PREVEND voor deze analyses gemiddeld maar 
ruim 6 jaar hebben gevolgd. Dus op basis van deze resultaten kunnen we een gevolg van 
het eten van veel eiwit op de nierfunctie op de lange termijn niet helemaal uitsluiten. De 
resultaten voor het krijgen van een hart- en vaatziekte als gevolg van de hoeveelheid eiwit 
in de voeding tonen wel een effect aan. Zowel de mensen die heel weinig eiwit eten als de 
mensen die veel eiwit eten, hebben meer kans op het krijgen van een hart- en vaatziekte. De 
mensen die heel weinig eiwit eten zijn waarschijnlijk mensen waar de gezondheidssituatie 
slecht van is, waardoor ze minder eiwit eten, maar waardoor ook hun kans op het krijgen 
van een hart- en vaatziekte verhoogd is. Deze data suggereren dat in de algemene bevolking 
het eten van veel eiwit op de korte termijn geen nierfunctieverlies tot gevolg heeft, maar 
wel geassocieerd is met een verhoogde kans op het krijgen van een hart- en vaatziekte. Een 
verlaging in de hoeveelheid eiwit in het eten zou daarom zeker een gunstige invloed kunnen 
hebben. Het is belangrijk ons te realiseren dat hier alleen spontane eiwitinname is onderzocht. 
Hierdoor kan niet worden uitgesloten dat een concrete verlaging van eiwitinname middels 
een interventie wel een gunstige invloed op de snelheid van nierfunctie achteruitgang zou 
kunnen hebben.
Ook  in  hoofdstuk  5  staat  de  zoektocht  naar  voorspellers  voor  verlies  van  nierfunctie 
centraal. In dit hoofdstuk is gekeken welke factoren goede voorspellers voor verlies van 
Figuur 2. Verloop van de nierfunctie in 
de verschillende onderzoeksgroepen.112 113
Nederlandse Samenvatting
nierfunctie zijn. De volgende factoren, welke bekend zijn als factoren die het optreden van 
hart- en vaatziekten mede bepalen en welke beïnvloed kunnen worden, zijn onderzocht: 
leeftijd, roken, voorkomen van bepaalde ziekten in de familie zoals nierziekten en hart- 
en  vaatziekten,  tailleomtrek,  gebruik  van  bloeddrukverlagende  medicatie,  cholesterol, 
cholesterol  verlagende  medicatie,  bloedsuikerspiegel,  bloedsuikerspiegel  verlagende 
medicatie, C-reactieve protein, albuminurie, ureum uitscheiding in de urine (als maat voor 
de hoeveelheid eiwit in de voeding), natrium uitscheiding in de urine (als maat voor de 
hoeveelheid zout in de voeding), en nierfunctie. In een analyse waar geen rekening met de 
andere risicofactoren wordt gehouden of alleen met leeftijd en geslacht bleken bij zowel 
mannen als vrouwen bloeddruk, bloedsuikerspiegel en uitscheiding van albumine in de urine 
geassocieeerd met de afname van de nierfunctie. In een analyse waarbij rekening wordt 
gehouden met de andere genoemde eigenschappen zijn bij mannen een hogere uitscheiding 
van albumine in de urine, bloedsuikerspiegel en bloeddruk nog steeds voorspellers voor 
meer verlies van nierfunctie. Een grotere tailleomtrek en een hoger cholesterol gehalte 
daarentegen  zijn  geassocieerd  met  minder  verlies  van  nierfunctie.  Bij  vrouwen  zijn  de 
resultaten iets anders: alleen bloedsuikerspiegel, bloeddruk en cholesterol zijn geassocieerd 
met nierfunctieverlies, terwijl het triglyceriden gehalte geassocieerd is met een gunstiger 
beloop van nierfunctie. Deze analyses laten zien dat er in normale bevolking beïnvloedbare 
voorspellers voor verlies van nierfunctie zijn en dat deze verschillend zijn voor mannen en 
vrouwen. In dit hoofdstuk is er alleen gekeken of het mogelijk is om met een eenmalige 
meting van een mogelijke risicofactor het verlies van nierfunctie te voorspellen voor de jaren 
daarna. 
Het  zou  natuurlijk  ook  zo  kunnen  zijn  dat  juist  met  behulp  van  de  verandering  in  een 
risicofactor het verloop van de nierfunctie daarna goed kan worden voorspeld. Dit is in 
hoofdstuk 6 onderzocht. Voor deze analyses zijn de gegevens van de eerste drie metingen 
van de PREVEND studie gebruikt. In totaal werden ruim 5.600 deelnemers, die gemiddeld 
6.5 jaar zijn gevolgd voor deze analyses gebruikt. Voor deze analyses werd als uitkomst de 
verandering in nierfunctie tussen de tweede en derde meting gebruikt en de verandering 
in de risicofactoren tussen de eerste en tweede tweede als mogelijke risicofactoren. In 
deze studie is het effect van veranderingen in albumine uitscheiding in de urine, bloeddruk, 
bloedsuikerspiegel, cholesterol, tailleomtrek, rookgedrag, gebruik van bloeddrukverlagende 
medicijnen onderzocht. Op basis van eerdere bevindingen zijn deze analyses apart voor 
mannen en vrouwen uitgevoerd. Voor mannen lieten de analyses waarin geen rekening is 
gehouden met de andere eigenschappen een verband tussen een toename in albumine 
uitscheiding in de urine, bloeddruk, cholesterol en nierfunctieachteruitgang zien. Dezelfde 
soort analyses voor vrouwen lieten zien dat in vrouwen een stijging in bloedsuikerspiegel 
geassocieerd was met een toename in de nierfunctie. Uit de analyses met correcties voor 
de andere eigenschappen voor mannen bleek dat een toename in bloeddruk, cholesterol 
en albuminurie gevolgd werd door versnelde nierfunctieachteruitgang. Opmerkelijk was 
verder dat in het uiteindelijk model de verandering in bloeddruk een betere voorspeller 
bleek te zijn dan de waarde van de eerste meting. Uit deze analyses voor vrouwen konden 
we concluderen dat ook als we rekening houden met de andere factoren, een stijging van de 
bloedsuikerspiegel tussen de eerste en tweede meting een toename in nierfunctie tussen 
de tweede en derde meting to gevolg had. Mogelijk komt deze stijging in nierfunctie door 
hyperfiltratie (een proces waardoor de nieren eigenlijk te hard gaan werken waardoor er 
schade en daarna nierfunctieverlies optreedt) en mogelijk zal er na langere follow-up juist 
een daling in de nierfunctie worden gevonden. Deze resultaten hebben aangetoond dat 114 115
de verandering in de onderzochte risicofactoren bij kunnen kan dragen aan het inschatten 
van het risico op versnelde nierfunctieachteruitgang. Hierbij moet natuurlijk wel worden 
opgemerkt dat er dan langer moet worden gewacht voordat het risico kan worden ingeschat 
omdat de risicofactor twee keer moet worden gemeten met een bepaalde periode tussen de 
metingen en dat het herhaald meten ook meer kosten met zich meebrengt. 
De resultaten uit de hoofdstukken 5 en 6 zijn in hoofdstuk 7 omgezet in een bruikbaar 
instrument voor de klinische praktijk; de zogenaamde Renal Risk Score. Voor de ontwikkeling 
van deze risico score zijn gegevens van 6.809 deelnemers van het PREVEND cohort gebruikt, 
die ongeveer zeven jaar zijn gevolgd. Het doel van dit instrument is zo goed mogelijk het 
risico op het krijgen van slecht functionerende nieren te voorspellen aan de hand van een 
aantal gemakkelijk te meten eigenschappen van een persoon. In deze analyses zijn mensen 
met slecht functionerende nieren gedefinieerd als mensen die horen bij de groep met de 
20% snelste afname van nierfunctie en het hebben van één nierfunctie schatting beneden 
een bepaald afkappunt (hier is 60 ml/min/1.73m2 als afkappunt gebruikt, mensen die een 
nierfunctie beneden deze waarde hebben worden geclassificeerd als chronische nierziekte 
patiënt). De groep mensen met slecht functionerende nieren was gemiddeld 62 jaar, 43% 
van deze groep bestond uit mannen en het nierfunctie verlies in deze groep was negen 
keer zo groot als bij de mensen zonder slecht functionerende nieren. De resultaten van 
dit onderzoek laten zien dat op basis van de nierfunctie tijdens de eerste meting, leeftijd, 
albumine uitscheiding in de urine, bloeddruk, C-reactieve protein en een voorgeschiedenis 
van hoge bloeddruk het risico op het krijgen van slecht functionerende nieren binnen zeven 
jaar geschat kan worden. Om na te gaan of de ontwikkelde Renal Risk Score ook goed 
onderscheid kan maken tussen mensen met een hoog en laag risico zijn er aanvullende 
analyses gedaan en hieruit bleek de risico score goed bruikbaar te zijn. Om deze data om 
te zetten in een klinisch bruikbaar instrument hebben we een score formulier ontwikkeld. 
Hieruit is op basis van de klinische data van iedere patiënt het bijbehorende risico te bepalen. 
Uit de resultaten van dit proefschrift kunnen we een aantal algemene conclusies trekken. 
Er zijn een aantal voorspellers voor nierfunctieachteruitgang, namelijk macroalbuminurie 
en  de  bekende  cardiovasculaire  risicofactoren,  waaronder  een  hoge  bloeddruk  en 
bloedsuikerspiegel. Hierbij moet worden opgemerkt dat deze verschillend zijn voor mannen 
en vrouwen. Zowel eenmalig gemeten risicofactoren als een verandering in een risicofactor 
kunnen goede voorspellers voor nierfunctieverlies zijn. Vooral de beïnvloedbare risicofactoren 
voor nierfunctieverlies kunnen worden gebruikt om mensen met een verhoogde kans op 
het ontwikkelen van een chronische nierziekte op te sporen. Dit kan worden gedaan door 
met behulp van de ontwikkelde “Renal Risk Score”, op basis van een aantal kenmerken van 
een persoon, het risico op het ontwikkelen van een chronische nierziekte vast te stellen. 
Hopelijk zullen dit soort instrumenten samen met onderzoek naar nieuwe voorspellers in 
de nabije toekomst er voor zorgen dat mensen met een hoog risico op het ontwikkelen 
van een chronische nierziekte in een vroeg stadium van hun ziekte worden opgespoord en 
behandeld. Op deze manier kan dialyse en/of niertransplantatie mogelijk worden uitgesteld 
of zelfs worden afgewend.
Om  de  ‘Renal  Risk  Score’  optimaal  te  gebruiken  in  de  klinische  praktijk,  is  nog  meer 
onderzoek nodig. Dit toekomstige onderzoek zou zich onder andere moeten richten op de 
zoektocht naar nieuwe voorspellers, deze zouden aan de ‘Renal Risk Score’ kunnen worden 
toegevoegd. De economische aspecten van het gebruik van de ‘Renal Risk Score’ zullen zeker 114 115
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ook met behulp van kosten-effectiviteitanalyses in kaart moeten worden gebracht. Dit gaat 
met name een belangrijke rol spelen bij de discussie of er nieuwe voorspellers, waar dure 
laboratorium bepalingen voor nodig zijn, moeten worden toegevoegd aan de ‘Renal Risk 
Score’. Ook zal er aandacht moeten zijn voor de psychologische effecten van het gebruik 
van een risicoscore. Hiermee kunnen we denken aan het effect van het krijgen van een vals-
positieve uitslag (dus een onterechte slechte uitslag). De bovenstaande overwegingen geven 
aan dat er op dit gebied nog veel werk te verrichten is maar de ‘Renal Risk Score’ is zeker een 
veelbelovend instrument voor de klinische praktijk.116daNKwOORd118 119
Better let as net…!! Eindelijk mag ik het laatste gedeelte van dit boekje schrijven. Na vier   
ontzettend leerzame, intensieve, maar voornamelijk erg leuke jaren in Groningen, en bijna 
twee jaar in het LUMC waarin ik “even” dit boekje af zou maken naast mijn werk, is het af!
Terugkijkend op de afgelopen jaren realiseer ik mij dat er ontzettend veel mensen een directe 
of indirecte bijdrage aan dit boekje hebben geleverd. 
Allereerst wil ik mijn eerste promotor, professor P.E. de Jong, bedanken. Beste Paul, wat ben 
ik blij dat ik met de data van het PREVEND onderzoek heb mogen werken Bedankt dat je 
alweer heel wat jaren geleden met dit mooie onderzoek bent gestart! Ik heb er bewondering 
voor hoe snel je altijd mijn manuscripten voorzag van opbouwende kritiek. Jouw kritische 
blik en enthousiasme had ik zeker niet willen missen! 
In de tweede plaats wil ik mijn tweede promotor, professor R.P. Stolk, bedanken. Beste 
Ronald, ik ben erg blij dat je halverwege mijn promotieonderzoek als epidemioloog betrokken 
raakte bij mijn onderzoek. Temeer omdat mijn toekomst binnen de klinische epidemiologie 
ligt, ben ik je dankbaar voor je methodologische bijdrage aan mijn onderzoek.
Vervolgens wil ik mijn co-promotor, Dr. R.T. Gansevoort, bedanken. Beste Ron, jouw kritische 
blik, positieve insteek en gedrevenheid voor de PREVEND studie hebben een belangrijke 
bijdrage aan mijn proefschrift geleverd! Door jou ben ik ingewijd in de wereld van klinisch 
denken. Het heeft even geduurd voordat ik je benaderingen kon volgen maar ik heb hier nog 
steeds baat bij! Het heeft je soms moeite gekost om mij weer te motiveren het echt af te 
ronden maar gelukkig ben je erin geslaagd! 
Beste Paul en Ron, ik wil jullie ook graag bedanken voor jullie steun bij het volgen van de post-
doctorale opleiding Epidemiologie aan de Vrije Universiteit. Het volgen van deze opleiding 
heeft niet alleen bijgedragen aan de kwaliteit van mijn boekje maar is ook bepalend geweest 
voor mijn verdere toekomst.
Graag wil ik de leden van de beoordelingscommissie, professor H.J.G. Bilo, professor J.L. 
Hillege en professor R.T. Krediet bedanken voor het beoordelen van mijn proefschrift.
Verder gaat mijn dank uit naar Dr. D.F. Jansen. Beste Desiree, bedankt voor je hulp bij het 
uitvoeren van de longitudinale data-analyse en voor je gezelligheid!
Dr. M.W. Heymans, beste Martijn bedankt voor je hulp bij het bootstrappen! Al met al is het 
een mooi hoofdstuk geworden.
Natuurlijk wil ik ook Prof. D. de Zeeuw en Dr. S.J.L. Bakker, beste Dick, beste Stephan bedankt 
voor jullie bijdrage aan de inhoud van dit proefschrift.
Graag wil ik alle medewerkers van het Trial Coördination Center die in de loop van de tijd 
hebben meegewerkt aan de totstandkoming van de PREVEND database bedanken voor hun 
inzet! 
Ook de mensen van het laboratorium die zich bezig hebben gehouden met het doen van 
alle  duizenden  bepalingen  wil  ik  graag  bedanken  voor  hun  belangrijke  bijdrage  aan  dit 
proefschrift en de PREVEND studie in het algemeen.118 119
Dankwoord
Beste Winie, ontzettend bedankt voor alle ondersteuning! Ik kon altijd bij je terecht met al 
mijn vragen en ik mis onze gesprekjes in de Brug. Beste Aukje, bedankt voor je hulp bij het 
plannen van (soms bijna onmogelijke) afspraken.
Een belangrijk onderdeel van een promotie-traject zijn collega-AIO’s! Tijdens het werk, de 
lunches (bij De Buurvrouw, als het even kon lekker op het terras in het zonnetje..), de vele 
congressen, werkbesprekingen en borrels heb ik genoten van jullie aanwezigheid! Beste 
nieuwe en oude nefro AIO’s, Alaa, Anna, Arjan, Astrid, Azideh, Carolien, Dorien, Else, Femke, 
Folkert, Guiseppe (helaas heb ik jou en je humor veel te kort mogen meemaken), Hilde, Inge, 
Jan, Jelena, Judith, Kiran, Leendert, Maartje, Mieneke, Mirjam, Pramod, Rutger, Sascha, 
Solmaz, Steef, Titia, Tsjitske, bedankt voor alle contacten!
Ook de collega-AIO’s van de afdelingen pathologie en klinische farmacologie wil ik graag 
bedanken. Andrea, Cornelis, Eelke, Els, Gemma, Heleen, Hiddo, Inge, Jarir, Maria, Mirjam, 
Mirjan  en  Wynand  de  gezamenlijke  werkbesprekingen  en  congres-bezoeken  hebben 
mij inzicht in andere vakgebieden gegeven, zorgden voor afwisseling en voor nog meer 
gezelligheid, bedankt hiervoor! 
Het dagelijkse (soms uurlijkse) contact met mijn kamergenootjes in het oude Triadegebouw 
is voor mij erg stimulerend geweest! Auke, ik heb genoten van je kritische blik en het tot in 
detail bespreken van de weekenden op de maandagochtend! Bedankt dat ik je paranimf 
mocht zijn! Ferdau, het zal voor jou zeker wennen zijn geweest tussen alle dames in de AIO-
kamers en bij de PREVEND poli. Ik waardeer je brede interesse. Een flits-bezoekje aan Grun’n 
is niet compleet als ik niet even met jou heb bijgepraat en heb gehoord welke hoofdstad je 
nu weer hebt bezocht! Jacoline, het was zo gezellig (soms zelfs een beetje te..) in Groningen. 
Ik ben blij dat we nu in het LUMC met enige regelmaat weer kunnen bijpraten, ik kijk altijd 
uit naar onze afspraken! Marije, heerlijk was het om met jou te kletsen over van alles en 
nog wat, soms urenlang (we konden elkaar goed van het werk houden). Heel veel succes 
met je laatste loodjes, zet ‘m op! Lucia, jouw komst naar het Triadegebouw, heeft de kamers 
letterlijk en figuurlijk opgefleurd! Verder wil ik graag de andere onderzoekers, die in de loop 
van de jaren kortere of langere tijd in het Triadegebouw onderzoek hebben gedaan, Aigul, 
Aminu, Christiane, Emilio (helaas vond je in Nederland niet hetgeen je zocht), Maurits en 
Yvonne bedanken. De twee doktoren Akin en Riko wil ik ook bedanken voor hun klinische blik 
en mooie verhalen uit de kliniek, ik heb ervan genoten!
Natuurlijk wil ik ook de nieuwe lichting PREVEND/Triadegebouw AIO’s, Hanneke, Lieneke 
en Wendy bedanken voor hun gezelligheid als ik weer eens even aan kwam waaien voor 
besprekingen in Groningen. Heel veel succes met jullie boekjes, maak er wat moois van!
Het Triadegebouw doet mij natuurlijk ook meteen denken aan de doktersassistentes en de 
vele studenten van de polikliniek van PREVEND. Anna, Annemarie, Annet, Annie, Martha en 
Roelie, allereerst bedankt voor jullie grote bijdrage aan de data-verzameling van de PREVEND 
studie en voor alle kopjes koffie, gezellige koffie-momenten en persoonlijke gesprekken! De 
poli van PREVEND is natuurlijk ook de plek waar alle data wordt verzameld, dit is alleen 
mogelijk omdat de deelnemers van PREVEND steeds bereid waren mee te werken aan dit 
project, ik wil u hier allemaal hartelijk voor bedanken!
Joost, bedankt voor het ontwerpen van de voorkant van mijn boekje! Heerlijk dat ik me daar 
niet druk over heb hoeven maken. Lieve Joost en Fredrica natuurlijk ook bedankt voor de 120
gezellige etentjes in Amsterdam en Naarden. Fredrica, hopelijk kunnen we snel weer een 
keer een mooie schaatstocht (of als er geen ijs komt wandeltocht) maken!
Lieve paranimfen, geweldig dat jullie 15 december naast mij staan, top! Lieve Esther, ik 
heb genoten van onze tijd samen in het Triadegebouw. Ik bewonder het enthousiasme en 
doorzettingsvermogen waarmee je alles doet! Voor de wetenschap hoop ik dat je in de 
toekomst je klinisch werk zult combineren met boeiende onderzoeksprojecten…  Lieve Tynke, 
al sinds onze Goeman-tijd ben je een hele goede vriendin. Nog steeds denk ik vaak terug 
aan onze prachtige weken in Azië! De (ver)dwaaltochtjes door China Town, onze bijzondere 
planning en de vele gesprekken (vaak midden in de nacht). Ik hoop dat we in de toekomst 
nog vaak samen op pad gaan!
Het  afronden  van  mijn  boekje  hebben  vooral  mijn  nieuwe  EPI-collega’s  in  het  LUMC 
van dichtbij meegemaakt. Beste Friedo, bedankt voor de nieuwe inzichten in het doen 
van epidemiologisch onderzoek, het leren geven van onderwijs en voor je geduld, het is 
nu eindelijk af… In het bijzonder wil ik het nierclubje bedanken. Diana, Marion, Dinanda,   
Christiane, Moniek, Wieneke, Tessa, Gürbey, Iris, Yvette, Celine, en Tamara, bedankt voor 
de prettige sfeer en jullie oprechte interesse in de stand van zaken wat betreft mijn boekje! 
Ik hoop dat we met z’n allen nog veel mooie onderzoeksprojecten zullen gaan uitvoeren. 
Beste Els en Ray, bedankt voor jullie klinische input tijdens de besprekingen in het Hans Mak 
Instituut. Ik hoop dat jullie nog lang, zij het waarschijnlijk meer vanaf de zijlijn, betrokken 
blijven bij onze projecten! 
 
Lieve vrienden, een promotietraject is alleen vol te houden met goede vrienden die voor 
afleiding zorgen en oprechte interesse tonen. Ingelien & Oedsen, Fenna & Michiel, Tynke & 
Martin, Eds & Ellen (en natuurlijk Benjamin), Wouter, Peter, Jeroen & Marcia, Tom & Simone. 
A new job, a new house and the movement from Groningen to Naarden was not always 
easy…. I am very glad I met a lot of very nice people in Lelystad! Lely-people, originally from 
all over the world, thanks for all the BBQ’s, parties, dinners and the Sinterklaas celebration 
(indeed with poems and ‘surprises’..). 
Lieve familie, jullie mogen zeker niet in dit dankwoord ontbreken! Lieve Wil, ondanks alles 
had en heb je steeds interesse in mijn promotie getoond, bedankt! Piet, helaas kun je de 
afronding van mijn boekje en het feest niet meer meemaken. Wat zou je trots zijn geweest… 
Maarten en Machteld, bedankt voor de gezellige avondjes klaverjassen, eerst in Groningen 
en nu in het midden van het land. Kleine Joep, wat ben jij een heerlijke afleiding! 
Leave heit en mem, bedankt foar alle oandacht en motiverende wurden! Gerdien & Chris 
we ha mekoar de leste tiid fjirstente min sjoen. Mar at we mekoar sjogge is it altyd goed. 
Bedankt foar alle gesellichheid en tillefoangesprekken! Lytse Mirte, wat binst in grut wûnder! 
Wat genietsje ik fan dyn oanwêzigens!
En tenslotte….lieve Bram, ontzettend bedankt voor alles. Terwijl ik mijn dankwoord schrijf, 
heb jij een dag vrij genomen om de lay-out van mijn proefschrift af te maken… Dit geeft wel 
aan hoe betrokken je bent! Succes met je eigen boekje, het wordt vast heel mooi! We gaan 
een zonnige toekomst tegemoet!lIST Of pUblIcaTIONS122
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